In response to the COVID-19 pandemic, the DrugBank team has created this information dashboard to provide a comprehensive summary of research in an effort to help interested parties find the information they need quickly and effectively. If you are interested in licensing DrugBank data for commercial use, please contact us.

COVID-19 OUTBREAK SUMMARY: Coronavirus disease 2019 (named COVID-19 on February 11, 2020 by the World Health Organization (WHO) 1,2) was first identified in Wuhan, China near the end of 2019 1. It is caused by the virus known as SARS-CoV-2 (previously called 2019-nCoV). This name was chosen because the virus is related to the coronavirus that caused the SARS outbreak of 2003. The two viruses are different despite their genetic similarity 3. COVID-19 is believed to be less lethal but much more infectious than SARS-CoV 4. Until the recent outbreak, this virus had not been identified in humans 5.

Disclaimer: This dashboard is intended for research purposes only, and is not to be used for self-diagnosis. If you believe you are experiencing symptoms of COVID-19, please reach out to a medical professional. While we do our best to maintain accuracy and provide up-to-date data and information, we do not guarantee that.
Covid drug dev
COVID-19: Finding the Right Fit

Identifying Potential Treatments Using a Data-Driven Approach

Download the White Paper
COVID-19 Highlights
Aug 23, 2021

The FDA moves from emergency use authorization to full approval of the Pfizer-BioNTech COVID-19 vaccine. The full package insert can be viewed here.

Apr 7, 2021

Pfizer has unveiled an oral antiviral candidate, PF-07321332, targeted against the main protease of SARS-CoV-2. The drug is currently undergoing Phase I clinical trials and, if successful, could become the first orally administered early intervention in the treatment of COVID-19.

Mar 29, 2021

Canada's National Advisory Committee on Immunization (NACI) recommends that AstraZeneca COVID-19 vaccine should not be used in adults under 55 years of age because of safety concerns. Rare cases of serious blood clots were reported in some immunized patients - notably among young women - in Europe. Investigations are ongoing to assess the link between the vaccine and blood clots.

Mar 11, 2021

European Medicines Agency (EMA) investigating as a number of European countries suspend AstraZeneca vaccine as a precautionary measure against possible thromboembolic events. The EMA's safety committee states that "the benefits of the vaccine continue to outweigh the risks" and that "there is no indication that vaccination has caused these conditions."

Mar 5, 2021

Health Canada has approved Johnson & Johnson's single-dose COVID-19 vaccine, Ad26.COV2.S, for use in patients 18 years of age and older, becoming Canada's fourth-approved COVID-19 vaccine. Canada has ordered 10 million doses, to begin arriving in April, with options for up to 28 million more.

Feb 27, 2021

The FDA issued the third Emergency Use Authorization (EUA) for Ad26.COV2.S, a vaccine developed by Janssen, to prevent COVID-19 infections in individuals 18 years of age and older. This vaccine is administered as a single dose and was 66-85% effective in preventing moderate to severe/critical COVID-19 in clinical trials.

Feb 26, 2021

Health Canada has approved AstraZeneca's COVID-19 vaccine candidate AZD1222 for the active immunization of patients 18 years of age and older. Canada has secured 20 million doses which are expected to arrive in the second and third quarters of 2021.

Feb 2, 2021

Results of a phase 3 trial of Russia's Sputnik V vaccine, published in The Lancet, appear to show the vaccine is safe and effective.

Dec 23, 2020

Health Canada has approved Moderna's COVID-19 vaccine (mRNA-1273 SARS-CoV-2) for the active immunization against COVID-19 in patients 18 years of age or older, with up to 168,000 doses set to arrive in Canada by the end of December.

Dec 18, 2020

The FDA issued the second Emergency Use Authorization (EUA) for the Moderna COVID-19 vaccine to prevent COVID-19 infections in individuals 18 years of age and older. In clinical trials, the vaccine was 94.1% effective in preventing COVID-19 disease with significantly less COVID-19 infections in the vaccine group than placebo.

Dec 11, 2020

The FDA issued the first Emergency Use Authorization (EUA) for the Pfizer/BioNTech COVID-19 vaccine to prevent COVID-19 infections in individuals 16 years of age and older. In clinical trials, the vaccine was 95% effective in preventing COVID-19 disease.

Dec 11, 2020

GlaxoSmithKline and Sanofi stated that their potential COVID-19 vaccine will not be ready until late next year after early trials showed an insufficient immune response in volunteers over 60 years of age. The results were released after it was confirmed that a manufacturing problem resulted in volunteers receiving less of the vaccine than intended. The companies are planning to launch a new early-stage trial of the vaccine in February.

Dec 9, 2020

Health Canada has approved the Pfizer/BioNTech COVID-19 vaccine, with the first doses being administered to approximately 124,500 Canadians working in frontline healthcare and to long-term care residents as early as next week. It is expected that approximately 249,000 complete doses of the two-dose vaccine will be available by the end of the year.

Dec 9, 2020

After 2 healthcare workers experienced anaphylactoid reactions following administration of the Pfizer/BioNTech COVID-19 vaccine, the Medicines and Healthcare Products Regulatory Agency in the UK has recommended that the vaccine should not be administered to individuals with a history of allergic reactions to food, medications, or vaccines. The allergic reactions occurred in 2 out of thousands of individuals administered the vaccine. Both healthcare workers, who have a history of allergic reactions, are recovering. NHS indicates that this advice is intended as a precautionary measure, which is common when new vaccines are released.

Dec 2, 2020

The UK becomes the first country in the world to approve Pfizer and BioNTech's BNT162b2 mRNA-based COVID-19 vaccine after the MHRA deemed it safe and effective. The UK has ordered 40 million doses, with 800,000 expected to arrive in-country within the next week.

Nov 30, 2020

Moderna reports final results of their 30,000-person Phase 3 trial of mRNA-1273 for COVID-19 with an overall efficacy of 94.1% and complete protection against severe COVID-19. The company announced they will now seek Emergency Use Authorization (EUA) from the FDA and a similar preliminary approval from the European Medicines Agency.

Nov 23, 2020

AZD1222, a replication-deficient adenovirus engineered to express the SARS-CoV-2 spike (S) protein, has shown 70% overall efficacy in preventing COVID-19 based on interim results from clinical trials in the UK and Brazil. AstraZeneca has announced they will seek conditional/early approval worldwide, as well as an Emergency Use Listing from the World Health Organization while collecting additional safety and efficacy data. AZD1222 is likely easier to distribute than comparable mRNA-based vaccines, given its stability at 2-8 degrees Celsius for six months or more.

Nov 19, 2020

The WHO Guideline Development Group (WHO GDG) has released guidelines against using Remdesivir to treat COVID-19 patients, stating that the drug does not improve mortality rate or recovery time.

Nov 18, 2020

Pfizer and BioNTech announced the conclusion of the Phase III trial of their COVID-19 vaccine candidate BNT162b2. Initial analysis of the data shows a 95% efficacy which appears consistent regardless of patient demographics. The companies also announced the achievement of a crucial safety milestone required by the US Food and Drug Administration (FDA) prior to filing a request for Emergency Use Authorization (EUA).

Nov 16, 2020

Moderna announced that its lead vaccine candidate mRNA-1273 offered 94.5% protection against symptomatic COVID-19 in an interim analysis of their ongoing phase 3 trial. These interim results suggest a possible benefit in preventing severe COVID-19, as all 11 severe cases occurred in the placebo group. Following the accrual of additional safety and efficacy information, the company intends to seek Emergency Use Authorization from the FDA.

Nov 10, 2020

The FDA announced an Emergency Use Authorization (EUA) for the monoclonal antibody bamlanivimab for the treatment of patients aged 12 years and older weighing at least 40 kg who are at high risk of progressing to severe COVID-19.

Nov 9, 2020

Pfizer and BioNTech announced that their lead vaccine candidate BNT162b2 offered over 90% protection against SARS-CoV-2 infection in an interim analysis of their ongoing phase 3 trial. The interim results capture 94 COVID-19 cases out of a final target endpoint of 164 cases required for final analysis. Following the accrual of additional safety information by the third week of November, the companies announced they would seek Emergency Use Authorization from the FDA.

Oct 22, 2020

Remdesivir becomes the first COVID-19 treatment to receive FDA approval. It is indicated for use in adult and pediatric patients aged 12 years and over weighing at least 40 kilograms with COVID-19 severe enough to require hospitalization. Pediatric patients weighing between 3.5 and 40 kg remain covered under a revised Emergency Use Authorization (EUA).

Oct 15, 2020

Interim results published on the MedRxiv pre-print server of the WHO's Solidarity trial suggest no benefit on hospitalization duration, initiation of ventilation, or mortality for four repurposed antiviral drugs for the treatment of COVID-19. These drugs included Remdesivir, Hydroxychloroquine, Lopinavir (co-administered with Ritonavir), and Interferon-β1a. The trial is ongoing with additional therapeutics for COVID-19.

Oct 13, 2020

Johnson & Johnson announced a study pause in the ongoing ENSEMBLE trial of their Ad26.COV2.S COVID-19 vaccine. The patient is currently being evaluated by an independent data safety monitoring board.

Sep 8, 2020

Reports of a serious adverse event in a participant of a Phase III trial for an AstraZeneca COVID-19 vaccine has put the trial on pause while researchers review safety data. A spokesperson for the pharmaceutical company confirmed that this is part of standard protocol to maintain the integrity of the vaccine development process.

Aug 25, 2020

AstraZeneca has initiated a phase I clinical trial with a COVID-19 antibody cocktail drug, known as AZD7442.

Aug 24, 2020

China announces "urgent use" regulations that allowed for limited public use of Sinopharm's trial COVID-19 vaccines as far back as July 22.

Aug 15, 2020

A rapid saliva-based COVID-19 test has been approved by the FDA for Emergency Use Authorization. The test was developed by researchers at Yale University and is set to be cheaper and faster than traditional testing methods, such as the nasopharyngeal (NP) swab, while delivering nearly identical outcomes to NP swabbing.

Aug 13, 2020

Researchers from UC San Francisco have developed a product called ‘AeroNabs’, which utilizes engineered nanobodies to prevent the SARS-CoV-2 virus spike proteins from binding to ACE2 receptors in the airway and lungs. In contrast to vaccines, AeroNabs are aerosolized and may be delivered via inhaler or nasal spray. The efficacy and safety of the product have yet to be determined in clinical trials.

Aug 11, 2020

Russia approves the SARS-CoV-2 vaccine called "Sputnik V". The vaccine was developed by the Gamaleya Research Institute of Epidemiology and Microbiology.

Aug 4, 2020

A synthetic monoclonal antibody derived from a patient who recovered from COVID-19 termed LY-CoV555 is set to enter phase three clinical trials as part of the NIH's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. The trial will be carried out globally through existing clinical trial networks, including INSIGHT, PETAL, CTSN, and CONNECTS.

Jul 28, 2020

Health Canada authorizes the use of remdesivir for the treatment of severe COVID-19 symptoms.

Jul 27, 2020

Moderna's MRNA-1273 begins phase 3 clinical trials.

Jul 27, 2020

The joint vaccine development program between BioNTech and Pfizer announces their lead candidate to begin a global phase 2/3 clinical trials will be BNT162b2. BNT162b2 is one of two candidates, along with BNT162b1, to have received FDA fast-track designation on July 13, 2020, and is a nucleoside modified mRNA vaccine encoding an optimized full-length version of the SARS-CoV-2 spike (S) protein.

Jul 20, 2020

A clinical trial at the University of Oxford demonstrated that the novel vaccine, ChAdOx1 nCoV-19, induces a T-cell mediated immune response and neutralizing antibodies against SARS-CoV-2, the virus responsible for causing COVID-19.

Jul 14, 2020

Moderna's SARS-CoV-2 vaccine, MRNA-1273, has phase 1 trial results published in the New England Journal of Medicine

Jul 13, 2020

Two vaccine candidates jointly developed by Pfizer and BioNTech, termed BNT162b1 and BNT162b2, have been granted fast track designation by the FDA. The companies have announced their intention to make 100 million doses by the end of 2020, pending further regulatory approval.

Jul 10, 2020

Gilead reports a 62% reduction in mortality risk and improved clinical outcome in patients treated with remdesivir.

Jul 10, 2020

Anecdotal evidence from smaller studies, combined with evidence from a more extensive Swedish study, suggests that memory T cell responses may be present in patients previously exposed to SARS-CoV-2, regardless of their serological status.

Jul 7, 2020

Regeneron Pharmaceuticals receives $450 million from the U.S. government for the manufacture of their double-antibody cocktail REGN-COV2. The agreement covers production and storage of between 70,000 to 300,000 treatment doses or between 420,000 to 1,300,000 prevention doses, with an anticipated completion date of fall 2020.

Jun 30, 2020

FDA publishes guidelines for the development of COVID-19 vaccines.

Jun 26, 2020

FDA approves the phase II clinical trial conducted by Celltex Therapeutics to investigate the prophylactic efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) in subjects who have never been infected with COVID-19 but are at a high risk of contracting the virus.

Jun 23, 2020

INOVIO pharmaceuticals has received $71 million in funding from the U.S. Department of Defence for the large-scale manufacture of CELLECTRA® 3PSP devices. These devices are used to deliver DNA vaccines, such as INOVIO's COVID-19 INO-4800 vaccine, into a patient's skin using electroporation technology.

Jun 22, 2020

Preliminary serological survey data out of New Jersey suggests the asymptomatic spread of SARS-CoV-2 may be a less significant driver of infection rates than previously thought. Further large-scale assessments of serological data are required to confirm these findings.

Jun 16, 2020

Researchers have screened over 1000 unique B cell clones from recovered COVID-19 patients to identify blocking and neutralizing antibodies. These antibodies represent a starting point for large-scale production and potential use in protecting at-risk groups such as healthcare workers.

Jun 16, 2020

Interim results from the RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial ongoing through the University of Oxford has shown clinical benefit with the use of dexamethasone. This inexpensive steroid medication reduced deaths for COVID-19 patients requiring a ventilator by one third and for patients requiring oxygen by one fifth. The beneficial effects observed are believed to be due to the ability of dexamethasone to mitigate the severity of host immune-derived cytokine storms.

Jun 16, 2020

Early clinical trial results with dexamethasone show that this drug improves survival of COVID-19 patients with severe respiratory symptoms.

Jun 15, 2020

FDA revokes emergency use authorization for hydroxychloroquine

Jun 14, 2020

AstraZeneca has signed a deal with the European Inclusive Vaccines Alliance (IVA) for 400 million doses of the AZD1222 vaccine currently under development by the University of Oxford, pending final approval. Globally, AstraZeneca has set a target of two billion vaccine doses.

Jun 11, 2020

Regeneron commences clinical trials with REGN-COV2, an experimental antibody cocktail for both the prevention and treatment of COVID-19.

Jun 8, 2020

New Zealand ends social distancing as their last known COVID-19 patient recovers.

Jun 8, 2020

Lilly has partnered with Shanghai-based biotech company, Junshi, to commence clinical trials in China with an experimental COVID-19 antibody.

Jun 4, 2020

On June 4th, a previously published study that challenged the safety and effectiveness of hydroxychloroquine and chloroquine for the treatment fo COVID-19 was retracted. This decision appears to have been made based on an inability to confirm the quality of the original data.

May 28, 2020

Mounting evidence suggests an involvement of the vascular endothelium in explaining COVID-19 symptomatology. The presence of blood clots combined with symptoms including peripheral hypoxia, heart attacks, and stroke suggest that blood vessel damage may be a hallmark of COVID-19 infection.

May 28, 2020

The LIBERATE clinical trial investigates the efficacy of a unique formulation of ibuprofen in hospitalized UK patients with COVID-19 after animal studies show promising results of ibuprofen ameliorating acute respiratory distress syndrome associated with the infection. Opinions differ over the use of ibuprofen in COVID-19, as there is inconclusive evidence for or against the use of NSAIDs in the treatment of COVID-19 patients.

May 25, 2020

The World Health Organization has temporarily suspended the hydroxychloroquine arm of the Solidarity Trial for the treatment for COVID-19 due to safety concerns raised in other trials.

May 22, 2020

A multinational registry analysis published in The Lancet involving data for 96 032 patients from 671 hospitals across six continents was unable to confirm a benefit to hydroxychloroquine or chloroquine, either alone or combined with a macrolide antibiotic, for the treatment of Covid-19. Rather, these treatments were associated with decreased survival and increased incidence of ventricular arrhythmias.

May 18, 2020

Moderna reported encouraging results from phase I trials of a novel lipid nanoparticle (NLP)-encapsulated mRNA vaccine (designated mRNA-1273) encoding a stabilized form of the SARS-CoV-2 Spike (S) protein. The phase I results reported that all 45 participants across three dose levels seroconverted within 15 days and, out of eight tested for neutralizing ability, all antibody samples are capable of neutralizing live SARS-Cov-2 in vitro. Moderna has been granted clearance to begin phase II trials as of May 6.

May 16, 2020

Health Canada approves the first Canadian vaccine trials, led by a team of researchers at Dalhousie University in partnership with the Chinese manufacturer, CanSino Biologics. The Canadian Phase I study will build on the Ad5-nCoV vaccine trials that have already begun in China.

May 13, 2020

A possible link is made between COVID-19 and a novel severe Kawasaki-like disease in children, which involves the inflammation in the walls of arteries and other symptoms such as persistent fever, rash, red eyes. Further investigations are ongoing.

May 6, 2020

Laurent Pharmaceuticals, a Montreal-based company, receives Health Canada's approval to initiate its RESOLUTION clinical trial. This Phase II clinical trial investigates the potential therapeutic use of LAU-7b in reducing the severity of COVID-19 and preventing further disease progression into Acute Respiratory Distress Syndrome (ARDS).

May 4, 2020

Researchers in the Netherlands have developed a humanized monoclonal antibody, 47D11, capable of inhibiting both SARS-CoV and SARS-CoV-2 cell infection through binding to the S1B domain of the viral spike protein.

May 1, 2020

FDA grants emergency use authorization for remdesivir

Apr 24, 2020

FDA issues a warning against the use of both hydroxychloroquine and chloroquine outside of medical facilities, due to serious and potentially life-threatening heart rhythm complications.

Apr 23, 2020

Alongside more than 100 projects for the development of the COVID-19 vaccine around the world, a research team at Oxford University begins the Phase I clinical trial for its ChAdOx1 nCoV-19 vaccine in healthy volunteers.

Mar 28, 2020

FDA grants emergency use authorization for hydroxychloroquine

Mar 18, 2020

The WHO launches the Solidarity clinical trial. The study will compare four treatment options - remdesivir, lopinavir/ritonavir (with and without interferon beta-1a), and hydroxychloroquine or chloroquine - against standard of care to assess their effectiveness against COVID-19.

Mar 16, 2020

Moderna Therapeutics begins Phase I trial for its potential COVID-19 vaccine, mRNA-1273

Experimental Unapproved Treatments for COVID-19
DrugDescription
RitonavirAn HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection.
ChloroquineAn antimalarial drug used to treat susceptible infections with P. vivax, P. malariae, P. ovale, and P. falciparum. It is also used for second line treatment for rheumatoid arthritis.
DarunavirA HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection in patients with history of prior antiretroviral therapies.
LopinavirAn HIV-1 protease inhibitor used in combination with ritonavir to treat human immunodeficiency virus (HIV) infection.
GalidesivirGalidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various...
FavipiravirAn antiviral used to manage influenza, and that has the potential to target other viral infections.
UmifenovirA dual direct-acting antiviral/host-targeting agent used in the treatment and prophylaxis of influenza and other respiratory viruses.
Human interferon betaA polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).
TriazavirinAn antiviral used to treat several strains of influenza.
TMC-310911TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections....
Moderna COVID-19 VaccineAn mRNA vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, in patients aged 18 years and older.
Ad5-nCoVAd5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute...
AstraZeneca COVID-19 VaccineA two-dose replication-deficient adenovirus vector vaccine used to prevent COVID-19 caused by SARS-CoV-2.
FingolimodA sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19.
MethylprednisoloneA corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
LeronlimabA humanized monoclonal antibody being investigated
AzithromycinA macrolide antibiotic used to treat a variety of bacterial infections.
N4-HydroxycytidineA cytidine analog being investigated to treat COVID-19.
MolnupiravirAn orally bioavailable isopropylester cytidine analog being investigated to treat COVID-19.
ElbasvirAn antiviral and NS5A inhibitor used to treat hepatitis C infections.
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
GS-441524An experimental nucleoside analog antiviral investigated for its use in the treatment of Ebola and SARS-CoV-2 infections.
TridecactideAn investigational modified alpha melanocyte stimulating hormone being studied for the treatment of COVID-19.
MetenkefalinAn investigational endogenous opioid being studied for the treatment of COVID-19.
VazegepantVazegepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. If FDA approved, it will...
IbuprofenAn NSAID and non-selective COX inhibitor used to treat mild-moderate pain, fever, and inflammation.
Anti-SARS-CoV-2 REGN-COV2Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...
DexamethasoneA glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders.
COVID-19 convalescent plasmaCOVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. This investigational COVID-19 treatment is...
INO-4800INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that...
BNT162b1 SARS-CoV-2 VaccineBNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding...
BNT162a1 SARS-CoV-2 VaccineBNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in...
BNT162c2 SARS-CoV-2 VaccineBNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in...
ColchicineAn alkaloid used in the symptomatic relief of pain in attacks of gout and to treat the inflammatory symptoms of Familial Mediterranean Fever (FMF).
BamlanivimabA neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.
AZD7442AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the...
GC-376 free acidGC-376 is a 3C-like protease (3CLpro or Mpro) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells . The compound...
GC-373GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, GC-376 free acid[A219031,A219036]. It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease that...
IfenprodilN-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer...
AbivertinibAbivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). It has been investigated for use in...
EtesevimabEtesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661]
BaricitinibA Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist.
SubasumstatSubasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid...
Alunacedase alfaAlunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
ZansecimabZansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
GoflikiceptGoflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe...
AzvudineAzvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).
MosedipimodMosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
ThymoquinoneThymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.
CD24FcCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
Tin protoporphyrin IXNot Available
Rexin GRexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer....
AT-527Not Available
MeplazumabMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Oleic monoethanolamideNot Available
MAS825Not Available
ATYR1923ATYR1923 is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2...
Pam2csk4Not Available
CarrimycinNot Available
InbakiceptNot Available
PF-07304814PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the...
PF-07321332An oral protease inhibitor in clinical trials for the treatment of SARS-CoV-2 infections.
FostamatinibA spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia after attempting one other treatment.
SotrovimabA monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.
MM3122Not Annotated
Potential Drug Targets
DrugTarget
RitonavirHuman immunodeficiency virus type 1 protease
DarunavirHuman immunodeficiency virus type 1 protease
LopinavirHuman immunodeficiency virus type 1 protease
MethylprednisoloneGlucocorticoid receptor
LeronlimabC-C chemokine receptor type 5
TocilizumabInterleukin-6 receptor subunit alpha
ColchicineTubulin beta chain
GalidesivirRNA-directed RNA polymerase L
FavipiravirRNA-directed RNA polymerase catalytic subunit
TMC-310911HIV-1 protease
FingolimodSphingosine 1-phosphate receptor 5
BevacizumabVascular endothelial growth factor A
Azithromycin23S ribosomal RNA
ElbasvirNonstructural protein 5A
GS-441524Replicase polyprotein 1ab
VazegepantCalcitonin gene-related peptide type 1 receptor
IbuprofenProstaglandin G/H synthase 2
Anti-SARS-CoV-2 REGN-COV2Spike glycoprotein
BamlanivimabSpike glycoprotein
GC-376 free acidReplicase polyprotein 1ab
GC-373Replicase polyprotein 1ab
IfenprodilGlutamate receptor ionotropic, NMDA 2B
AbivertinibEpidermal growth factor receptor
EtesevimabSpike glycoprotein
ATYR1923Neuropilin-2
PF-07304814Replicase polyprotein 1ab
PF-07321332Replicase polyprotein 1ab
FostamatinibTyrosine-protein kinase SYK
SotrovimabSpike glycoprotein
MM3122Transmembrane protease serine 2
ChloroquineTumor necrosis factor
ChloroquineGlutathione S-transferase A2
Human interferon betaInterferon alpha/beta receptor 1
BevacizumabComplement C1q subcomponent subunit A
AzithromycinProtein-arginine deiminase type-4
GS-441524RNA-directed RNA polymerase L
MetenkefalinDelta-type opioid receptor
IbuprofenProstaglandin G/H synthase 1
GC-376 free acidReplicase polyprotein 1a
GC-373Replicase polyprotein 1a
IfenprodilGlutamate receptor ionotropic, NMDA 1
AbivertinibTyrosine-protein kinase BTK
FostamatinibAdenosine receptor A3
ChloroquineToll-like receptor 9
BevacizumabComplement C1q subcomponent subunit B
MetenkefalinMu-type opioid receptor
GC-376 free acidReplicase polyprotein 1ab
GC-373Replicase polyprotein 1ab
IfenprodilG protein-activated inward rectifier potassium channel 1
Fostamatinibvesicular monoamine transporter 2 (VMAT2)
BevacizumabComplement C1q subcomponent subunit C
DexamethasoneGlucocorticoid receptor
GC-376 free acidReplicase polyprotein 1a
GC-373Replicase polyprotein 1ab
IfenprodilG protein-activated inward rectifier potassium channel 2
FostamatinibFatty-acid amide hydrolase 1
ChloroquineGlutathione S-transferase
FingolimodHistone deacetylase 1
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-A
GC-376 free acidReplicase polyprotein 1ab
GC-373Replicase polyprotein 1a
IfenprodilG protein-activated inward rectifier potassium channel 4
BaricitinibTyrosine-protein kinase JAK1
FostamatinibEquilibrative nucleoside transporter 1
BevacizumabHigh affinity immunoglobulin gamma Fc receptor I
BaricitinibTyrosine-protein kinase JAK2
FostamatinibUDP-glucuronosyltransferase 1-1
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-a
DexamethasoneNuclear receptor subfamily 0 group B member 1
DexamethasoneAnnexin A1
FostamatinibcGMP-specific 3',5'-cyclic phosphodiesterase
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-b
IbuprofenApoptosis regulator Bcl-2
FostamatinibArachidonate 5-lipoxygenase
ChloroquineHigh mobility group protein B1
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-c
IbuprofenThrombomodulin
FostamatinibCathepsin S
ChloroquineGlutathione S-transferase Mu 1
FingolimodSphingosine 1-phosphate receptor 1
IbuprofenFatty acid-binding protein, intestinal
BaricitinibProtein-tyrosine kinase 2-beta
FostamatinibCathepsin L1
ChloroquineAngiotensin-converting enzyme 2
FingolimodSphingosine 1-phosphate receptor 4
MethylprednisoloneAnnexin A1
IbuprofenPeroxisome proliferator-activated receptor gamma
BaricitinibTyrosine-protein kinase JAK3
FostamatinibTyrosine-protein kinase ABL1
FingolimodSphingosine 1-phosphate receptor 3
IbuprofenCystic fibrosis transmembrane conductance regulator
FostamatinibCalcium-dependent protein kinase 1
IbuprofenPeroxisome proliferator-activated receptor alpha
FostamatinibSerine/threonine-protein kinase PknB
IbuprofenPlatelet glycoprotein Ib alpha chain
FostamatinibRibosomal protein S6 kinase alpha-6
IbuprofenProtein S100-A7
FostamatinibNon-receptor tyrosine-protein kinase TYK2
RitonavirNuclear receptor subfamily 1 group I member 2
FostamatinibAtypical kinase COQ8A, mitochondrial
DexamethasoneNitric oxide synthase, inducible
DexamethasoneNuclear receptor subfamily 1 group I member 2
FostamatinibTyrosine-protein kinase JAK1
FostamatinibHepatocyte growth factor receptor
FostamatinibSerine/threonine-protein kinase NIM1
FostamatinibSerine/threonine-protein kinase MST4
FostamatinibcAMP-dependent protein kinase catalytic subunit alpha
FostamatinibSerine/threonine-protein kinase 24
FostamatinibSerine/threonine-protein kinase 3
FostamatinibTyrosine-protein kinase Tec
FostamatinibSerine/threonine-protein kinase 33
FostamatinibSerine/threonine-protein kinase 35
FostamatinibSerine/threonine-protein kinase 36
FostamatinibSerine/threonine-protein kinase 38
FostamatinibSerine/threonine-protein kinase 38-like
FostamatinibSTE20/SPS1-related proline-alanine-rich protein kinase
FostamatinibSerine/threonine-protein kinase TAO1
FostamatinibSerine/threonine-protein kinase TAO2
FostamatinibSerine/threonine-protein kinase TAO3
FostamatinibSerine/threonine-protein kinase TBK1
FostamatinibAngiopoietin-1 receptor
FostamatinibDual specificity testis-specific protein kinase 1
FostamatinibTGF-beta receptor type-1
FostamatinibTGF-beta receptor type-2
FostamatinibTyrosine-protein kinase receptor Tie-1
FostamatinibSerine/threonine-protein kinase tousled-like 1
FostamatinibSerine/threonine-protein kinase tousled-like 2
FostamatinibTRAF2 and NCK-interacting protein kinase
FostamatinibNon-receptor tyrosine-protein kinase TNK1
FostamatinibActivated CDC42 kinase 1
FostamatinibSerine/threonine-protein kinase TNNI3K
FostamatinibTestis-specific serine/threonine-protein kinase 1
FostamatinibDual specificity protein kinase TTK
FostamatinibTyrosine-protein kinase TXK
FostamatinibTyrosine-protein kinase receptor TYRO3
FostamatinibSerine/threonine-protein kinase ULK1
FostamatinibSerine/threonine-protein kinase ULK2
FostamatinibSerine/threonine-protein kinase ULK3
FostamatinibWee1-like protein kinase
FostamatinibTyrosine-protein kinase Yes
FostamatinibMitogen-activated protein kinase kinase kinase 19
FostamatinibMitogen-activated protein kinase kinase kinase MLT
FostamatinibTyrosine-protein kinase ZAP-70
FostamatinibAP2-associated protein kinase 1
FostamatinibAbelson tyrosine-protein kinase 2
FostamatinibActivin receptor type-1
FostamatinibActivin receptor type-1B
FostamatinibAtypical kinase COQ8B, mitochondrial
FostamatinibALK tyrosine kinase receptor
FostamatinibAnkyrin repeat and protein kinase domain-containing protein 1
FostamatinibAurora kinase A
FostamatinibAurora kinase B
FostamatinibAurora kinase C
FostamatinibTyrosine-protein kinase receptor UFO
FostamatinibTyrosine-protein kinase Blk
FostamatinibBMP-2-inducible protein kinase
FostamatinibBone morphogenetic protein receptor type-1B
FostamatinibBone morphogenetic protein receptor type-2
FostamatinibCytoplasmic tyrosine-protein kinase BMX
FostamatinibSerine/threonine-protein kinase B-raf
FostamatinibTyrosine-protein kinase BTK
FostamatinibCalcium/calmodulin-dependent protein kinase type 1
FostamatinibCalcium/calmodulin-dependent protein kinase type 1D
FostamatinibCalcium/calmodulin-dependent protein kinase type 1G
FostamatinibCalcium/calmodulin-dependent protein kinase type II subunit alpha
FostamatinibCalcium/calmodulin-dependent protein kinase type II subunit beta
FostamatinibCalcium/calmodulin-dependent protein kinase type II subunit delta
FostamatinibCalcium/calmodulin-dependent protein kinase type II subunit gamma
FostamatinibCalcium/calmodulin-dependent protein kinase kinase 1
FostamatinibCalcium/calmodulin-dependent protein kinase kinase 2
FostamatinibPeripheral plasma membrane protein CASK
FostamatinibKappa-casein
FostamatinibCyclin-dependent kinase 1
FostamatinibSerine/threonine-protein kinase MRCK gamma
FostamatinibCyclin-dependent kinase 4
FostamatinibCyclin-dependent kinase-like 1
FostamatinibCyclin-dependent kinase-like 2
FostamatinibSerine/threonine-protein kinase Chk1
FostamatinibSerine/threonine-protein kinase Chk2
FostamatinibCitron Rho-interacting kinase
FostamatinibDual specificity protein kinase CLK1
FostamatinibDual specificity protein kinase CLK2
FostamatinibDual specificity protein kinase CLK3
FostamatinibDual specificity protein kinase CLK4
FostamatinibMacrophage colony-stimulating factor 1 receptor
FostamatinibTyrosine-protein kinase CSK
FostamatinibCasein kinase I isoform alpha
FostamatinibCasein kinase II subunit alpha
FostamatinibCasein kinase II subunit alpha'
FostamatinibDeath-associated protein kinase 1
FostamatinibDeath-associated protein kinase 2
FostamatinibDeath-associated protein kinase 3
FostamatinibSerine/threonine-protein kinase DCLK1
FostamatinibSerine/threonine-protein kinase DCLK2
FostamatinibSerine/threonine-protein kinase DCLK3
FostamatinibEpithelial discoidin domain-containing receptor 1
FostamatinibDiscoidin domain-containing receptor 2
FostamatinibDual specificity tyrosine-phosphorylation-regulated kinase 1A
FostamatinibDual specificity tyrosine-phosphorylation-regulated kinase 1B
FostamatinibEpidermal growth factor receptor
FostamatinibEukaryotic translation initiation factor 2-alpha kinase 1
FostamatinibInterferon-induced, double-stranded RNA-activated protein kinase
FostamatinibeIF-2-alpha kinase GCN2
FostamatinibEphrin type-A receptor 1
FostamatinibEphrin type-A receptor 2
FostamatinibEphrin type-A receptor 3
FostamatinibEphrin type-A receptor 4
FostamatinibEphrin type-A receptor 5
FostamatinibEphrin type-A receptor 6
FostamatinibEphrin type-A receptor 7
FostamatinibEphrin type-A receptor 8
FostamatinibEphrin type-B receptor 1
FostamatinibEphrin type-B receptor 2
FostamatinibEphrin type-B receptor 4
FostamatinibEphrin type-B receptor 6
FostamatinibReceptor tyrosine-protein kinase erbB-2
FostamatinibReceptor tyrosine-protein kinase erbB-4
FostamatinibSerine/threonine-protein kinase/endoribonuclease IRE1
FostamatinibTyrosine-protein kinase Fer
FostamatinibTyrosine-protein kinase Fes/Fps
FostamatinibFibroblast growth factor receptor 1
FostamatinibFibroblast growth factor receptor 2
FostamatinibFibroblast growth factor receptor 3
FostamatinibTyrosine-protein kinase Fgr
FostamatinibVascular endothelial growth factor receptor 1
FostamatinibReceptor-type tyrosine-protein kinase FLT3
FostamatinibVascular endothelial growth factor receptor 3
FostamatinibSerine/threonine-protein kinase mTOR
FostamatinibTyrosine-protein kinase FRK
FostamatinibTyrosine-protein kinase Fyn
FostamatinibCyclin-G-associated kinase
FostamatinibGlycogen synthase kinase-3 alpha
FostamatinibGlycogen synthase kinase-3 beta
FostamatinibTyrosine-protein kinase HCK
FostamatinibHomeodomain-interacting protein kinase 2
FostamatinibHomeodomain-interacting protein kinase 3
FostamatinibSerine/threonine-protein kinase ICK
FostamatinibInhibitor of nuclear factor kappa-B kinase subunit beta
FostamatinibInhibitor of nuclear factor kappa-B kinase subunit epsilon
FostamatinibInsulin receptor
FostamatinibInsulin receptor-related protein
FostamatinibInterleukin-1 receptor-associated kinase 1
FostamatinibInterleukin-1 receptor-associated kinase 3
FostamatinibInterleukin-1 receptor-associated kinase 4
FostamatinibTyrosine-protein kinase ITK/TSK
FostamatinibTyrosine-protein kinase JAK2
FostamatinibTyrosine-protein kinase JAK3
FostamatinibVascular endothelial growth factor receptor 2
FostamatinibSerine/threonine-protein kinase SIK3
FostamatinibMast/stem cell growth factor receptor Kit
FostamatinibSerine/threonine-protein kinase LATS1
FostamatinibTyrosine-protein kinase Lck
FostamatinibLIM domain kinase 1
FostamatinibLIM domain kinase 2
FostamatinibLeucine-rich repeat serine/threonine-protein kinase 2
FostamatinibLeukocyte tyrosine kinase receptor
FostamatinibTyrosine-protein kinase Lyn
FostamatinibDual specificity mitogen-activated protein kinase kinase 2
FostamatinibDual specificity mitogen-activated protein kinase kinase 3
FostamatinibDual specificity mitogen-activated protein kinase kinase 5
FostamatinibDual specificity mitogen-activated protein kinase kinase 6
FostamatinibMitogen-activated protein kinase kinase kinase 1
FostamatinibMitogen-activated protein kinase kinase kinase 10
FostamatinibMitogen-activated protein kinase kinase kinase 11
FostamatinibMitogen-activated protein kinase kinase kinase 12
FostamatinibMitogen-activated protein kinase kinase kinase 13
FostamatinibMitogen-activated protein kinase kinase kinase 15
FostamatinibMitogen-activated protein kinase kinase kinase 2
FostamatinibMitogen-activated protein kinase kinase kinase 3
FostamatinibMitogen-activated protein kinase kinase kinase 4
FostamatinibMitogen-activated protein kinase kinase kinase 6
FostamatinibMitogen-activated protein kinase kinase kinase 9
FostamatinibMitogen-activated protein kinase kinase kinase kinase 1
FostamatinibMitogen-activated protein kinase kinase kinase kinase 2
FostamatinibMitogen-activated protein kinase kinase kinase kinase 3
FostamatinibMitogen-activated protein kinase kinase kinase kinase 4
FostamatinibMitogen-activated protein kinase kinase kinase kinase 5
FostamatinibMitogen-activated protein kinase 10
FostamatinibMitogen-activated protein kinase 13
FostamatinibMitogen-activated protein kinase 14
FostamatinibMitogen-activated protein kinase 15
FostamatinibMitogen-activated protein kinase 4
FostamatinibMitogen-activated protein kinase 7
FostamatinibMitogen-activated protein kinase 9
FostamatinibMAP kinase-activated protein kinase 5
FostamatinibSerine/threonine-protein kinase MARK1
FostamatinibSerine/threonine-protein kinase MARK2
FostamatinibMAP/microtubule affinity-regulating kinase 3
FostamatinibMAP/microtubule affinity-regulating kinase 4
FostamatinibCLIP-associating protein 1
FostamatinibMicrotubule-associated serine/threonine-protein kinase 1
FostamatinibMegakaryocyte-associated tyrosine-protein kinase
FostamatinibMaternal embryonic leucine zipper kinase
FostamatinibTyrosine-protein kinase Mer
FostamatinibMisshapen-like kinase 1
FostamatinibMAP kinase-interacting serine/threonine-protein kinase 1
FostamatinibMAP kinase-interacting serine/threonine-protein kinase 2
FostamatinibMacrophage-stimulating protein receptor
FostamatinibMuscle, skeletal receptor tyrosine-protein kinase
FostamatinibMyosin light chain kinase, smooth muscle
FostamatinibMyosin light chain kinase 2, skeletal/cardiac muscle
FostamatinibMyosin light chain kinase 3
FostamatinibMyosin light chain kinase family member 4
FostamatinibMyosin-IIIa
FostamatinibSerine/threonine-protein kinase Nek1
FostamatinibSerine/threonine-protein kinase Nek11
FostamatinibSerine/threonine-protein kinase Nek2
FostamatinibSerine/threonine-protein kinase Nek3
FostamatinibSerine/threonine-protein kinase Nek4
FostamatinibSerine/threonine-protein kinase Nek5
FostamatinibSerine/threonine-protein kinase Nek9
FostamatinibHigh affinity nerve growth factor receptor
FostamatinibBDNF/NT-3 growth factors receptor
FostamatinibNT-3 growth factor receptor
FostamatinibNUAK family SNF1-like kinase 1
FostamatinibNUAK family SNF1-like kinase 2
FostamatinibSerine/threonine-protein kinase OSR1
FostamatinibSerine/threonine-protein kinase PAK 1
FostamatinibSerine/threonine-protein kinase PAK 2
FostamatinibSerine/threonine-protein kinase PAK 3
FostamatinibSerine/threonine-protein kinase PAK 4
FostamatinibSerine/threonine-protein kinase PAK 6
FostamatinibSerine/threonine-protein kinase PAK 5
FostamatinibCyclin-dependent kinase 16
FostamatinibCyclin-dependent kinase 17
FostamatinibPlatelet-derived growth factor receptor alpha
FostamatinibPlatelet-derived growth factor receptor beta
Fostamatinib3-phosphoinositide-dependent protein kinase 1
FostamatinibCyclin-dependent kinase 15
FostamatinibPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform
FostamatinibPhosphatidylinositol 4-kinase beta
FostamatinibPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta
FostamatinibPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma
FostamatinibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
FostamatinibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
FostamatinibSerine/threonine-protein kinase pim-1
FostamatinibSerine/threonine-protein kinase pim-3
FostamatinibPhosphatidylinositol 5-phosphate 4-kinase type-2 beta
FostamatinibPhosphatidylinositol 5-phosphate 4-kinase type-2 gamma
FostamatinibMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase
FostamatinibSerine/threonine-protein kinase N1
FostamatinibSerine/threonine-protein kinase N2
FostamatinibSerine/threonine-protein kinase PLK1
FostamatinibSerine/threonine-protein kinase PLK2
FostamatinibSerine/threonine-protein kinase PLK3
FostamatinibSerine/threonine-protein kinase PLK4
Fostamatinib5'-AMP-activated protein kinase catalytic subunit alpha-1
Fostamatinib5'-AMP-activated protein kinase
FostamatinibcAMP-dependent protein kinase catalytic subunit beta
FostamatinibProtein kinase C delta type
FostamatinibProtein kinase C epsilon type
FostamatinibProtein kinase C gamma type (PRKCG)
FostamatinibProtein kinase C iota type
FostamatinibProtein kinase C theta type
FostamatinibSerine/threonine-protein kinase D1
FostamatinibcGMP-dependent protein kinase 2
FostamatinibSerine/threonine-protein kinase PRP4 homolog
FostamatinibFocal adhesion kinase 1
FostamatinibProtein-tyrosine kinase 2-beta
FostamatinibProtein-tyrosine kinase 6
FostamatinibRAF proto-oncogene serine/threonine-protein kinase
FostamatinibProto-oncogene tyrosine-protein kinase receptor Ret
FostamatinibSerine/threonine-protein kinase RIO1
FostamatinibSerine/threonine-protein kinase RIO2
FostamatinibSerine/threonine-protein kinase RIO3
FostamatinibReceptor-interacting serine/threonine-protein kinase 1
FostamatinibReceptor-interacting serine/threonine-protein kinase 2
FostamatinibReceptor-interacting serine/threonine-protein kinase 4
FostamatinibRho-associated protein kinase 2
FostamatinibProto-oncogene tyrosine-protein kinase ROS
FostamatinibRibosomal protein S6 kinase alpha-1
FostamatinibRibosomal protein S6 kinase alpha-3
FostamatinibSerine/threonine-protein kinase SBK1
FostamatinibUncharacterized serine/threonine-protein kinase SBK3
FostamatinibSerine/threonine-protein kinase Sgk3
FostamatinibSerine/threonine-protein kinase SIK1
FostamatinibSerine/threonine-protein kinase SIK2
FostamatinibSTE20-like serine/threonine-protein kinase
FostamatinibSNF-related serine/threonine-protein kinase
FostamatinibProto-oncogene tyrosine-protein kinase Src
FostamatinibTyrosine-protein kinase Srms
FostamatinibSerine/threonine-protein kinase 10
FostamatinibSerine/threonine-protein kinase 16
FostamatinibSerine/threonine-protein kinase 17A
FostamatinibSerine/threonine-protein kinase 17B
FostamatinibSerine/threonine-protein kinase 32A
Start DateDrugTitlePurposePhaseStatusIdentifier
2021-06-15Acetylsalicylic acidLow Dose Aspirin in Moderate to Severe SARS- CoV-2 Infected Patients : A Pilot Randomized Controlled TrialTreatmentNot AvailableActive Not RecruitingCTRI/2020/08/027503
2021-03-01Human Umbilical Cord Mesenchymal Stem CellsPhase I, Randomized, Double Blinded, Placebo Control Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 With Moderate to Severe SymptomsTreatment1Active Not RecruitingNCT04490486
2021-01-10BudesonideOlfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled TrialTreatment4Active Not RecruitingNCT04374474
2021-01-01ChulaCov19 mRNA vaccineA Phase 1 / 2, Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of the ChulaCov19 mRNA Vaccine in Healthy AdultsTreatment1Active Not RecruitingNCT04566276
2020-12-01Human Umbilical Cord Mesenchymal Stem CellsA Phase 1 Study of the Safety and Tolerability of BX-U001 for the Treatment of Severe COVID-19 Pneumonia With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS).Treatment1Active Not RecruitingNCT04452097
2020-12-01Anti-SARS-CoV-2 immunoglobulinTREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19 : A PHASE I / II STUDYTreatment1, 2Active Not RecruitingNCT04573855
2020-12-01NiclosamidePhase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and SymptomsTreatment2Active Not RecruitingNCT04436458
2020-12-01CholecalciferolProof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19Treatment4Active Not RecruitingNCT04565392
2020-12-01Ascorbic acidProof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19Treatment4Active Not RecruitingNCT04565392
2020-12-01FamotidineProof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19Treatment4Active Not RecruitingNCT04565392
2020-12-01NitazoxanideA Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)Treatment2Active Not RecruitingNCT04563208
2020-12-01RibavirinA Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)Treatment2Active Not RecruitingNCT04563208
2020-12-01SofosbuvirA Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2Prevention2Active Not RecruitingNCT04561063
2020-12-01NitazoxanideA Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2Prevention2Active Not RecruitingNCT04561063
2020-12-01DaclatasvirA Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2Prevention2Active Not RecruitingNCT04561063
2020-12-01COVID-19 convalescent plasmaAssessment of the Safety and Efficacy of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above IllnessTreatment1, 2Active Not RecruitingNCT04521036
2020-12-01Nitric OxideRandomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental OxygenTreatment2Active Not RecruitingNCT04398290
2020-12-01ArtesunateEvaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19Treatment2Active Not RecruitingNCT04387240
2020-12-01ArtemisininEvaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19Treatment2Active Not RecruitingNCT04387240
2020-12-01IsotretinoinEvaluation of the Safety and Efficacy of Isotretinoin in Treatment of COVID-19 : Clinical StudyTreatment3Active Not RecruitingNCT04361422
2020-12-01IN01Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC)Treatment1Active Not RecruitingNCT04537130
2020-12-01Tranexamic acidAntiviral Effects of Tranexamic Acid (TXA) as a Preventative Treatment Following COVID-19 ExposurePrevention3Active Not RecruitingNCT04550338
2020-12-01Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsA Phase I / ?a Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 PneumoniaTreatment1, 2Active Not RecruitingNCT04527224
2020-12-01FisetinCOVID-FIS : A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing HomesTreatment2Active Not RecruitingNCT04537299
2020-11-30RAPA-501-AlloPhase I / Phase II Trial of Off-the-Shelf Allogeneic Hybrid TREG / Th2 Cell (RAPA-501-ALLO) Therapy for Severe, Post-Intubation Stage 3 COVID-19 DiseaseTreatment1, 2Active Not RecruitingNCT04482699
2020-11-19Rubella virus vaccineInvestigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control groupTreatment3Active Not RecruitingIRCT20200802048266N1
2020-11-19Mumps virus strain B level jeryl lynn live antigenInvestigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control groupTreatment3Active Not RecruitingIRCT20200802048266N1
2020-11-19Measles virus vaccine live attenuatedInvestigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control groupTreatment3Active Not RecruitingIRCT20200802048266N1
2020-11-14KBP-COVID-19A Phase I / II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-COVID-19 Vaccine in Healthy Seronegative Adults Aged 18-49 and 50-70Prevention1, 2Active Not RecruitingNCT04473690
2020-11-13Trefoil Factor 2Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK / PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patientsTreatment0Active Not RecruitingChiCTR2000035633
2020-11-13Interferon KappaClinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK / PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patientsTreatment0Active Not RecruitingChiCTR2000035633
2020-11-01Angiotensin 1-7A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized PatientsTreatment1, 2Active Not RecruitingNCT04570501
2020-11-01RavulizumabC5 Complement Inhbition Using Ravulizumab for the Treatment of COVID-19 Induced Thrombotic MicroangiopathyTreatment3Active Not RecruitingNCT04570397
2020-11-01DexamethasoneA Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Study Evaluating AVM0703 in Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04366115
2020-11-01PH94BA Phase 2a Open-label Study of the Efficacy and Safety of PRN PH94B Neuroactive Nasal Spray in the Treatment of Adjustment Disorder With Anxiety (AjDA) Associated With COVID-19Treatment2Active Not RecruitingNCT04404192
2020-11-01UlinastatinA Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Ulinastatin for the Treatment of COVID-19 in Hospitalized PatientsTreatment1, 2Active Not RecruitingNCT04393311
2020-11-01BicalutamideA Phase II Trial to Promote Recovery From COVID-19 With Endocrine TherapyTreatment2Active Not RecruitingNCT04374279
2020-11-01RuxolitinibSafety and Efficacy of Ruxolitinib for COVID-19Treatment2, 3Active Not RecruitingNCT04348071
2020-11-01BaricitinibSafety and Efficacy of Baricitinib for COVID-19Treatment2, 3Active Not RecruitingNCT04340232
2020-11-01QuetiapineA Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated DeliriumTreatment4Active Not RecruitingNCT04513314
2020-11-01Valproic acidA Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated DeliriumTreatment4Active Not RecruitingNCT04513314
2020-11-01NiclosamideA Phase 2 Randomized Double Blind, Placebo-controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19Treatment2Active Not RecruitingNCT04542434
2020-11-01Oral Polio VaccineA Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19Prevention3Active Not RecruitingNCT04540185
2020-11-01BrexanoloneA Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19Treatment3Active Not RecruitingNCT04537806
2020-11-01CornA Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka® Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRCPreventionNot AvailableActive Not RecruitingNCT04537585
2020-11-01Cultivated mushroomA Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka® Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRCPreventionNot AvailableActive Not RecruitingNCT04537585
2020-11-01SoybeanA Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka® Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRCPreventionNot AvailableActive Not RecruitingNCT04537585
2020-11-01IsoquercetinAn Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19)Treatment2Active Not RecruitingNCT04536090
2020-11-01ArtesunateMalaria as a risk factor for COVID-19 in western Kenya and Burkina FasoTreatment3Active Not RecruitingPACTR202009642148520
2020-11-01PyronaridineMalaria as a risk factor for COVID-19 in western Kenya and Burkina FasoTreatment3Active Not RecruitingPACTR202009642148520
2020-11-01RitonavirA Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir / Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last YearTreatment2Active Not RecruitingNCT04455958
2020-11-01LopinavirA Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir / Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last YearTreatment2Active Not RecruitingNCT04455958
2020-10-31NitrogenPhase 1b Safety Trial for S-Nitrosylation Therapy to Treat COVID-19 Induced Respiratory DistressTreatment1Active Not RecruitingNCT04528771
2020-10-31Tranexamic acidA Phase 2 Study to Evaluate LB1148 for the Treatment of Pulmonary Dysfunction Associated With COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04390217
2020-10-31Efineptakin alfaA Phase I and Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2Treatment1Active Not RecruitingNCT04498325
2020-10-31ChlorpromazineEvaluation of efficacy and safety of adding Chlorpromazine to Atazanavir / Ritonavir regimen in the treatment of COVID-19 patients, a randomized double-blind clinical trialTreatment2Active Not RecruitingIRCT20200913048708N1
2020-10-31LanadelumabA Phase 1b, Randomized, Double-blind, Single and Repeat Dosing Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab When Added to Standard-of-Care in Subjects Hospitalized With COVID-19 PneumoniaTreatment1Active Not RecruitingNCT04460105
2020-10-30Virus Specific T-CellBAT IT : Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19Treatment1Active Not RecruitingNCT04401410
2020-10-30LinagliptinEffects of DPP4 Inhibition on COVID-19 Patients With Type 2 DiabetesTreatment4Active Not RecruitingNCT04341935
2020-10-30BGB-DXP593A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19Treatment2Active Not RecruitingNCT04551898
2020-10-30Human Umbilical Cord Mesenchymal Stem CellsUmbilical cord-derived mesenchymal stromal cells therapy for SARS-CoV-2 infection (COVID-19) related Acute Respiratory Distress SyndromeTreatment1Active Not RecruitingJPRN-JapicCTI-205465
2020-10-27LenalidomideDouble-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 DiseaseTreatment4Active Not RecruitingNCT04361643
2020-10-26SomatotropinThe Impact of Growth Hormone in Obese Cases With Covid-19Treatment4Active Not RecruitingNCT04532554
2020-10-22V590A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy AdultsPrevention1Active Not RecruitingNCT04569786
2020-10-22TranscrocetinateEvaluation of trans sodium crocetinate spray against on mild to moderate ARDS induced by COVID-19 patients : A Randomized Open label Clinical TrialTreatment2Active Not RecruitingIRCT20081019001369N7
2020-10-20AdalimumabAdalimumab in COVID-19 to prevent respiratory failure in community care (AVID-CC) : A randomised controlled trialTreatment2Active Not RecruitingISRCTN33260034
2020-10-20Anti-SARS-CoV-2 equine immunoglobulin fragmentsPilot Study to Evaluate Safety and Efficacy of Anti-SARS-CoV-2 Equine Immunoglobulin F(ab')2 Fragments (INOSARS) in Hospitalized Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04514302
2020-10-19TocilizumabTocilizumab for the treatment of COVID-19 in intensive care patients : effect on days free of ventilatory support.Treatment1, 2Active Not RecruitingACTRN12620000580976
2020-10-15AlteplaseTissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS) : A Multicentral Randomized Trial (AtTAC-trial)Treatment3Active Not RecruitingNCT04453371
2020-10-15AtazanavirRandomized Controlled Phase 2 / 3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 InfectionPrevention2, 3Active Not RecruitingNCT04452565
2020-10-15DexamethasoneRandomized Controlled Phase 2 / 3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 InfectionPrevention2, 3Active Not RecruitingNCT04452565
2020-10-15Povidone-iodineA Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19Prevention4Active Not RecruitingNCT04517188
2020-10-10Nitric OxideInhaled Nitric Oxide for Treatment of SARS-CoV-2 Infection : An Open-Label, Multicenter, Parallel, Randomized Controlled TrialTreatment2Active Not RecruitingRBR-8nfx26
2020-10-09F-652A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22 : IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19Treatment2Active Not RecruitingNCT04498377
2020-10-07DaclatasvirAntiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOnTreatment2, 3Active Not RecruitingNCT04468087
2020-10-07AtazanavirAntiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOnTreatment2, 3Active Not RecruitingNCT04468087
2020-10-07SofosbuvirAntiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOnTreatment2, 3Active Not RecruitingNCT04468087
2020-10-07AcalabrutinibA 2-Part, Phase I, Open-label, Single-dose, Sequential, Randomized, Crossover Study of Acalabrutinib Tablet Suspension Delivered Via Nasogastric Tube in Healthy Subjects to Evaluate Relative Bioavailability and Proton-pump Inhibitor (Rabeprazole) EffectTreatment1Active Not RecruitingNCT04564040
2020-10-07DexamethasoneEfficacy of Dexamethasone Treatment for Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19)Treatment4Active Not RecruitingNCT04545242
2020-10-06MosedipimodPhase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDSTreatment2Active Not RecruitingNCT04569227
2020-10-06PiclidenosonPiclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled TrialTreatment2Active Not RecruitingNCT04333472
2020-10-06NiclosamidePhase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 PatientsTreatment1Active Not RecruitingNCT04541485
2020-10-05IvermectinA randomized double-blind placebo-controlled trial of oral ivermectin outpatient treatment, to prevent hospitalisation, of those at high risk for hospitalization due to SARS-CoV-2 (COVID-19)Treatment3Active Not RecruitingACTRN12620000982910
2020-10-05COVID-19 convalescent plasmaVA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1)Treatment3Active Not RecruitingNCT04539275
2020-10-03LanadelumabLanadelumab for Treatment of COVID-19 DiseaseTreatment1, 2Active Not RecruitingNCT04422509
2020-10-01HydroxychloroquineThe Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomized, placebo-controlled prophylaxis study (COPCOV)Treatment3Active Not RecruitingPACTR202009786901147
2020-10-01MVA-SARS-2-SAn Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-SPrevention1Active Not RecruitingNCT04569383
2020-10-01TafenoquineA Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 DiseaseTreatment2Active Not RecruitingNCT04533347
2020-10-01IvermectinOutpatient Use of Ivermectin in COVID-19Treatment3Active Not RecruitingNCT04530474
2020-10-01DipyridamoleA Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 InfectionTreatment3Active Not RecruitingNCT04410328
2020-10-01Acetylsalicylic acidA Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 InfectionTreatment3Active Not RecruitingNCT04410328
2020-10-01TretinoinAerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative TreatmentTreatment2Active Not RecruitingNCT04396067
2020-10-01MontelukastRepurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms : The COvid-19 Symptom MOntelukast (COSMO) TrialTreatment3Active Not RecruitingNCT04389411
2020-10-01HeparinInterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)Treatment4Active Not RecruitingNCT04406389
2020-10-01FondaparinuxInterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)Treatment4Active Not RecruitingNCT04406389
2020-10-01ArgatrobanInterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)Treatment4Active Not RecruitingNCT04406389
2020-10-01EnoxaparinInterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)Treatment4Active Not RecruitingNCT04406389
2020-10-01HydroxychloroquinePROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT)Treatment2, 3Active Not RecruitingISRCTN88057279
2020-10-01ZincEffect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical TrialTreatment3Active Not RecruitingNCT04392427
2020-10-01NitazoxanideEffect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical TrialTreatment3Active Not RecruitingNCT04392427
2020-10-01RibavirinEffect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical TrialTreatment3Active Not RecruitingNCT04392427
2020-10-01IvermectinEffect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical TrialTreatment3Active Not RecruitingNCT04392427
2020-10-01HydroxychloroquineHydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia TrialTreatment4Active Not RecruitingNCT04382625
2020-10-01AstraZeneca COVID-19 VaccineA phase Ib / II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya (COV004)Treatment1Active Not RecruitingPACTR202005681895696
2020-10-01Remestemcel-LProspective Phase II Study : MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDSTreatment2Active Not RecruitingNCT04377334
2020-10-01LinagliptinEfficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19Treatment3Active Not RecruitingNCT04371978
2020-10-01Ascorbic acidEarly Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (EVICT-CORONA-ALI)Treatment2Active Not RecruitingNCT04344184
2020-10-01BacTRL-spikeA Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy AdultsPrevention1Active Not RecruitingNCT04334980
2020-10-01Acetylsalicylic acidAspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial TrialTreatment3Active Not RecruitingNCT04343001
2020-10-01SimvastatinAspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial TrialTreatment3Active Not RecruitingNCT04343001
2020-10-01LosartanAspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial TrialTreatment3Active Not RecruitingNCT04343001
2020-10-01Zinc gluconateRandomized, Double -Blind, Placebo Controlled, Trial to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMUSupportive CareNot AvailableActive Not RecruitingNCT04558424
2020-10-01Ascorbic acidRandomized, Double -Blind, Placebo Controlled, Trial to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMUSupportive CareNot AvailableActive Not RecruitingNCT04558424
2020-10-01EdoxabanEfficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital SettingTreatment3Active Not RecruitingNCT04516941
2020-10-01ColchicineEfficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital SettingTreatment3Active Not RecruitingNCT04516941
2020-10-01SirolimusEffects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of Acute Respiratory Distress Syndrome (RAPA-CARDS)Treatment1, 2Active Not RecruitingNCT04482712
2020-10-01EthanolDisinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin .Treatment3Active Not RecruitingNCT04554433
2020-10-01Acetylsalicylic acidDisinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin .Treatment3Active Not RecruitingNCT04554433
2020-10-01CamostatA Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild COVID-19Treatment2Active Not RecruitingNCT04524663
2020-10-01OxygenMulticentre Randomized Controlled Trial of Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 PatientsTreatment2, 3Active Not RecruitingNCT04500626
2020-10-01HeparinCan Nebulised HepArin Reduce morTality and Time to Extubation in Patients With COVID-19 Requiring Mechanical Ventilation Meta-Trial (CHARTER-MT) : Protocol for an Investigator-initiated International Meta-trial of Randomised StudiesTreatment2, 3Active Not RecruitingNCT04545541
2020-10-01EthinylestradiolEstrogen Therapy in Non-severe COVID-19 Patients : Proposed Treatment Scheme in a Tertiary HospitalTreatmentNot AvailableActive Not RecruitingNCT04539626
2020-10-01NorelgestrominEstrogen Therapy in Non-severe COVID-19 Patients : Proposed Treatment Scheme in a Tertiary HospitalTreatmentNot AvailableActive Not RecruitingNCT04539626
2020-10-01RivaroxabanEffect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT)Treatment2Active Not RecruitingEUCTR2020-002282-33-DE
2020-10-01AlvelestatA Phase Ib / II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)Treatment1, 2Active Not RecruitingNCT04539795
2020-10-01AlprostadilEffectiveness and Safety of the Administration of Intravenous Prostaglandin E1 Analog in the Reduction of Mortality and Complications of Patients With COVID-19Treatment2Active Not RecruitingNCT04536363
2020-10-01COVID-19 convalescent plasmaPhase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 InfectionTreatment2Active Not RecruitingNCT04456413
2020-09-30EpigallocatechinA Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Protect Health Workers Against COVID-19 by Using Previfenon® as Chemoprophylaxis During a SARS-CoV-2 Outbreak. The HERD StudyPrevention2, 3Active Not RecruitingNCT04446065
2020-09-30Tranexamic acidExploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in InpatientsTreatment2Active Not RecruitingNCT04338126
2020-09-30COVID-19 convalescent plasmaA Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized ChildrenTreatment2Active Not RecruitingNCT04377568
2020-09-30DuvelisibA Pilot Study of Duvelisib to Combat COVID-19Treatment2Active Not RecruitingNCT04372602
2020-09-30Angiotensin 1-7Angiotensin-(1,7) Treatment in COVID-19 : the ATCO TrialTreatment2, 3Active Not RecruitingNCT04332666
2020-09-30BucillamineMulti-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19Treatment3Active Not RecruitingNCT04504734
2020-09-30CoVac-1P-pVAC-SARS-CoV-2 : Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in AdultsPrevention1Active Not RecruitingNCT04546841
2020-09-30IfenprodilAN OPEN LABEL PHYSICIAN INITIATED 28 DAY PHASE 2A STUDY OF IFENPRODIL ON LUNG FUNCTION IN CONFIRMED COVID-19 INFECTED PATIENTS WITH SEVERE PNEUMONIATreatment2Active Not RecruitingKCT0005307
2020-09-30Anti-SARS-CoV-2 immunoglobulinAn International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19 - Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)Treatment3Active Not RecruitingEUCTR2020-002542-16-GB
2020-09-29NasoVAXPhase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04442230
2020-09-29Ad5-nCoVA Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and OlderPrevention1Active Not RecruitingNCT04552366
2020-09-29CK0802Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)Treatment1Active Not RecruitingNCT04468971
2020-09-28CitrullineProspective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) IllnessTreatment2Active Not RecruitingNCT04570384
2020-09-28Gam-COVID-Vac?linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-?oV-2 Infection Prophylactic Treatment in Republic of BelarusPrevention3Active Not RecruitingNCT04564716
2020-09-28ZincZinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic : A Randomized StudyTreatmentNot AvailableActive Not RecruitingNCT04551339
2020-09-28NiclosamideA Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)Treatment3Active Not RecruitingNCT04558021
2020-09-28Inactivated SARS-Cov-2 VaccineA Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 YearsPrevention1, 2Active Not RecruitingNCT04551547
2020-09-26Ad5-nCoVThe Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 YearsPrevention1Active Not RecruitingNCT04568811
2020-09-25UB-612A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult VolunteersPrevention1Active Not RecruitingNCT04545749
2020-09-25DapansutrileA Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release SyndromeTreatment2Active Not RecruitingNCT04540120
2020-09-25TenecteplaseTenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19Treatment2Active Not RecruitingNCT04505592
2020-09-25MolgramostimGranulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia - GI-COVIDTreatment2Active Not RecruitingEUCTR2020-001654-21-DE
2020-09-25HydroxychloroquineEvaluation of safety and efficacy of post exposure prophylaxis with hydroxychloroquine aiming at prevention of COVID-19 for medical care workersTreatment1Active Not RecruitingJPRN-jRCTs051200060
2020-09-25OzoneEstudo Multicentrico da prática Integrativa e complementar de Ozonioterapia em pacientes ambulatoriais com Covid- 19Treatment1, 2Active Not RecruitingRBR-97nt6j
2020-09-24MolgramostimGranulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)Treatment2Active Not RecruitingNCT04569877
2020-09-24Ad5-nCoVA Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOVPrevention2Active Not RecruitingNCT04566770
2020-09-24LopinavirFavipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19Treatment2Active Not RecruitingNCT04499677
2020-09-24FavipiravirFavipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19Treatment2Active Not RecruitingNCT04499677
2020-09-24RitonavirFavipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19Treatment2Active Not RecruitingNCT04499677
2020-09-23AcetylcysteineDetermination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe DiseaseTreatment4Active Not RecruitingNCT04419025
2020-09-23NVX-CoV2373A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United KingdomTreatment3Active Not RecruitingEUCTR2020-004123-16-GB
2020-09-22Tribulus terrestrisThe effect of herbal tea (including mallow flower, chicory seeds, sweet violet flower, Melilotus officinalis and Bindii) on improving respiratory symptoms in patients with Covid-19Treatment3Active Not RecruitingIRCT20200806048318N1
2020-09-22Melilotus officinalis pollenThe effect of herbal tea (including mallow flower, chicory seeds, sweet violet flower, Melilotus officinalis and Bindii) on improving respiratory symptoms in patients with Covid-19Treatment3Active Not RecruitingIRCT20200806048318N1
2020-09-22NoscapineEvaluation and comparison of the effectiveness of two herbal products containing Noscapine (Opiucough and Noscough) on clinical symptoms and para-clinical parameters in adults hospitalized with severe COVID-19Treatment2Active Not RecruitingIRCT20180103038199N3
2020-09-22COVID-19 convalescent plasmaEvaluation of Convalescent Plasma Therapy for COVID-19 PatientsTreatment0Active Not RecruitingIRCT20200503047281N1
2020-09-22CelecoxibEvaluation of short-term effects of Celecoxib on clinical improvement of COVID-19 patients : A randomized clinical trial studyTreatment1RecruitingIRCT20200907048644N1
2020-09-22Eucalyptus oilEvaluation of therapeutic effects of oral eucalyptus tablets on the treatment process of patients with Covid 19 infection.Treatment3Active Not RecruitingIRCT20200913048701N1
2020-09-22BromhexineVerification of the efficacy of Bromhexine-hydrochloride in treatment of patients with COVID19 diseaseTreatment3Active Not RecruitingIRCT20200818048444N1
2020-09-21AtazanavirA Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot StudyTreatment2Active Not RecruitingPACTR202008855701534
2020-09-21NitazoxanideA Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot StudyTreatment2Active Not RecruitingPACTR202008855701534
2020-09-21AcetylcysteineA Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 PatientsTreatment2, 3Active Not RecruitingNCT04573153
2020-09-21LevocarnitineA Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 PatientsTreatment2, 3Active Not RecruitingNCT04573153
2020-09-21Nicotinamide ribosideA Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 PatientsTreatment2, 3Active Not RecruitingNCT04573153
2020-09-21SerineA Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 PatientsTreatment2, 3Active Not RecruitingNCT04573153
2020-09-21MaravirocOpen-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2Treatment1Active Not RecruitingNCT04435522
2020-09-21RitonavirA Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot StudyTreatment2Active Not RecruitingNCT04459286
2020-09-21AtazanavirA Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot StudyTreatment2Active Not RecruitingNCT04459286
2020-09-21NitazoxanideA Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot StudyTreatment2Active Not RecruitingNCT04459286
2020-09-21COVID-19 convalescent plasmaA Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission : Co-CLARITY TrialTreatment2, 3Active Not RecruitingNCT04567173
2020-09-21COVID-19 convalescent plasmaA Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19Treatment3Active Not RecruitingNCT04516811
2020-09-21AntroquinonolA Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19Treatment2Active Not RecruitingNCT04523181
2020-09-21Biomodulin TSafety and effectiveness of BIOMODULINA T in a long-lived population at high risk of COVID-19 infection. Interventional Study (COVID-19)TreatmentNot AvailableActive Not RecruitingRPCEC00000335
2020-09-20Anti-SARS-CoV-2 immunoglobulinA Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19Treatment2Active Not RecruitingNCT04555148
2020-09-20Omega-3 fatty acidsImpact of Different Treatment Modalities on Immunity Against COVID-19Treatment2, 3Active Not RecruitingNCT04553705
2020-09-20QuinineImpact of Different Treatment Modalities on Immunity Against COVID-19Treatment2, 3Active Not RecruitingNCT04553705
2020-09-19QazCovid-inRandomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-IN®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and ElderPrevention1, 2Active Not RecruitingNCT04530357
2020-09-18Anti-SARS-CoV-2 IgYA Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)Prevention1Active Not RecruitingNCT04567810
2020-09-18LeflunomideA Phase 1 / 2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent MalignancyTreatment1, 2Active Not RecruitingNCT04532372
2020-09-18RemdesivirA Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient SettingTreatment3Active Not RecruitingNCT04501952
2020-09-18Ascorbic acidThe Effect of Melatonin and Vitamin C on COVID-19Supportive CareNot AvailableActive Not RecruitingNCT04530539
2020-09-18MelatoninThe Effect of Melatonin and Vitamin C on COVID-19Supportive CareNot AvailableActive Not RecruitingNCT04530539
2020-09-18CVnCoVCOVID-19 : A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of AgePrevention2Active Not RecruitingNCT04515147
2020-09-17FavipiravirAn Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia - An open-label randomized controlled study -Treatment3Active Not RecruitingEUCTR2020-002728-35-HU
2020-09-17FluvoxamineA randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-19 patientsTreatment2Active Not RecruitingEUCTR2020-002299-11-HU
2020-09-17Human immunoglobulin GA Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care UnitTreatment2Active Not RecruitingNCT04480424
2020-09-17COVID-19 convalescent plasmaStudy on the use of Convalescent plasma therapy as a COVID-19 treatment - Study on the use of Convalescent plasma therapy as a COVID-19 treatmentTreatmentNot AvailableActive Not RecruitingJPRN-jRCTs031200124
2020-09-16TofacitinibA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04469114
2020-09-16Inactivated SARS-Cov-2 VaccineRandomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 YearsPrevention3Active Not RecruitingNCT04560881
2020-09-16OzanimodA Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot TrialTreatment2Active Not RecruitingNCT04405102
2020-09-16IvermectinA placebo-controlled, randomized, double-blind study in COvid-19 patients with iveRmectin ; An inVEstigator iniTiaTEd trial - CORVETTE-01Treatment2Active Not RecruitingJPRN-jRCT2031200120
2020-09-15Conestat alfaRecombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 : a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)Treatment2Active Not RecruitingNCT04530136
2020-09-15CitrullineCACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress SyndromeTreatmentNot AvailableActive Not RecruitingNCT04404426
2020-09-15COVID-19 convalescent plasmaExpanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04338360
2020-09-15MVC-COV1901A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901Prevention1Active Not RecruitingNCT04487210
2020-09-15Ad5-nCoVA Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase ? Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and OlderPrevention3Active Not RecruitingNCT04526990
2020-09-15Prolectin-MEffect of Prolectin-M ; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers : A Proof of Concept, Open Label Randomized Controlled TrialTreatmentNot AvailableActive Not RecruitingNCT04512027
2020-09-15Human immunoglobulin GIntravenous Immunoglobulins for the Treatment of Covid-19 Patients : a Clinical TrialTreatment3Active Not RecruitingNCT04548557
2020-09-15HydroxychloroquineLocal Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers ; a Pilot StudyTreatment1Active Not RecruitingNCT04497519
2020-09-15Vitamin DA Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household MembersTreatment3Active Not RecruitingNCT04536298
2020-09-15Descartes-30Phase I / IIA Study of Descartes-30 in Acute Respiratory Distress SyndromeTreatment1, 2Active Not RecruitingNCT04524962
2020-09-15Human Amniotic FluidA Phase I / II Randomized Double-blinded Placebo-controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04497389
2020-09-15RemdesivirA Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy VolunteersTreatment1Active Not RecruitingNCT04480333
2020-09-14FavipiravirGlasgow Early Treatment Arm FavIpiravir : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patientsTreatment2Active Not RecruitingISRCTN31062548
2020-09-14DecitabineDecitabine for COVID-19 Pneumonia-ARDS Treatment : DART TrialTreatment2Active Not RecruitingNCT04482621
2020-09-14RemdesivirA Phase 1b / 2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by InhalationTreatment1, 2Active Not RecruitingNCT04539262
2020-09-14LopinavirA Pilot study platform to investigate the pharmacodynamics on QT-prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy volunteersTreatment2Active Not RecruitingEUCTR2020-002314-40-AT
2020-09-14RibavirinA Pilot study platform to investigate the pharmacodynamics on QT-prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy volunteersTreatment2Active Not RecruitingEUCTR2020-002314-40-AT
2020-09-14OnionEvaluation of safety and efficacy of T-AYU-HM Premium and Onion Steam vaporisation / nebulization in Covid-19 patients (mild to moderate)Treatment2Active Not RecruitingCTRI/2020/08/027477
2020-09-11Ad5-nCoVMulticenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult VolunteersPrevention3Active Not RecruitingNCT04540419
2020-09-11Bacillus calmette-guerin substrain danish 1331 live antigenUsing BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial.Prevention3Active Not RecruitingNCT04542330
2020-09-11Biomodulin TSafety and effectiveness of BIOMODULIN T in protective therapy in events of local transmission of COVID-19. Interventional Study (COVID-19)TreatmentNot AvailableActive Not RecruitingRPCEC00000334
2020-09-11Bacillus calmette-guerin substrain danish 1331 live antigenBCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial - BRACETreatment3Active Not RecruitingEUCTR2020-002503-19-GB
2020-09-11Remestemcel-LTherapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients : Randomized, Double-blind, and Placebo-controlledTreatment1Active Not RecruitingNCT04535856
2020-09-10TranscrocetinateOpen-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected SubjectsTreatment1, 2Active Not RecruitingNCT04573322
2020-09-10LopinavirCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2, 3Active Not RecruitingNCT04466241
2020-09-10RitonavirCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2, 3Active Not RecruitingNCT04466241
2020-09-10TelmisartanCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2, 3Active Not RecruitingNCT04466241
2020-09-10AtorvastatinCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2, 3Active Not RecruitingNCT04466241
2020-09-10ThymalfasinA Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With LymphocytopeniaTreatment2Active Not RecruitingNCT04487444
2020-09-10Dental Mesenchymal Pulp Stem CellsStudy the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia- A Phase 2&3 Clinical TrialTreatment2, 3RecruitingIRCT20140911019125N8
2020-09-10SofosbuvirA Multicentre, Quadruple-blind, Randomized, Parallel-group Study to Compare the Efficacy of Sofosbuvir and Daclatasvir vs. Placebo in the Outpatient Treatment of COVID-19 in adultsTreatment3RecruitingIRCT20200831048568N1
2020-09-10DaclatasvirA Multicentre, Quadruple-blind, Randomized, Parallel-group Study to Compare the Efficacy of Sofosbuvir and Daclatasvir vs. Placebo in the Outpatient Treatment of COVID-19 in adultsTreatment3RecruitingIRCT20200831048568N1
2020-09-10RavulizumabA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress SyndromeTreatment3RecruitingJPRN-jRCT2031200126
2020-09-10AstraZeneca COVID-19 VaccineA PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY IN ADULTS TO DETERMINE THE SAFETY, EFFICACY, AND IMMUNOGENICITY OF AZD1222, A NON-REPLICATING CHADOX1 VECTOR VACCINE, FOR THE PREVENTION OF COVID-19Treatment3Active Not RecruitingPER-059-20
2020-09-10CVnCoVCOVID-19 : A PHASE 2A, PARTIALLY OBSERVER-BLIND, MULTICENTER, CONTROLLED, DOSE-CONFIRMATION CLINICAL TRIAL TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE INVESTIGATIONAL SARS-COV-2 MRNA VACCINE CVNCOV IN ADULTS >60 YEARS OF AGE AND 18 TO 60 YEARS OF AGETreatment2Active Not RecruitingPER-054-20
2020-09-10TocilizumabCOVIDOSE-2 : A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive VentilationTreatment2Active Not RecruitingNCT04479358
2020-09-09Ascorbic acidTherapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial : The International ALLIANCE StudyTreatment2Active Not RecruitingNCT04395768
2020-09-09Avasopasem manganeseA Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)Treatment2Active Not RecruitingNCT04555096
2020-09-09BNT162b3A Multi-site, Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy AdultsPrevention1, 2Active Not RecruitingNCT04537949
2020-09-08ZofinA Phase I / II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs PlaceboTreatment1, 2Active Not RecruitingNCT04384445
2020-09-08Bardoxolone methylBARCONA : A Phase II / III, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)Treatment2, 3Active Not RecruitingNCT04494646
2020-09-08TenecteplaseLow-Dose Tenecteplase in Covid-19 Patients With Acture Pulmonary Embolism : A Randomized, Double-Blind, Placebo-Controlled TrialTreatment4Active Not RecruitingNCT04558125
2020-09-08TreamidMulticenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04527354
2020-09-08BGB-DXP593A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy SubjectsBasic Science1Active Not RecruitingNCT04532294
2020-09-08UmifenovirPhase 3, Randomized, Double-blind, Placebo control trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients.Treatment3Active Not RecruitingCTRI/2020/09/027535
2020-09-07IvermectinEffectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel at All Levels of Care, During the 2020 Pandemic : A Randomized Clinical Controled TrialPrevention3Active Not RecruitingNCT04527211
2020-09-07Gam-COVID-VacRandomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-?oV-2 Infection Prophylactic TreatmentPrevention3Active Not RecruitingNCT04530396
2020-09-07Janssen COVID-19 VaccineA Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and OlderPrevention3Active Not RecruitingNCT04505722
2020-09-07COVID-19 convalescent plasmaRANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF THE USE OF PLASMA FROM CONVALESCENT PATIENTS WITH THE NEW CORONAVIRUS DISEASE (COVID-19) FOR THE EXPERIMENTAL TREATMENT OF PATIENTS HOSPITALIZED IN THE CENTRO MEDICO NAVAL "CIRUJANO MAYOR SANTIAGO TAVARA"Treatment2Active Not RecruitingPER-060-20
2020-09-07PioglitazoneNon-blinded, Randomized and Controlled Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19Treatment4Active Not RecruitingNCT04535700
2020-09-07PrednisoneRandomized, Open, Parallel, Single-center, Non-inferiority Clinical Trial, With an Active Control Group, Comparing Two Oral Prednisone Regimens With the Aim of Optimizing the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 InfectionTreatment4Active Not RecruitingNCT04534478
2020-09-04BamlanivimabA Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19 - Therapeutics for Inpatients with COVID-19 (TICO)Treatment2Active Not RecruitingEUCTR2020-003278-37-DK
2020-09-04RintatolimodPhase 1 / 2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 InfectionSupportive Care1, 2Active Not RecruitingNCT04379518
2020-09-04Interferon alfa-2bPhase 1 / 2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 InfectionSupportive Care1, 2Active Not RecruitingNCT04379518
2020-09-04Azadirachta indica leafUse of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal MucosaTreatmentNot AvailableActive Not RecruitingNCT04357990
2020-09-04St. John's WortUse of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal MucosaTreatmentNot AvailableActive Not RecruitingNCT04357990
2020-09-04Rubella virus vaccineAn International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare WorkersPrevention3Active Not RecruitingNCT04333732
2020-09-04Measles virus vaccine live attenuatedAn International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare WorkersPrevention3Active Not RecruitingNCT04333732
2020-09-04Mumps virus strain B level jeryl lynn live antigenAn International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare WorkersPrevention3Active Not RecruitingNCT04333732
2020-09-04TocilizumabAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized StudyTreatment3Active Not RecruitingNCT04361032
2020-09-04DeferoxamineAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized StudyTreatment3Active Not RecruitingNCT04361032
2020-09-04DalteparinA Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19Treatment4Active Not RecruitingNCT04505774
2020-09-04HeparinA Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19Treatment4Active Not RecruitingNCT04505774
2020-09-04EnoxaparinA Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19Treatment4Active Not RecruitingNCT04505774
2020-09-04FondaparinuxA Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19Treatment4Active Not RecruitingNCT04505774
2020-09-04TinzaparinA Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19Treatment4Active Not RecruitingNCT04505774
2020-09-04DaclatasvirEfficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)Treatment3Active Not RecruitingNCT04535869
2020-09-04SofosbuvirEfficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)Treatment3Active Not RecruitingNCT04535869
2020-09-04Sodium chlorideImpact of Nasopharyngeal wash on Virion Load in COVID-19 PatientsTreatment1, 2Active Not RecruitingCTRI/2020/08/027465
2020-09-03AlmitrineEfficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia : a Randomized Controlled Double-blind Study From the Skip-icu ConsortiumTreatment3Active Not RecruitingNCT04357457
2020-09-03SARS-CoV-2 vaccineImmunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and OlderPrevention1, 2Active Not RecruitingNCT04537208
2020-09-03SofosbuvirPhase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19Treatment2Active Not RecruitingNCT04532931
2020-09-03DaclatasvirPhase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19Treatment2Active Not RecruitingNCT04532931
2020-09-03NitazoxanidePhase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19Treatment2Active Not RecruitingNCT04532931
2020-09-03FavipiravirPhase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19Treatment2Active Not RecruitingNCT04532931
2020-09-03AmodiaquinePhase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19Treatment2Active Not RecruitingNCT04532931
2020-09-03ArtesunatePhase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19Treatment2Active Not RecruitingNCT04532931
2020-09-03PyronaridinePhase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19Treatment2Active Not RecruitingNCT04532931
2020-09-02MavrilimumabMavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Active Not RecruitingNCT04463004
2020-09-02BNT162b3A Multi-site, Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of a BNT162 Vaccine Against COVID-19Treatment1Active Not RecruitingEUCTR2020-003267-26-DE
2020-09-02Janssen COVID-19 VaccineA Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and OlderTreatment2Active Not RecruitingEUCTR2020-002584-63-DE
2020-09-02AzithromycinRandomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological MalignanciesTreatment2Active Not RecruitingNCT04392128
2020-09-02HydroxychloroquineRandomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological MalignanciesTreatment2Active Not RecruitingNCT04392128
2020-09-02Nitric OxideUse of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19Treatment1Active Not RecruitingNCT04383002
2020-09-02IvermectinAssessment of response of ivermectin on virological clearance in COVID 19 : single centre, open labelled, randomised controlled trialTreatmentNot AvailableActive Not RecruitingCTRI/2020/08/027394
2020-09-01XAV-19A Randomized, Double-blind, Placebo-controlled Phase 2 (2a and 2b) Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate PneumoniaTreatment2Active Not RecruitingNCT04453384
2020-09-01FavipiravirControl of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID)Prevention2Active Not RecruitingNCT04448119
2020-09-01Remestemcel-LA Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement TherapyTreatment1, 2Active Not RecruitingNCT04445220
2020-09-01Nitric OxideMulti-Center, Double-Blinded, Placebo-Controlled, Phase II Clinical Efficacy Study Evaluating NORS To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Mild COVID-19Treatment2Active Not RecruitingNCT04443868
2020-09-01FluoxetinePilot Randomized Controlled Trial : Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)Treatment1Active Not RecruitingNCT04570449
2020-09-01TocilizumabAn Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseTreatment3Active Not RecruitingNCT04424056
2020-09-01AnakinraAn Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseTreatment3Active Not RecruitingNCT04424056
2020-09-01RuxolitinibAn Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseTreatment3Active Not RecruitingNCT04424056
2020-09-01TamoxifenCombination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19Treatment2Active Not RecruitingNCT04568096
2020-09-01TretinoinCombination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19Treatment2Active Not RecruitingNCT04568096
2020-09-01LosartanSafety and efficacy of a pharmacological strategy using Losartan in hospital patients with COVID-19Treatment1Active Not RecruitingACTRN12620000731998
2020-09-01ThymalfasinA Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Elderly Renal Dialysis PatientsPrevention2Active Not RecruitingNCT04428008
2020-09-01IbudilastA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress SyndromeTreatment2Active Not RecruitingNCT04429555
2020-09-01VXA-CoV2-1A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult VolunteersPrevention1Active Not RecruitingNCT04563702
2020-09-01DemeclocyclineMulticenter Study to evaluate efficacy and safety of Demethylchlortetracycline in Patients of COVID-19 (COVID-DMC)Treatment2Active Not RecruitingJPRN-jRCTs051200049
2020-09-01Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsAn Exploratory Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infection (COVID-19)Treatment1Active Not RecruitingJPRN-JapicCTI-205416
2020-09-01HydroxychloroquinePrevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)Prevention2, 3Active Not RecruitingNCT04400019
2020-09-01MelatoninSelective Estrogen Modulation and Melatonin in Early COVID-19Treatment2Active Not RecruitingNCT04531748
2020-09-01ToremifeneSelective Estrogen Modulation and Melatonin in Early COVID-19Treatment2Active Not RecruitingNCT04531748
2020-09-01DefibrotideDefibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS)Treatment1Active Not RecruitingNCT04530604
2020-09-01MethylprednisoloneSteroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study DesignTreatment3Active Not RecruitingNCT04528888
2020-09-01HeparinSteroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study DesignTreatment3Active Not RecruitingNCT04528888
2020-09-01EnoxaparinSteroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study DesignTreatment3Active Not RecruitingNCT04528888
2020-09-01AbivertinibA Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19Treatment2Active Not RecruitingNCT04528667
2020-09-01Vitamin DHigh Dose Vitamin-D Substitution in Patients With COVID-19 : a Randomized Controlled, Multi Center StudyTreatmentNot AvailableActive Not RecruitingNCT04525820
2020-09-01MetforminMET-Covid Trial - METformin for Prevention and Outpatient Treatment of COVID-19Treatment2, 3Active Not RecruitingNCT04510194
2020-09-01Sodium chlorideInvestigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19Health Services Research1Active Not RecruitingNCT04419610
2020-09-01COVID-19 convalescent plasmaA Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.Treatment2, 3Active Not RecruitingNCT04395170
2020-09-01IsotretinoinIsotretinoin in Treatment of COVID-19 (Randomized)Treatment3Active Not RecruitingNCT04353180
2020-09-01HydroxychloroquineIMPACT RAPPORT : IMPact of Antimalarials on Covid Infections : a Case Control sTudy of RAPPORTBasic ScienceNot AvailableActive Not RecruitingNCT04347798
2020-09-01ChloroquineIMPACT RAPPORT : IMPact of Antimalarials on Covid Infections : a Case Control sTudy of RAPPORTBasic ScienceNot AvailableActive Not RecruitingNCT04347798
2020-09-01Virus Specific T-CellViral Specific T-cells (VSTs) for Treatment of SARS-CoV-2 / COVID-19Treatment2Active Not RecruitingNCT04406064
2020-09-01NiclosamideNiclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)Treatment2Active Not RecruitingNCT04399356
2020-09-01OxytocinPhase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19Treatment2Active Not RecruitingNCT04386447
2020-09-01Human Umbilical Cord Mesenchymal Stem CellsSafety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19 : A Randomized Controlled TrialTreatment1, 2Active Not RecruitingNCT04390152
2020-09-01Peginterferon lambda-1aA Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical IllnessTreatment2Active Not RecruitingNCT04388709
2020-09-01HydroxychloroquinePROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT) : a Basket Trial of Prophylactic Interventions Amongst At-risk PatientsPrevention2, 3Active Not RecruitingNCT04389359
2020-09-01Recombinant Bacterial ACE2 Receptors-like EnzymeRecombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2Treatment1Active Not RecruitingNCT04375046
2020-09-01Povidone-iodinePovidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2Treatment2Active Not RecruitingNCT04371965
2020-09-01RuxolitinibRuxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe / Very Severe COVID-19 IllnessTreatmentNot AvailableActive Not RecruitingNCT04337359
2020-09-01DexamethasoneTargeted Steroids for ARDS Due to COVID-19 Pneumonia : A Pilot Randomized Clinical TrialTreatment2Active Not RecruitingNCT04360876
2020-09-01ImatinibA RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.Treatment2Active Not RecruitingNCT04357613
2020-09-01RibavirinAn Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19Treatment1Active Not RecruitingNCT04356677
2020-09-01Remestemcel-LAn open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumoniaTreatment1Active Not RecruitingChiCTR2000030944
2020-09-01Natural Killer CellAn open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumoniaTreatment1Active Not RecruitingChiCTR2000030944
2020-09-01AcetylcysteineInflammatory regulation effect of N-acetylcysteine on COVID-19 treatment, pilot, double blinded randomized placebo controlled multicenter clinical trialTreatment3, 4Active Not RecruitingISRCTN60069084
2020-09-01LenzilumabCOVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study Arm 4 : Effect of Lenzilumab in cancer patients with severe COVID-19 infection.Treatment3Active Not RecruitingACTRN12620000844943
2020-09-01SelinexorCOVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 3 : Effect of selinexor in cancer patients with moderate COVID-19 infection.Treatment3Active Not RecruitingACTRN12620000841976
2020-09-01Interferon alfaCOVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 2 : Effect of daily Interferon-alpha on cancer patients with known positive contact with COVID-19.Treatment3Active Not RecruitingACTRN12620000842965
2020-09-01Interferon alfaCOVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 1 : Effect of daily Interferon-alpha on cancer patients without known positive contact with COVID-19.Treatment3Active Not RecruitingACTRN12620000843954
2020-09-01Varicella zoster vaccine (recombinant)Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents : A Randomized, Doubled-Blinded, Comparative Group Observational StudyBasic Science1Active Not RecruitingNCT04523246
2020-09-01Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsAn Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 InfectionTreatment1Active Not RecruitingNCT04522986
2020-09-01Stem-cell derived exosome vesicle productsExtracellular Vesicle Infusion Treatment for Severe COVID-19Treatment2Active Not RecruitingNCT04493242
2020-09-01COVID-19 convalescent plasmaA Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation : the CONFIDENT TrialTreatment2Active Not RecruitingNCT04558476
2020-09-01ColchicinePhase 2 / 3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate / Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care CenterTreatment2, 3Active Not RecruitingNCT04492358
2020-09-01PrednisonePhase 2 / 3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate / Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care CenterTreatment2, 3Active Not RecruitingNCT04492358
2020-09-01DisulfiramVirologic and Immunologic Response to Disulfiram in Early Symptomatic COVID+ OutpatientsTreatment2Active Not RecruitingNCT04485130
2020-09-01CanakinumabCanakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia TrialTreatment3Active Not RecruitingNCT04510493
2020-09-01BicalutamideRandomized Trial of Bicalutamide to Block TMPRSS2 in Males With COVID-19 InfectionTreatment3Active Not RecruitingNCT04509999
2020-09-01Autologous peripheral blood-derived CD34+ cellsCLBS119 (Autologous Peripheral Blood Derived CD34+ Cells) for Repair of COVID-19 Induced Pulmonary DamageTreatment1Active Not RecruitingNCT04522817
2020-09-01CSL324A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04519424
2020-09-01CholecalciferolPRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams (PROTECT)Prevention3Active Not RecruitingNCT04483635
2020-09-01IvermectinA Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04482686
2020-09-01DoxycyclineA Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04482686
2020-09-01ApixabanFREEDOM COVID Anticoagulation Strategy Randomized TrialTreatment4Active Not RecruitingNCT04512079
2020-09-01EnoxaparinFREEDOM COVID Anticoagulation Strategy Randomized TrialTreatment4Active Not RecruitingNCT04512079
2020-09-01HeparinCan Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Mechanical Ventilation in IrelandTreatment1, 2Active Not RecruitingNCT04511923
2020-09-01GenisteinA Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 PatientsTreatment2Active Not RecruitingNCT04482595
2020-09-01RazuprotafibA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE Study)Treatment2Active Not RecruitingNCT04511650
2020-09-01IvermectinIvermectin Inhalation Forms in the Management of COVID-19 Egyptian PatientsTreatment2Active Not RecruitingNCT04510233
2020-09-01ColchicineColchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)Treatment2, 3Active Not RecruitingNCT04510038
2020-09-01HydroxychloroquineReal-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and / or Gougerot's DiseaseTreatmentNot AvailableActive Not RecruitingNCT04481633
2020-09-01RamelteonAdjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19Treatment2Active Not RecruitingNCT04470297
2020-09-01Peginterferon beta-1aA Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19)Treatment3Active Not RecruitingNCT04552379
2020-09-01CalcifediolA Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)Treatment2Active Not RecruitingNCT04551911
2020-09-01RibavirinAn Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19Treatment1Active Not RecruitingNCT04551768
2020-09-01DoxycyclineThe Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases : a Randomized Double Blind Placebo Controlled TrialTreatment2Active Not RecruitingNCT04551755
2020-09-01IvermectinThe Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases : a Randomized Double Blind Placebo Controlled TrialTreatment2Active Not RecruitingNCT04551755
2020-09-01BCG vaccineBacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity TrialPrevention3Active Not RecruitingNCT04534803
2020-09-01AK119A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy SubjectsTreatment1Active Not RecruitingNCT04516564
2020-09-01Alpha-1-proteinase inhibitorA Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19Treatment2Active Not RecruitingNCT04547140
2020-09-01Anti-SARS-CoV-2 immunoglobulinAn International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19Treatment3Active Not RecruitingNCT04546581
2020-09-01FamotidineA Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 InfectionTreatment1Active Not RecruitingNCT04545008
2020-09-01CysteineA Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 InfectionTreatment1Active Not RecruitingNCT04545008
2020-09-01Poractant alfaMulticenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS)Treatment2Active Not RecruitingNCT04502433
2020-09-01Aminolevulinic acidAn Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04542850
2020-09-01Ferric sodium citrateAn Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04542850
2020-09-01EdoxabanHamburg Edoxaban for Anticoagulation in COVID-19 StudyTreatment3Active Not RecruitingNCT04542408
2020-09-01CyclosporineUtility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 PandemicTreatment1, 2Active Not RecruitingNCT04540926
2020-09-01ColchicineImpact of Colchicine in Hospitalized Colombian Patients With COVID-19Treatment3Active Not RecruitingNCT04539873
2020-09-01AviptadilInhaled Aviptadil for the Prevention of COVID-19 Related ARDS : a Randomized, Placebo Controlled, Multicenter TrialTreatment1Active Not RecruitingNCT04536350
2020-09-01AsunerceptA Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 DiseaseTreatment2Active Not RecruitingNCT04535674
2020-09-01SelinexorCOVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study.Treatment3Active Not RecruitingNCT04534725
2020-09-01LenzilumabCOVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study.Treatment3Active Not RecruitingNCT04534725
2020-09-01Interferon alfaCOVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study.Treatment3Active Not RecruitingNCT04534725
2020-09-01Artemisia annua leafRandomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive OutpatientsTreatment2Active Not RecruitingNCT04530617
2020-09-01CamostatRandomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive OutpatientsTreatment2Active Not RecruitingNCT04530617
2020-09-01Mycobacterium w. Vaccine"Randomized Controlled Trial Of Immunomodulator Mycobacterium w In Mild And Moderate Cases of Covid-19 Pneumonia"Treatment3Active Not RecruitingCTRI/2020/08/027475
2020-09-01Interferon beta-1bRandomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-ß-1a (IFNß-1a) in COVID-19 PatientsTreatment2Active Not RecruitingNCT04449380
2020-09-01TocilizumabRole of Tocilizumab in Patients with Moderate to Severe COVID-19 PneumoniaBasic ScienceNot AvailableActive Not RecruitingCTRI/2020/08/027246
2020-09-01Vitamin DReducing Asymptomatic Infection With Vitamin D in Coronavirus DiseasePreventionNot AvailableActive Not RecruitingNCT04476680
2020-08-31HydroxychloroquinePost Exposure Prophylaxis (PEP) in Healthcare Workers Exposed to COVID-19 Patients : A Double-blind Randomized Clinical TrialPrevention2, 3Active Not RecruitingNCT04437693
2020-08-31Fish oilRandomized, Open-label, Parallel Study to Investigate Safety and Efficacy of CARDIO Softgels Plus Best Standard-of-care vs. Best Standard-of-care Alone on a Former Smoker and / or Steroid-resistant Asthma Population With COVID-19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04465513
2020-08-31CurcuminEvaluation the effectiveness of curcumin in the treatment of patients with covid-19 sever acute respiratory syndromeTreatment2, 3RecruitingIRCT20200418047119N1
2020-08-31AG0302-COVID19A Randomized, Open-label, Non-controlled Phase I / II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy AdultsPrevention1, 2Active Not RecruitingNCT04527081
2020-08-31Recombinant Human ThrombopoietinThe Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 PandemicTreatment2Active Not RecruitingNCT04516837
2020-08-31EltrombopagThe Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 PandemicTreatment2Active Not RecruitingNCT04516837
2020-08-31LedipasvirSelection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trialTreatment3Active Not RecruitingCTRI/2020/08/027345
2020-08-31SofosbuvirSelection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trialTreatment3Active Not RecruitingCTRI/2020/08/027345
2020-08-31DaclatasvirSelection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trialTreatment3Active Not RecruitingCTRI/2020/08/027345
2020-08-31IvermectinEffectiveness of Ivermectin in preventing development of symptomatic Covid-19 among primary contacts of newly diagnosed Covid-19 positive patients at a tertiary care hospital in North India - an interventional studyTreatment3Active Not RecruitingCTRI/2020/08/027282
2020-08-30TenofovirEffectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir / Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical TrialPrevention2, 3Active Not RecruitingNCT04519125
2020-08-30EmtricitabineEffectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir / Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical TrialPrevention2, 3Active Not RecruitingNCT04519125
2020-08-30DexamethasoneTime to Recover of Anosmia and / or Ageusia and Early Corticosteroid UseTreatment4Active Not RecruitingNCT04528329
2020-08-28Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older : A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind StudyPrevention1Active Not RecruitingNCT04530656
2020-08-28SecukinumabUse of Anti-IL-17 in patients with the severe acute respiratory syndrome (SARS) associated with Covid-19Treatment2Active Not RecruitingRBR-5vpyh4
2020-08-28LosmapimodA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)Treatment3Active Not RecruitingNCT04511819
2020-08-28Janssen COVID-19 VaccineA Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and OlderPrevention2Active Not RecruitingNCT04535453
2020-08-28IvermectinIvermectin as a potential treatment for COVID 19 : A double blind randomized placebo-controlled trialTreatmentNot AvailableActive Not RecruitingCTRI/2020/08/027225
2020-08-27NitazoxanideThe C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk : a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor SettingTreatment2, 3Active Not RecruitingNCT04523090
2020-08-27DexamethasoneHigher vs. Lower Doses of Dexamethasone in Patients With COVID-19 and Severe HypoxiaTreatment3Active Not RecruitingNCT04509973
2020-08-27COVID-19 convalescent plasmaIGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-SARS-CoV2 Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19Treatment2Active Not RecruitingNCT04524507
2020-08-27V591A Phase 1 / Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older ParticipantsPrevention1, 2Active Not RecruitingNCT04498247
2020-08-27Bacillus calmette-guerin substrain danish 1331 live antigenBACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT SERIOUS RESPIRATORY TRACT INFECTION AND COVID-19 IN VULNERABLE ELDERLY – AN ADAPTIVE RANDOMIZED CONTROLLED TRIAL - BCG-PRIMETreatment4Unknown StatusEUCTR2020-003470-47-NL
2020-08-27SotrovimabA Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized PatientsTreatment2, 3Active Not RecruitingNCT04545060
2020-08-26DexamethasoneTiming of Corticosteroids in COVID-19Treatment4Active Not RecruitingNCT04530409
2020-08-26AstraZeneca COVID-19 VaccineA Phase III Open-label Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19Prevention3Active Not RecruitingNCT04540393
2020-08-25OpaganibOpaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2 / 3 Study, in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia - -Treatment2Active Not RecruitingEUCTR2020-002677-95-IT
2020-08-25CenicrivirocCharité Trial of Cenicriviroc (CVC) Treatment for COVID-19 PatientsTreatment2Active Not RecruitingNCT04500418
2020-08-25COVID-19 convalescent plasmaPhase 2b / 3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients.Treatment2, 3Active Not RecruitingNCT04388410
2020-08-25BCG vaccineBacillus Calmette-Guérin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled TrialPrevention4Active Not RecruitingNCT04537663
2020-08-24Placental Mesenchymal Stem CellsDSC-COVID-19 : An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19TreatmentNot AvailableActive Not RecruitingNCT04451291
2020-08-24Mesenchymoangioblast-derived mesenchymal stem cellsA Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With COVID-19Treatment1, 2Active Not RecruitingNCT04537351
2020-08-24AdimrSC-2fA Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy VolunteersPrevention1Active Not RecruitingNCT04522089
2020-08-24FINLAY-FR-1Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01Treatment1, 2Active Not RecruitingRPCEC00000332
2020-08-24OM85Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85Prevention3Active Not RecruitingNCT04496245
2020-08-24AstraZeneca COVID-19 VaccineA Phase 2 / 3, Observer-Blind, Randomized, Controlled Study to Determine the Safety and Immunogenicity of Covishield (COVID-19 Vaccine) in Healthy Indian Adults - ICMR / SII-COVISHIELDTreatment2, 3Active Not RecruitingCTRI/2020/08/027170
2020-08-23AstraZeneca COVID-19 VaccineA Phase I / II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19Prevention1, 2Active Not RecruitingNCT04568031
2020-08-22MelatoninEvaluation of the efficacy and safety of Melatonin in patients with COVID-19 : a randomized clinical trialTreatment3Active Not RecruitingIRCT20200506047323N5
2020-08-22Sodium chlorideEvaluating the effectiveness of intravenous ozonized saline in treatment of severe COVID-19 disease : A randomized Control trialTreatment3Active Not RecruitingIRCT20200730048253N1
2020-08-22OzoneEvaluating the effectiveness of intravenous ozonized saline in treatment of severe COVID-19 disease : A randomized Control trialTreatment3Active Not RecruitingIRCT20200730048253N1
2020-08-22HydroxychloroquineEvaluation and comparison of the effectiveness of Hydroxychloroquin versus Clarithromycin in recovery of dyspnea and Caugh at the end of the acute phase of COVID-19 treatmentTreatment3Active Not RecruitingIRCT20200718048129N1
2020-08-22ClarithromycinEvaluation and comparison of the effectiveness of Hydroxychloroquin versus Clarithromycin in recovery of dyspnea and Caugh at the end of the acute phase of COVID-19 treatmentTreatment3Active Not RecruitingIRCT20200718048129N1
2020-08-22GarlicThe effect of garlic and cinnamon essential oil on the treatment of patients with corona (COVID-19)TreatmentNot AvailableActive Not RecruitingIRCT20200705048011N1
2020-08-22CinnamonThe effect of garlic and cinnamon essential oil on the treatment of patients with corona (COVID-19)TreatmentNot AvailableActive Not RecruitingIRCT20200705048011N1
2020-08-22IvermectinEvaluation effects of the standard regimen along with ivermectin on treatment of corona virus type 2 pneumoniaTreatment3Active Not RecruitingIRCT20190624043993N2
2020-08-22IsotretinoinThe evaluation of isotretinoin effects on treatment of COVID-19 infectionsTreatment3Active Not RecruitingIRCT20190624043993N3
2020-08-22EthanolProphylaxis and treatment of COVID-19 using a nasal spray containing 3% dimethyl sulfoxide (DMSO) and 20% ethanol solutionTreatment3RecruitingIRCT20200727048217N1
2020-08-22Dimethyl sulfoxideProphylaxis and treatment of COVID-19 using a nasal spray containing 3% dimethyl sulfoxide (DMSO) and 20% ethanol solutionTreatment3RecruitingIRCT20200727048217N1
2020-08-22DiphenhydramineClinical Trial on Diphenhydramine Compound in Covid-19 TreatmentTreatment3RecruitingIRCT20200504047298N3
2020-08-22WaterEvaluation of the effect of inhaled solution based on silver colloid with the brand name colloide silver nasal spray 10ppm to control COVID-19-induced lung infection and increase patients' respiratory volumeTreatment3Active Not RecruitingIRCT20190226042851N1
2020-08-22SilverEvaluation of the effect of inhaled solution based on silver colloid with the brand name colloide silver nasal spray 10ppm to control COVID-19-induced lung infection and increase patients' respiratory volumeTreatment3Active Not RecruitingIRCT20190226042851N1
2020-08-22Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccineA randomized, observer-blind, placebo-controlled, Phase I / II study to evaluate the safety, reactogenicity and immunogenicity of Receptor Binding Domain (RBD) SARS-CoV-2 (COVID-19) Hepatitis B surface antigen (HBsAg) virus like particle (VLP) Vaccine in Healthy AdultsTreatment1, 2Active Not RecruitingACTRN12620000817943
2020-08-22VadadustatVadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04478071
2020-08-21OpaganibOpaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2 / 3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive PneumoniaTreatment2, 3Active Not RecruitingNCT04467840
2020-08-21COVID-19 convalescent plasmaStudy to assess and establish safety of convalescent plasma (CVP) drawn from mild symptomatic COVID-19 patients. - mCCPBasic ScienceNot AvailableActive Not RecruitingCTRI/2020/08/027285
2020-08-20GlycineControlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical VentilationTreatmentNot AvailableActive Not RecruitingNCT04443673
2020-08-20AtorvastatinEffect of atorvastatin on mortality rate and symptom improvement in hospitalized patients with COVID-19Treatment2RecruitingIRCT20190831044653N5
2020-08-20Interferon beta-1athe Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19Treatment2Active Not RecruitingNCT04521400
2020-08-20CyclosporineRandomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of Covid-19(+) Non-ICU Hospital InpatientsTreatment2Active Not RecruitingNCT04492891
2020-08-20COVID-19 convalescent plasmaPERUCONPLASMA : Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19Treatment2Active Not RecruitingNCT04497324
2020-08-20FavipiravirA Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 PatientsTreatment3Active Not RecruitingNCT04529499
2020-08-20CHO Cells Recombinant VaccineA randomized, double-blind, placebo-controlled phase I clinical trial for evaluation of the safety and tolerability of recombinant novel coronavirus vaccines (CHO cells) in healthy people aged 60 years and abovePrevention1Active Not RecruitingChiCTR2000035691
2020-08-20Inosine pranobexAn Open-Label, Prospective, Randomized, Comparative, Parallel Group, Multi-Center, Proof of Concept Study to Assess the Efficacy and Safety of Inosine Pranobex Added to Current Standard of Care (CSC) in COVID-19 Patients.Treatment2Active Not RecruitingCTRI/2020/08/027162
2020-08-19CysteineOpen Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe PneumoniaTreatmentNot AvailableActive Not RecruitingNCT04570254
2020-08-19PentoxifyllineOpen Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe PneumoniaTreatmentNot AvailableActive Not RecruitingNCT04570254
2020-08-19Ascorbic acidOpen Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe PneumoniaTreatmentNot AvailableActive Not RecruitingNCT04570254
2020-08-19MelatoninOpen Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe PneumoniaTreatmentNot AvailableActive Not RecruitingNCT04570254
2020-08-19Vitamin EOpen Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe PneumoniaTreatmentNot AvailableActive Not RecruitingNCT04570254
2020-08-19ChloroquineA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-08-19LopinavirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-08-19OseltamivirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-08-19DarunavirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-08-19RitonavirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-08-19FavipiravirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-08-19BamlanivimabAdaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)Treatment2, 3Active Not RecruitingNCT04518410
2020-08-19IvermectinIvermectin to Prevent Hospitalizations in COVID-19 : Randomized, Double-blind, Placebo-controlledTreatment2, 3Active Not RecruitingNCT04529525
2020-08-19Pediococcus acidilacticiEfficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota : A Randomized Clinical TrialTreatmentNot AvailableActive Not RecruitingNCT04517422
2020-08-19Lactobacillus plantarumEfficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota : A Randomized Clinical TrialTreatmentNot AvailableActive Not RecruitingNCT04517422
2020-08-19Collagen-polyvinylpyrrolidoneEffect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot TrialTreatment1Active Not RecruitingNCT04517162
2020-08-18OzoneStudy of intra-venous ozonated auto-hemotherapy on severe cases of COVID-19 : A randomized clinical trialTreatmentNot AvailableActive Not RecruitingIRCT20200616047792N1
2020-08-18COVID-19 convalescent plasmaEfficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory SupportTreatment2Active Not RecruitingNCT04528368
2020-08-18FenofibrateFEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019TreatmentNot AvailableActive Not RecruitingNCT04517396
2020-08-18AZD7442A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy AdultsTreatment1Active Not RecruitingNCT04507256
2020-08-18DexamethasoneHigher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia : the COVID STEROID 2 trial - COVID STEROID 2Treatment3Active Not RecruitingEUCTR2020-003363-25-DK
2020-08-18SargramostimA Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute HypoxemiaTreatment2Active Not RecruitingNCT04411680
2020-08-18RosuvastatinEffectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04359095
2020-08-18TenofovirEffectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04359095
2020-08-18ColchicineEffectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04359095
2020-08-18EmtricitabineEffectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04359095
2020-08-18OM85Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85Treatment3Active Not RecruitingACTRN12620000473965
2020-08-18OxygenMulticenter, prospective, randomized, double-blind clinical trial for the use of Hyperbaric Oxygen Therapy in patients hospitalized with Covid-19TreatmentNot AvailableActive Not RecruitingRBR-2fvjjm
2020-08-17Matrix-MA Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIVPrevention2Active Not RecruitingNCT04533399
2020-08-17NVX-CoV2373A Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIVPrevention2Active Not RecruitingNCT04533399
2020-08-17Zinc citrateTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-08-17CholecalciferolTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-08-17HydroxychloroquineTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-08-17Ascorbic acidTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-08-17MecobalaminTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-08-17AstraZeneca COVID-19 VaccineA Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19Treatment3Active Not RecruitingNCT04516746
2020-08-17AcetylcysteineSafety and efficacy of intranasal delivery of BromAc® (Bromelain & Acetylcysteine) in swab positive SARS-CoV-2 patients – inactivating the COVID-19 virus by cleavage of the spike and other glycoproteinsTreatment1Active Not RecruitingACTRN12620000788976
2020-08-17BromelainsSafety and efficacy of intranasal delivery of BromAc® (Bromelain & Acetylcysteine) in swab positive SARS-CoV-2 patients – inactivating the COVID-19 virus by cleavage of the spike and other glycoproteinsTreatment1Active Not RecruitingACTRN12620000788976
2020-08-17Citrus bioflavonoidsA single centric, prospective, open label, interventional study to evaluate the efficacy and safety of CitriobioShield as an adjunct with standard of care therapy in improving immunity in mild to moderate COVID 19 patients through inhalation of fog.TreatmentNot AvailableActive Not RecruitingCTRI/2020/08/027085
2020-08-17Mumps virus strain B level jeryl lynn live antigenUse of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / InflammationPrevention3Active Not RecruitingNCT04475081
2020-08-17Rubella virus vaccineUse of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / InflammationPrevention3Active Not RecruitingNCT04475081
2020-08-17Measles virus vaccine live attenuatedUse of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / InflammationPrevention3Active Not RecruitingNCT04475081
2020-08-16SilibininTrial of Silymarin in Adults With COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04394208
2020-08-15SirolimusEfficacy and Safety of Sirolimus for Treating COVID-19 InfectionTreatment2Active Not RecruitingNCT04461340
2020-08-15Methylene blueMethylene Blue for the Treatment of COVID-19 : A Randomized Clinical TrialTreatment3RecruitingIRCT20090701002113N2
2020-08-15LopinavirPreventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-SurgTreatment3, 4Active Not RecruitingCTRI/2020/06/026196
2020-08-15RitonavirPreventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-SurgTreatment3, 4Active Not RecruitingCTRI/2020/06/026196
2020-08-15OxygenHigh Flow Nasal Oxygen Versus Continuous Positive Airway Pressure Helmet Evaluation : A Randomized Crossover Trial in COVID-19 PneumoniaSupportive CareNot AvailableActive Not RecruitingNCT04381923
2020-08-15Povidone-iodineEffect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal TitersTreatment1, 2Active Not RecruitingNCT04347954
2020-08-15Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsCOVID-19 Stem Cell Therapy : A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem CellsTreatment1Active Not RecruitingNCT04486001
2020-08-15EpoprostenolDouble-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical VentilationTreatment2Active Not RecruitingNCT04452669
2020-08-14Ascorbic acidLessening Organ Dysfunction With VITamin C - COVIDTreatment3Active Not RecruitingNCT04401150
2020-08-14COVID-19 convalescent plasmaConvalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) InfectionTreatment2Active Not RecruitingNCT04513158
2020-08-13PentoxifyllineEfficacy of Pentoxifylline as Add on Therapy in COVID19 PatientsTreatment1, 2Active Not RecruitingNCT04433988
2020-08-13NafamostatMulticentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in SenegalTreatment3Active Not RecruitingNCT04390594
2020-08-13NitazoxanidePhase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19Treatment3Active Not RecruitingNCT04486313
2020-08-13RivaroxabanA Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 InfectionTreatment3Active Not RecruitingNCT04508023
2020-08-13ThymalfasinA Prospective, Single-Center, Investigator Initiated Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α-1 (Tα1) in severe COVID-19 patientsTreatmentNot AvailableActive Not RecruitingCTRI/2020/08/027061
2020-08-12Zinc chlorideA Phase 2 evaluation of the efficacy of homoeopathic remedy Zincum Muriaticum as an adjuvant therapy to standard of care in adult patients with moderate to severe COVID-19 : Randomized, double-blind, parallel group, placebo controlled, multicenter trial (ZIMCOV)Treatment2Active Not RecruitingCTRI/2020/08/027005
2020-08-12COVID-19 convalescent plasmaEvaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19Treatment2Active Not RecruitingNCT04438057
2020-08-12CholecalciferolRandomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 PatientsTreatment4Active Not RecruitingNCT04411446
2020-08-12Vitamin DRandomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 PatientsTreatment4Active Not RecruitingNCT04411446
2020-08-12AZD-1656A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19Treatment2Active Not RecruitingNCT04516759
2020-08-11HydroxychloroquineTreatment of Covid-19 With Favipiravir Versus Hydroxychloroquine : a Randomized Comparator TrialTreatment2Active Not RecruitingNCT04387760
2020-08-11FavipiravirTreatment of Covid-19 With Favipiravir Versus Hydroxychloroquine : a Randomized Comparator TrialTreatment2Active Not RecruitingNCT04387760
2020-08-11COVID-19 convalescent plasmaClinical-trial of COVID-19 Convalescent Plasma in OutpatientsTreatment3Active Not RecruitingNCT04355767
2020-08-11Janssen COVID-19 VaccineA Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in AdultsPrevention1Active Not RecruitingNCT04509947
2020-08-11Cepeginterferon alfa-2BA Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - a2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19)Treatment2Active Not RecruitingNCT04480138
2020-08-11RemdesivirMulti-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DiscoveryTreatment3Active Not RecruitingEUCTR2020-000936-23-PT
2020-08-11CIGB-258 peptideEvaluation of the effect and safety of the CIGB-258 peptide in the treatment of seriously or critically ill patients due to COVID-19. (COVID-19)Treatment2CompletedRPCEC00000330
2020-08-11MelatoninA Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 InfectionTreatment2Active Not RecruitingNCT04474483
2020-08-10GRAd-COV2A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly SubjectsPrevention1Active Not RecruitingNCT04528641
2020-08-10BCG vaccineCOVID-19 : BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin EnhancementTreatment4Active Not RecruitingNCT04369794
2020-08-10Inactivated SARS-Cov-2 VaccineA Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in IndonesiaPrevention3Active Not RecruitingNCT04508075
2020-08-10TMV-083A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment PhasePrevention1Active Not RecruitingNCT04497298
2020-08-10DeferoxamineEvaluation of the effects of Desferal on clinical symptoms in patients with COVID-19Treatment2, 3Active Not RecruitingIRCT20200506047323N4
2020-08-10Placental Mesenchymal Stem CellsA Phase 1 clinical trial of intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with novel COVID-19 virus pneumonia.Treatment1Active Not RecruitingCTRI/2020/08/027043
2020-08-10Human Umbilical Cord Mesenchymal Stem CellsA Phase 1 clinical trial of intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with novel COVID-19 virus pneumonia.Treatment1Active Not RecruitingCTRI/2020/08/027043
2020-08-09CurcuminCurcumin for COVID-19 Pre Exposure Prophylaxis : A Randomised Controlled TrailTreatment4Active Not RecruitingCTRI/2020/07/026820
2020-08-08COVID-19 convalescent plasmaConvalescent Plasma for Patients With COVID-19 : A Randomized, Single Blinded, Parallel, Controlled Clinical StudyTreatment2, 3Active Not RecruitingNCT04332835
2020-08-08Mometasone furoateRole of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 PatientsTreatment3Active Not RecruitingNCT04484493
2020-08-07Icosapent ethylA Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE)Prevention4Active Not RecruitingNCT04505098
2020-08-07COVID-19 convalescent plasmaCSP #2030 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19Basic ScienceNot AvailableActive Not RecruitingNCT04545047
2020-08-07XAV-19A randomized, double-blind, placebo-controlled phase 2a and 2b study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia - POLYCORTreatment1Active Not RecruitingEUCTR2020-002574-27-FR
2020-08-07MW33A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW33 Injection in Healthy SubjectsTreatment1Active Not RecruitingNCT04533048
2020-08-06Conestat alfaRecombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 : a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).Treatment2Active Not RecruitingNCT04414631
2020-08-05BCG vaccineTo evaluate efficacy of Bacillus Calmette-Guerin (BCG) in Reducing the Incidence and severity of COVID-19 in the high-risk population (BRIC) : a phase III, Multicentric, Quadruple blind Randomized controlled trialTreatmentNot AvailableActive Not RecruitingCTRI/2020/07/026668
2020-08-05CurcuminInvestigating the effect of curcumin-piperine supplementation in accelerating the recovery period of patients with covid-19Treatment3Active Not RecruitingIRCT20200514047445N1
2020-08-05Peginterferon lambda-1aPegylated Interferon Lambda for Treatment of COVID-19 Infection- A Randomized Open Label Pilot TrialTreatment2Active Not RecruitingNCT04534673
2020-08-05ClopidogrelA Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsPrevention4Active Not RecruitingNCT04409834
2020-08-05EnoxaparinA Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsPrevention4Active Not RecruitingNCT04409834
2020-08-05HeparinA Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsPrevention4Active Not RecruitingNCT04409834
2020-08-05IfenprodilA Randomized Open Label Phase 2b / 3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 DiseaseTreatment2, 3Active Not RecruitingNCT04382924
2020-08-05Omega-3 fatty acidsThe Effect of Omega-3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19 ; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian PeoplePreventionNot AvailableActive Not RecruitingNCT04483271
2020-08-05Anti-SARS-CoV-2 immunoglobulinA Phase 1 / 2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With PneumoniaTreatment1, 2Active Not RecruitingNCT04550325
2020-08-05BCG vaccineBCG revaccination of health care professionals working in the COVID-19 pandemic, a preventive strategy to improve innate immune responseTreatmentNot AvailableActive Not RecruitingRBR-4kjqtg
2020-08-05Angiotensin 1-7Randomized clinical trial phase I / II for the use of angiotensin-(1-7) in the treatment of severe infection by Sara-CoV-2Treatment1, 2Active Not RecruitingRBR-35734p
2020-08-05CholecalciferolThe Effect of Weekly 50,000 IU Vitamin D3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19 ; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People With Vitamin D DeficiencyPreventionNot AvailableActive Not RecruitingNCT04476745
2020-08-04RemdesivirA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)Treatment3Active Not RecruitingNCT04492475
2020-08-04Interferon beta-1aA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)Treatment3Active Not RecruitingNCT04492475
2020-08-04BamlanivimabA Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19Treatment3Active Not RecruitingNCT04501978
2020-08-04RemdesivirA Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19Treatment3Active Not RecruitingNCT04501978
2020-08-03TurmericEfficacy of Ayurvedic Medicine Haldi 30 drops as an Add on medication to standard of care in adult patients of mild to moderate COVID 19. A Phase II randomized, single - blind, parallel group, placebo - controlled trial.Treatment2Active Not RecruitingCTRI/2020/07/026841
2020-08-03Aloe vera leafA clinical study to evaluate the efficacy of tablet of Aloe Vera gel (Aloe barbadenesis),Mur Makki (Commiphora myrrha) and Sanna-e-Makki (Senna Alexandrina) in the management of mild cases of confirmed Covid -19TreatmentNot AvailableActive Not RecruitingCTRI/2020/07/026669
2020-08-03LosartanRAAS blockagE in SARS COV-2 Critically ill patiEnts– a Randomized controlled trialTreatment4Active Not RecruitingISRCTN48734830
2020-08-03Remestemcel-LPhase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical VentilationTreatment1Active Not RecruitingNCT04397796
2020-08-03Platelet LysateAutologous Nebulized Platelet Lysate for Post COVID-19 SyndromeTreatmentNot AvailableActive Not RecruitingNCT04487691
2020-08-03RuxolitinibPHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM (RUXCOVID)Treatment3Active Not RecruitingPER-030-20
2020-08-03FisetinCOVID-FISETIN : A Phase 2 Placebo-Controlled Pilot Study in Covid-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized AdultsTreatment2Active Not RecruitingNCT04476953
2020-08-02MethylprednisoloneThe Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19Treatment3Active Not RecruitingNCT04499313
2020-08-02DexamethasoneThe Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19Treatment3Active Not RecruitingNCT04499313
2020-08-02BamlanivimabA Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff ; a NIAID and Lilly Collaborative StudyPrevention3Active Not RecruitingNCT04497987
2020-08-01COVID-19 convalescent plasmaA randomized control trial comparing convalescent plasma therapy plus standard treatment versus standard treatment alone in patients with severe COVID-19 pneumonia at a tertiary hospitalTreatment3Active Not RecruitingPACTR202007653923168
2020-08-01Centella asiaticaSurvey on depression, anxiety and stress during Covid-19 in general population of Hassan district and its management with Brahmi (Bacopa monnieri (L.) Pennell) - DAS-COVID-19-AYUTreatment2, 3Active Not RecruitingCTRI/2020/07/026952
2020-08-01FavipiravirAn Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 InfectionTreatment2Active Not RecruitingNCT04445467
2020-08-01AcetylcysteinePilot Double Blinded Randomized Placebo Controlled Multi Central Clinical Trial on Inflammatory Regulation Effect of NAC on COVID-19Treatment3Active Not RecruitingNCT04455243
2020-08-01Acetylsalicylic acidA Randomised Control Trial of Statin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection (RESIST Trial) - RESIST TrialTreatment2, 3Active Not RecruitingCTRI/2020/07/026791
2020-08-01AtorvastatinA Randomised Control Trial of Statin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection (RESIST Trial) - RESIST TrialTreatment2, 3Active Not RecruitingCTRI/2020/07/026791
2020-08-01Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsClinical Study for the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus 2019 (COVID-19)Treatment2Active Not RecruitingNCT04428801
2020-08-01AbivertinibA Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19Treatment2Active Not RecruitingNCT04440007
2020-08-01BetamethasoneEffect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 DiseaseTreatment1Active Not RecruitingNCT04569825
2020-08-01CamostatThe Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsTreatment1, 2Active Not RecruitingNCT04435015
2020-08-01COVID-19 convalescent plasmaPhase I Study of the Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2Treatment1Active Not RecruitingNCT04462848
2020-08-01NelfinavirClinical Trial Evaluating the Therapeutic Potential of Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian PatientsTreatment2Active Not RecruitingNCT04471662
2020-08-01FavipiravirClinical Trial Evaluating the Therapeutic Potential of Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian PatientsTreatment2Active Not RecruitingNCT04471662
2020-08-01DaclatasvirSofosbuvir With and Without Ribavirin in Treatment of COVID 19 PatientsTreatment2, 3Active Not RecruitingNCT04460443
2020-08-01SofosbuvirSofosbuvir With and Without Ribavirin in Treatment of COVID 19 PatientsTreatment2, 3Active Not RecruitingNCT04460443
2020-08-01LedipasvirSofosbuvir With and Without Ribavirin in Treatment of COVID 19 PatientsTreatment2, 3Active Not RecruitingNCT04460443
2020-08-01CholecalciferolRandomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01Vitamin K7Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01MenadioneRandomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01MagnesiumRandomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01Menaquinone 6Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01Magnesium glycinateRandomized, Double Blind, Parallel Group Study of Vitamin D3 & Magnesium in Covid 19 Infection - CovidTreatment2Active Not RecruitingCTRI/2020/06/026189
2020-08-01Vitamin DRandomized, Double Blind, Parallel Group Study of Vitamin D3 & Magnesium in Covid 19 Infection - CovidTreatment2Active Not RecruitingCTRI/2020/06/026189
2020-08-01RivaroxabanEffect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)Prevention3Active Not RecruitingNCT04416048
2020-08-01Placental Mesenchymal Stem CellsA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19Treatment2Active Not RecruitingNCT04389450
2020-08-01ProtoporphyrinEfficacy of Based MRI Contrast Media Against Covid-19Treatment1Active Not RecruitingNCT04371822
2020-08-01Angiotensin 1-7Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19Treatment2Active Not RecruitingNCT04401423
2020-08-01Ad5-nCoVA Randomized, Observer-Blind, Dose-escalation Phase I / II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in CanadaPrevention1, 2Active Not RecruitingNCT04398147
2020-08-01Remestemcel-LSingle Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID19-Induced ARDS : A Randomized, Controlled StudyTreatment1Active Not RecruitingNCT04345601
2020-08-01ChlorpromazineAdministration of Chlorpromazine as a Treatment for COVID-19Treatment2, 3Active Not RecruitingNCT04354805
2020-08-01NiclosamidePhase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Pharmacokinetics (PK) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in Healthy VolunteersTreatment1Active Not RecruitingNCT04524052
2020-08-01HeparinIntranasal Heparin Tolerability StudyPrevention1Active Not RecruitingNCT04490239
2020-08-01SildenafilSildenafil for Treating Patients With COVID-19 and Perfusion Mismatch : A Pilot Randomised TrialTreatment1, 2Active Not RecruitingNCT04489446
2020-08-01DuvelisibDuvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus InfectionTreatment2Active Not RecruitingNCT04487886
2020-08-01COVID-19 convalescent plasmaAssessment of the Safety of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above IllnessTreatment1Active Not RecruitingNCT04516954
2020-08-01DexamethasoneRandomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19Treatment2Active Not RecruitingNCT04513184
2020-08-01EbselenA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 PatientsTreatment2Active Not RecruitingNCT04484025
2020-08-01EbselenA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 PatientsTreatment2Active Not RecruitingNCT04483973
2020-08-01RivaroxabanA Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19Treatment2Active Not RecruitingNCT04504032
2020-08-01COVID-19 convalescent plasmaA Multi-Center, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of the Safety and Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Hospitalized Patients in Lagos StateTreatment2Active Not RecruitingPACTR202006760881890
2020-08-01AllocetraA Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory DysfunctionPrevention1Active Not RecruitingNCT04513470
2020-08-01TelmisartanEffectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19Treatment2Active Not RecruitingNCT04510662
2020-08-01Povidone-iodinePhase I / II Trial (Safety and Dosing) of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy SubjectsPrevention1, 2Active Not RecruitingNCT04510402
2020-08-01COVID-19 convalescent plasmaTherapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis / Plasmaféresis terapéutica en Pacientes Adultos críticamente Enfermos Con diagnóstico Confirmado de COVID-19Treatment2Active Not RecruitingNCT04480632
2020-08-01FavipiravirA Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and / or Favipiravir vs Currently Used Therapy in Severe Adults With COVID-19Treatment2Active Not RecruitingNCT04475991
2020-08-01MaravirocA Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and / or Favipiravir vs Currently Used Therapy in Severe Adults With COVID-19Treatment2Active Not RecruitingNCT04475991
2020-08-01RosuvastatinColchicine / Statins for the Prevention of COVID-19 Complications (COLSTAT) TrialTreatment3Active Not RecruitingNCT04472611
2020-08-01ColchicineColchicine / Statins for the Prevention of COVID-19 Complications (COLSTAT) TrialTreatment3Active Not RecruitingNCT04472611
2020-08-01FamotidineRole of Famotidine in the Symptomatic Improvement of Moderate to Severe COVID-19 PatientsTreatment3Active Not RecruitingNCT04504240
2020-08-01OpaganibTreatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen But Not Mechanical VentilationTreatment1, 2Active Not RecruitingNCT04502069
2020-08-01Efineptakin alfaA Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19Treatment1Active Not RecruitingNCT04501796
2020-08-01ApixabanCOVID-19 Outpatient Thrombosis Prevention Trial : A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of DiagnosisPrevention3Active Not RecruitingNCT04498273
2020-08-01Acetylsalicylic acidCOVID-19 Outpatient Thrombosis Prevention Trial : A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of DiagnosisPrevention3Active Not RecruitingNCT04498273
2020-08-01OtilimabA randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related diseaseTreatment2Active Not RecruitingPER-042-20
2020-08-01LinagliptinEffect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19Treatment3Active Not RecruitingNCT04542213
2020-08-01COVID-19 convalescent plasmaA Randomized, Double-blind, Placebo-controlled Trial of Anti-SARS-CoV-2 Plasma in Hospitalized Non-ICU Patients With COVID-19Treatment2Active Not RecruitingNCT04467151
2020-08-01AbataceptAbatacept for Patients With COVID-19 and Respiratory DistressTreatment1, 2Active Not RecruitingNCT04477642
2020-07-31CloveClinical trials to evaluate prophylactic action of Twakadi herbal tea in police professionals working in COVID19 pandemicTreatment3, 4Active Not RecruitingCTRI/2020/07/026925
2020-07-31Indian frankincenseA Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiCTreatment2Active Not RecruitingCTRI/2020/07/026789
2020-07-31ArtemisininA Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiCTreatment2Active Not RecruitingCTRI/2020/07/026789
2020-07-31CurcuminA Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiCTreatment2Active Not RecruitingCTRI/2020/07/026789
2020-07-31Ascorbic acidA Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiCTreatment2Active Not RecruitingCTRI/2020/07/026789
2020-07-31IvermectinRandomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19Treatment2Active Not RecruitingNCT04438850
2020-07-31Tenofovir alafenamideRandomized, Double-blind, Placebo-controlled Trial of TAF / FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)Prevention3Active Not RecruitingNCT04405271
2020-07-31EmtricitabineRandomized, Double-blind, Placebo-controlled Trial of TAF / FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)Prevention3Active Not RecruitingNCT04405271
2020-07-31IvermectinPilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 TransmissionTreatment2Active Not RecruitingNCT04390022
2020-07-31AZD-1656A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCADIA Trial - ARCADIATreatment2Active Not RecruitingEUCTR2020-002211-21-GB
2020-07-31IcatibantI-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsTreatment2Active Not RecruitingNCT04488081
2020-07-31RemdesivirI-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsTreatment2Active Not RecruitingNCT04488081
2020-07-31ApremilastI-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsTreatment2Active Not RecruitingNCT04488081
2020-07-31CenicrivirocI-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsTreatment2Active Not RecruitingNCT04488081
2020-07-31CholecalciferolThe Role of Vitamin D in Mitigating COVID-19 Infection Severity : Focusing on Reducing Health Disparities in South CarolinaPrevention4Active Not RecruitingNCT04482673
2020-07-31Ascorbic acidA comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine stormTreatment2Active Not RecruitingIRCT20200525047570N1
2020-07-31TocilizumabA comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine stormTreatment2Active Not RecruitingIRCT20200525047570N1
2020-07-31Interferon GammaA comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine stormTreatment2Active Not RecruitingIRCT20200525047570N1
2020-07-31AcalabrutinibAn Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19Treatment1Active Not RecruitingNCT04497948
2020-07-30NVX-CoV2373A Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV. COVID-19Treatment2RecruitingPACTR202009726132275
2020-07-30COVID-19 convalescent plasmaCompassionate Use of Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Prospective Observational Study (Amended Protocol)Basic ScienceNot AvailableActive Not RecruitingNCT04570982
2020-07-30Human Umbilical Cord Mesenchymal Stem CellsMulti-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)Treatment2Active Not RecruitingNCT04466098
2020-07-30Lithium carbonateA randomized control study to evaluate the therapeutic effects of Lithium in Covid-19 patientsTreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026193
2020-07-30ThimerosalA Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 InfectionTreatment2Active Not RecruitingNCT04522830
2020-07-30TocilizumabA Nested Interventional Cohort Study to Assess the Efficacy and Safety of Adjunctive Humanized Monoclonal Interleukin-6 Receptor Blocker Tocilizumab (TCZ) Therapy to Standard of Care for the Reduction of Hyperinflammation Related Mortality in SARS-Cov2 Positive PatientsTreatment3Active Not RecruitingNCT04423042
2020-07-30Recombinant Human Plasma GelsolinA Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 PneumoniaTreatment2Active Not RecruitingNCT04358406
2020-07-30EnoxaparinIntermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19Treatment3Active Not RecruitingNCT04486508
2020-07-30AtorvastatinIntermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19Treatment3Active Not RecruitingNCT04486508
2020-07-30HeparinIntermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19Treatment3Active Not RecruitingNCT04486508
2020-07-30IvermectinEvaluating the efficacy and safety of Ivermectin in the treatment of COVID-19 patients : A double-blind randomized controlled trial, phase IITreatment2RecruitingIRCT20200404046937N4
2020-07-30AviptadilRLF-100 (Aviptadil) Intermediate Population Expanded Access ProtocolTreatmentNot AvailableActive Not RecruitingNCT04453839
2020-07-30RUTI® VaccineDouble-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of the RUTI® Vaccine to Prevent SARS-CoV-2 InfectionPrevention3Active Not RecruitingNCT04453488
2020-07-29Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned MediaEmergency Use Pilot Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of COVID-19 Related Acute Respiratory Distress SyndromeTreatment1Active Not RecruitingNCT04565665
2020-07-29TofacitinibInvestigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC)Treatment2Active Not RecruitingNCT04415151
2020-07-29SitagliptinThe Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic PatientsTreatment3Active Not RecruitingNCT04365517
2020-07-29AnakinraEarly Treatment of Cytokine Storm Syndrome in Covid-19Treatment3Active Not RecruitingNCT04362111
2020-07-29RibavirinAn Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 InfectionTreatment2Active Not RecruitingNCT04494399
2020-07-29Interferon beta-1bAn Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 InfectionTreatment2Active Not RecruitingNCT04494399
2020-07-28CamostatRECOVER : Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 InhibitorTreatment2Active Not RecruitingNCT04470544
2020-07-28NimesulideThe role of Nimesulide in the treatment of COVID-19 infectionTreatmentNot AvailableActive Not RecruitingIRCT20200723048178N1
2020-07-27OxygenComparison of High Flow Nasal Oxygen and Non Invasive Ventilation in Acute Hypoxemic Respiratory Failure due to Severe COVID-19 pneumonia : A Randomized Controlled TrialTreatment3, 4Active Not RecruitingCTRI/2020/07/026835
2020-07-27ChloroquineEfficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 PatientsPrevention1Active Not RecruitingNCT04443270
2020-07-27Turmeric"Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ??Treatment1Active Not RecruitingCTRI/2020/07/026674
2020-07-27Ginger"Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ??Treatment1Active Not RecruitingCTRI/2020/07/026674
2020-07-27Glycyrrhiza glabra"Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ??Treatment1Active Not RecruitingCTRI/2020/07/026674
2020-07-27Licorice"Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ??Treatment1Active Not RecruitingCTRI/2020/07/026674
2020-07-27Black pepper"Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ??Treatment1Active Not RecruitingCTRI/2020/07/026674
2020-07-27Cinnamon"Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ??Treatment1Active Not RecruitingCTRI/2020/07/026674
2020-07-27OzoneA pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatmentTreatmentNot AvailableActive Not RecruitingCTRI/2020/07/026671
2020-07-27DexamethasoneRandomized Study Of the Effect of Dexamethasone and Methylprednisolone on levels of IL-6 and clinical outcome in severe COVID-19 - REDMICTreatmentNot AvailableActive Not RecruitingCTRI/2020/07/026608
2020-07-27MethylprednisoloneRandomized Study Of the Effect of Dexamethasone and Methylprednisolone on levels of IL-6 and clinical outcome in severe COVID-19 - REDMICTreatmentNot AvailableActive Not RecruitingCTRI/2020/07/026608
2020-07-27CamostatA Randomised Phase II / III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane FusionTreatment2, 3Active Not RecruitingNCT04455815
2020-07-27EpiVacCoronaSimple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)Prevention1, 2Active Not RecruitingNCT04527575
2020-07-27Moderna COVID-19 VaccineA Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and OlderPrevention3Active Not RecruitingNCT04470427
2020-07-27Magnesium sulfateEvaluation of the efficacy and safety of inhaled magnesium sulfate in combination with standard treatment in Covid-19 patients : a clinical trialTreatment3RecruitingIRCT20191211045691N1
2020-07-27NintedanibEfficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019 : Historical control study.Treatment2Active Not RecruitingJPRN-jRCTs051200036
2020-07-27PlasmaCordClinical study to evaluate the safety and tolerability of intravenous infusion of plasma from human umbilical cord and placental blood (Plasmacord®) in patients with Severe Acute Respiratory Syndrome resulting from Sars-Cov-2 infectionTreatment1, 2Active Not RecruitingRBR-4pfygr
2020-07-27Aspartyl-alanyl-diketopiperazineA Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampion™ in Adult COVID-19 Patients Requiring Oxygen SupplementationTreatment1Active Not RecruitingNCT04456452
2020-07-27MavrilimumabA Phase 2 / 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammationTreatment2, 3Active Not RecruitingNCT04447469
2020-07-26Anti-SARS-CoV-2 REGN-COV2A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult VolunteersTreatment1Active Not RecruitingNCT04519437
2020-07-26Taraxacum officinale leafDetermination of dandelion herbal capsule (Dandelherb) efficacy on symptom of patient with Covid-19 virus : a clinical trial studyTreatment3RecruitingIRCT20180513039641N2
2020-07-26Taraxacum officinale pollenDetermination of dandelion herbal capsule (Dandelherb) efficacy on symptom of patient with Covid-19 virus : a clinical trial studyTreatment3RecruitingIRCT20180513039641N2
2020-07-25Human Umbilical Cord Mesenchymal Stem CellsSafety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19Treatment1Active Not RecruitingNCT04467047
2020-07-25DAS-181DAS181 for COVID-19 : A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind StudyTreatment2, 3Active Not RecruitingNCT04354389
2020-07-25Interferon beta-1aEvaluation of the efficacy and safety of Favipiravir and Interferon beta compared to Lopinavir / Ritonavir and Interferon beta in patients with COVID-19Treatment3Active Not RecruitingIRCT20200506047323N3
2020-07-25FavipiravirEvaluation of the efficacy and safety of Favipiravir and Interferon beta compared to Lopinavir / Ritonavir and Interferon beta in patients with COVID-19Treatment3Active Not RecruitingIRCT20200506047323N3
2020-07-24ClazakizumabA study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. - CLiCK StudyTreatment2Active Not RecruitingEUCTR2020-002476-13-GB
2020-07-24iota-CarrageenanEfficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)Prevention4Active Not RecruitingNCT04521322
2020-07-24Nitric OxideA Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04476992
2020-07-23FavipiravirA Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19Treatment2, 3Active Not RecruitingNCT04464408
2020-07-23Human Umbilical Cord Mesenchymal Stem CellsPhase 1 / 2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19Treatment1, 2Active Not RecruitingNCT04494386
2020-07-23LosartanRandomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19Treatment2Active Not RecruitingNCT04447235
2020-07-23IvermectinRandomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19Treatment2Active Not RecruitingNCT04447235
2020-07-22IbrutinibRandomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-InTreatment2Active Not RecruitingNCT04439006
2020-07-22CopperA Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19.Treatment3Active Not RecruitingCTRI/2020/07/026515
2020-07-22Sodium copper chlorophyllinA Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19.Treatment3Active Not RecruitingCTRI/2020/07/026515
2020-07-22ResveratrolA Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19.Treatment3Active Not RecruitingCTRI/2020/07/026515
2020-07-22ResveratrolA Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19.Treatment2Active Not RecruitingCTRI/2020/07/026514
2020-07-22Sodium copper chlorophyllinA Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19.Treatment2Active Not RecruitingCTRI/2020/07/026514
2020-07-22CopperA Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19.Treatment2Active Not RecruitingCTRI/2020/07/026514
2020-07-22NelfinavirEvaluation of Nelfinavir for asymptomatic and mild COVID-19 : A multicenter open-label, blinded outcome, randomized controlled trial - NFV trial for asymptomatic and mild COVID-19Treatment1, 2Active Not RecruitingJPRN-jRCT2071200023
2020-07-22Nitrous acidTreatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite : A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical StudyTreatment2Active Not RecruitingNCT04401527
2020-07-22Human Umbilical Cord Mesenchymal Stem CellsClinical trial of efficacy and safety of mesenchymal stem cell transplantation in patients with COVID-19 pneumoniaTreatment3Active Not RecruitingIRCT20200426047206N2
2020-07-22CyclosporineEvaluating the effect of Cyclosporine in prognosis and clinical improvement in patients with COVID-19 : A Randomized Clinical Trial StudyTreatment3Active Not RecruitingIRCT20200426047206N3
2020-07-22IvermectinEvaluation of the effect of Ivermectin in hospitalized patients with COVID-19 in Imam Reza Hospital in MashhadTreatment3Active Not RecruitingIRCT20190602043787N3
2020-07-22FluvoxamineEffect of fluvoxamine medicine on cytokine level of COVID-19 patients, hospitalized in ICU wardTreatment2, 3Active Not RecruitingIRCT20131115015405N4
2020-07-22MavrilimumabA PHASE 2 / 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAVRILIMUMAB (KPL-301) TREATMENT IN ADULT SUBJECTS HOSPITALIZED WITH SEVERE COVID-19 PNEUMONIA AND HYPER-INFLAMMATIONTreatment2RecruitingPER-032-20
2020-07-22AtovaquoneAtovaquone for Treatment of COVID-19Treatment2Active Not RecruitingNCT04456153
2020-07-21BCG vaccinePrevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical TrialPrevention3Active Not RecruitingNCT04461379
2020-07-21Azadirachta indica leafProphylaxis with Neem Capsules (Azadirachta indica) in Healthcare personnel and relatives in Contact with COVID-19 PatientsTreatment3Active Not RecruitingCTRI/2020/07/026560
2020-07-21CAP-1002A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients With Severe COVID-19TreatmentNot AvailableActive Not RecruitingNCT04338347
2020-07-21LeflunomideTargeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19) - DEFEAT- Covid StudyTreatment2Active Not RecruitingEUCTR2020-002952-18-GB
2020-07-21LopinavirAn International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)Treatment3Active Not RecruitingNCT04483960
2020-07-21COVID-19 convalescent plasmaAn International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)Treatment3Active Not RecruitingNCT04483960
2020-07-21HydroxychloroquineAn International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)Treatment3Active Not RecruitingNCT04483960
2020-07-21RitonavirAn International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)Treatment3Active Not RecruitingNCT04483960
2020-07-21AtorvastatinEvaluation of atorvastatin tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad : A double-blind randomized placebo controlled clinical trialTreatment2Active Not RecruitingIRCT20200408046990N3
2020-07-21MontelukastEffect of Montelukast on inflammatory factors in patients with COVID-19Treatment3RecruitingIRCT20180624040213N2
2020-07-21RemdesivirA Phase 2 / 3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19Treatment2, 3Active Not RecruitingNCT04431453
2020-07-21CoronaVacDouble-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by SinovacPrevention3Active Not RecruitingNCT04456595
2020-07-20AprepitantA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19Treatment2Active Not RecruitingNCT04470622
2020-07-20Sodium bicarbonateA randomized open label parallel group trial to study the safety and efficacy of steam impregnated with 8.4 % Sodium Bicarbonate in patients with Covid-19 infectionTreatmentNot AvailableActive Not RecruitingCTRI/2020/07/026535
2020-07-20EflornithineAn open label, randomized, three treatment, three arm, parallel group, investigator initiated, comparative clinical trial to evaluate the safety and efficacy of Eflornithine against the standard of care in human adult hospitalized COVID-19 patientsTreatment2, 3Active Not RecruitingCTRI/2020/07/026529
2020-07-20IvermectinComparative Study of Hydroxychloroquine and Ivermectin in COVID-19 ProphylaxisPreventionNot AvailableActive Not RecruitingNCT04384458
2020-07-20HydroxychloroquineComparative Study of Hydroxychloroquine and Ivermectin in COVID-19 ProphylaxisPreventionNot AvailableActive Not RecruitingNCT04384458
2020-07-20HeparinEfficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia : A Randomized, Controlled, 2x2 Factorial StudyTreatment3Active Not RecruitingNCT04485429
2020-07-20MethylprednisoloneEfficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia : A Randomized, Controlled, 2x2 Factorial StudyTreatment3Active Not RecruitingNCT04485429
2020-07-20RitonavirCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2Active Not RecruitingPACTR202007720062393
2020-07-20LopinavirCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2Active Not RecruitingPACTR202007720062393
2020-07-20LopinavirAn open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19Treatment3Active Not RecruitingPACTR202006537901307
2020-07-20RitonavirAn open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19Treatment3Active Not RecruitingPACTR202006537901307
2020-07-20HydroxychloroquineAn open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19Treatment3Active Not RecruitingPACTR202006537901307
2020-07-20AbataceptPhase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory CompromiseTreatment2Active Not RecruitingNCT04472494
2020-07-20COVID-19 Spike-GM-CSF Protein Lactated Ringer's InjectionConducting an Initial Small, Controlled Clinical Trial to Assess for COVID-19 Therapeutic Biologics Activity (Proof-of-concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients.Treatment1Active Not RecruitingNCT03348670
2020-07-20BNT162b1 SARS-CoV-2 VaccineSafety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects : A Phase I, Randomized, Placebo-controlled, Observer-blind StudyTreatment1Active Not RecruitingChiCTR2000034825
2020-07-18MometasoneEffect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19Treatment1RecruitingIRCT20200522047542N1
2020-07-17RuxolitinibRandomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 InfectionTreatment2, 3Active Not RecruitingNCT04477993
2020-07-16FavipiravirFavipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARETreatment2Active Not RecruitingEUCTR2020-002106-68-GB
2020-07-16LopinavirFavipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARETreatment2Active Not RecruitingEUCTR2020-002106-68-GB
2020-07-16RitonavirFavipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARETreatment2Active Not RecruitingEUCTR2020-002106-68-GB
2020-07-16Inactivated SARS-Cov-2 VaccineRandomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Safety and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 18 Years and aboveTreatment3RecruitingChiCTR2000034780
2020-07-16COVID-19 convalescent plasmaANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)Treatment2Active Not RecruitingNCT04432272
2020-07-16ProbiorinseRandomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04458519
2020-07-16BudesonideUse of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and HospitalisationTreatment2Active Not RecruitingNCT04416399
2020-07-16HydroxychloroquineControlled clinical trial of hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care settingTreatment2Active Not RecruitingEUCTR2020-002038-33-FI
2020-07-16COVID-19 convalescent plasmaConvalescent Plasma for Severe COVID-19 Patients : a Randomized, Open-label, Phase 3 TrialTreatment3Active Not RecruitingNCT04547660
2020-07-16Inactivated SARS-Cov-2 VaccineMulticenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and AbovePrevention3Active Not RecruitingNCT04510207
2020-07-16TocilizumabComparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19Treatment2Active Not RecruitingNCT04476979
2020-07-16DexamethasoneComparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19Treatment2Active Not RecruitingNCT04476979
2020-07-15INO-4800A Phase I / IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy VolunteersPrevention1, 2Active Not RecruitingNCT04447781
2020-07-15Omega-3 fatty acidsCOVID-19 Anosmia StudyTreatment2Active Not RecruitingNCT04495816
2020-07-15ApilimodA Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19Treatment2Active Not RecruitingNCT04446377
2020-07-15Oral Polio VaccineOral Polio Vaccine as Potential Protection Against COVID-19 : A Cluster-randomised Trial in Guinea-BissauPrevention4Active Not RecruitingNCT04445428
2020-07-15Janssen COVID-19 VaccineA Randomized, Double-blind, Placebo-controlled Phase 1 / 2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and OlderTreatment1, 2Active Not RecruitingNCT04436276
2020-07-15Cinnamonâ??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â??TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026231
2020-07-15Cow milkâ??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â??TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026231
2020-07-15Gingerâ??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â??TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026231
2020-07-15Turmericâ??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â??TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026231
2020-07-15Vitamin DEfficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19 : Open Controlled Clinical TrialTreatment3Active Not RecruitingNCT04502667
2020-07-15SofosbuvirEfficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled TrialTreatment4Active Not RecruitingNCT04498936
2020-07-15NitazoxanideEfficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled TrialTreatment4Active Not RecruitingNCT04498936
2020-07-15LedipasvirEfficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled TrialTreatment4Active Not RecruitingNCT04498936
2020-07-15BCG vaccineBCG vaccine as preventive measure against COVID-19 in health care workersTreatment2, 3Active Not RecruitingRBR-5ysj54
2020-07-15FavipiravirA Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate TypeTreatment3Active Not RecruitingEUCTR2020-001608-40-DE
2020-07-15Vitamin DEfficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical TrialTreatment3Active Not RecruitingNCT04535791
2020-07-15CholecalciferolEfficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical TrialTreatment3Active Not RecruitingNCT04535791
2020-07-15Nitric OxideInhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2Treatment2Active Not RecruitingNCT04456088
2020-07-15HydroxychloroquineDevelopment and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19TreatmentNot AvailableActive Not RecruitingNCT04477083
2020-07-15EnzalutamideA Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04475601
2020-07-14IodineEfficacy of Iodine Complex in Mild to Moderate COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04473261
2020-07-14IvermectinSub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa : a Placebo Randomized Control Trial on Mild to Moderate COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04472585
2020-07-14ZincSub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa : a Placebo Randomized Control Trial on Mild to Moderate COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04472585
2020-07-14ClofazimineAn Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 InfectionTreatment2Active Not RecruitingNCT04465695
2020-07-14Interferon beta-1bAn Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 InfectionTreatment2Active Not RecruitingNCT04465695
2020-07-14RemdesivirA Phase 2 / 3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19Treatment2Active Not RecruitingEUCTR2020-001803-17-GB
2020-07-14ColchicineColchicine in Moderate Symptomatic COVID-19 Patients : Double Blind, Randomized, Placebo Controlled Trial to Observe the EfficacyTreatmentNot AvailableActive Not RecruitingNCT04527562
2020-07-14COVID-19 convalescent plasmaUse of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic OutbreakTreatment2Active Not RecruitingNCT04408040
2020-07-14IvermectinRandomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19Treatment2, 3Active Not RecruitingNCT04405843
2020-07-13RitonavirTOGETHER 3 Trial : An Adaptive Randomized Platform Trial to Investigate the Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults. COVID-19Treatment2Active Not RecruitingPACTR202007700757139
2020-07-13LopinavirTOGETHER 3 Trial : An Adaptive Randomized Platform Trial to Investigate the Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults. COVID-19Treatment2Active Not RecruitingPACTR202007700757139
2020-07-13BBV152An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy VolunteersPrevention1, 2Active Not RecruitingNCT04471519
2020-07-13EnzalutamideA prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) - COVIDENZATreatment2Active Not RecruitingEUCTR2020-002027-10-SE
2020-07-13TurmericA clinical study to evaluate the effect of AYUSH medicines in the management of COVID-19Treatment3, 4Active Not RecruitingCTRI/2020/07/026371
2020-07-13ZYCOV-DA prospective, randomized, adaptive, phase I / II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M / s Cadila Healthcare Limited by intradermal route in healthy subjectsTreatment1, 2Active Not RecruitingCTRI/2020/07/026352
2020-07-13OzonePhase I / II randomized controlled clinical trial to assess safety and efficacy of ozone therapy via rectal insufflation and minor auto haemotherapy as an adjuvant in mild to moderate Covid-19 subjects. - NilTreatment1, 2Active Not RecruitingCTRI/2020/07/026354
2020-07-13Alkaline PhosphataseAlkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19)TreatmentNot AvailableActive Not RecruitingNL8578
2020-07-13Rubella virus vaccineEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)Prevention3Active Not RecruitingNCT04357028
2020-07-13Measles virus vaccine live attenuatedEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)Prevention3Active Not RecruitingNCT04357028
2020-07-13Mumps virus strain B level jeryl lynn live antigenEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)Prevention3Active Not RecruitingNCT04357028
2020-07-13SARS-CoV-2 SclampA Phase 1 Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study To Evaluate The Safety And Immunogenicity Of An Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine (COVID-19 vaccine) In Healthy Adults Aged 18 To 55 Years OldTreatment1Active Not RecruitingACTRN12620000674932
2020-07-13ClazakizumabA Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 InfectionTreatment2Active Not RecruitingNCT04494724
2020-07-13SofosbuvirEvaluation of the effect of sofosbuvir / daclatasvir in COVID-19 patients : a double-blind randomized clinical trialTreatment3Active Not RecruitingIRCT20200624047908N1
2020-07-13DaclatasvirEvaluation of the effect of sofosbuvir / daclatasvir in COVID-19 patients : a double-blind randomized clinical trialTreatment3Active Not RecruitingIRCT20200624047908N1
2020-07-13SARS-CoV-2 SclampA Phase 1 randomised, double-blind, placebo-controlled, dosage-escalation, single centre study to evaluate the safety and immunogenicity of an adjuvanted SARS-CoV-2 Sclamp protein subunit vaccine (COVID-19 vaccine) In healthy adults aged 18 to 55 years and healthy older adults, aged 56 years and overTreatment1RecruitingISRCTN51232965
2020-07-13SARS-CoV-2 SclampA Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and OverPrevention1Active Not RecruitingNCT04495933
2020-07-13AstegolimabA PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA - COVASTILTreatment2Unknown StatusEUCTR2020-002713-17-ES
2020-07-13Efmarodocokin alfaA PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA - COVASTILTreatment2Unknown StatusEUCTR2020-002713-17-ES
2020-07-12Nitric OxideA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)Treatment3Active Not RecruitingNCT04421508
2020-07-12FavipiravirA Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19Treatment2Active Not RecruitingNCT04346628
2020-07-12CHO Cells Recombinant VaccineA Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 YearsPrevention2Active Not RecruitingNCT04466085
2020-07-11ZincProspective study to assess therapeutic role of Zinc in COVID-19 patientsTreatmentNot AvailableActive Not RecruitingCTRI/2020/07/026340
2020-07-11NafamostatAn Open Label, Randomized, Multicenter, Controlled Clinical Study to Evaluate the Efficacy and Safety of Nafamostat Mesilate in the Treatment of Moderate COVID-19 DiseaseTreatment2Active Not RecruitingCTRI/2020/06/026220
2020-07-11DactolisibRandomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults =65 Years in a Nursing Home in Which =1 Person(s) Have Lab Confirmed COVID19Prevention3Active Not RecruitingNCT04409327
2020-07-11Povidone-iodineEvaluation of the Effectiveness of Mouthwashes in Early Reducing the mouth Viral Load Among COVID-19 Patients : A double-blind randomized clinical trialTreatment3RecruitingIRCT20170117032025N7
2020-07-10Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)A Randomized, Double-blind, Placebo-controlled, Phase Ib / IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged ?60 YearsPrevention1, 2Active Not RecruitingNCT04470609
2020-07-10Coronavirus-Like Particle COVID-19 VaccineA Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of AgePrevention1Active Not RecruitingNCT04450004
2020-07-10MethylprednisoloneThe efficacy of methylprednisolone mini pulse on the treatment of COVID-19 patients admitted to intensive care unitTreatment3Active Not RecruitingIRCT20170716035126N4
2020-07-10ResveratrolRoutine use of over-the-counter Nutraceuticals, Resveretrol-Copper with standard treatment in Hospitalized Patients With Pneumonia / Acute Respiratory Distress Syndrome Due To SARS-CoV-2 (Covid-19)- Retrospective AnalysisBasic ScienceNot AvailableActive Not RecruitingCTRI/2020/06/026256
2020-07-10CopperRoutine use of over-the-counter Nutraceuticals, Resveretrol-Copper with standard treatment in Hospitalized Patients With Pneumonia / Acute Respiratory Distress Syndrome Due To SARS-CoV-2 (Covid-19)- Retrospective AnalysisBasic ScienceNot AvailableActive Not RecruitingCTRI/2020/06/026256
2020-07-10IvermectinA Clinical Trial to Study the Efficacy of â??Ivermectinâ?? in the prevention of Covid-19. .A Single Arm Study. â??Treatment3Active Not RecruitingCTRI/2020/06/026232
2020-07-10Cepeginterferon alfa-2BA phase II, randomized, controlled, open-label study to evaluate the efficacy and safety of Pegylated IFN alfa-2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Treatment2Active Not RecruitingCTRI/2020/06/026087
2020-07-10ABX-464A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).Treatment2Active Not RecruitingEUCTR2020-001673-75-DE
2020-07-10WormwoodEvaluation of the effect of Afsantin in the treatment of COVID 19 patientsTreatment3RecruitingIRCT20190415043279N6
2020-07-09CrizanlizumabCrizanlizumab for Treating COVID-19 VasculopathyTreatment2Active Not RecruitingNCT04435184
2020-07-09HeparinA randomised controlled trial of Nebulised Heparin in critically ill mechanically ventilated patients with COVID-19 to assess the effect on the duration of mechanical ventilation.Treatment3Active Not RecruitingACTRN12620000517976
2020-07-09RuxolitinibMATIS : Phase 2 / 3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia - Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS)Treatment2Active Not RecruitingEUCTR2020-001750-22-GB
2020-07-09FostamatinibMATIS : Phase 2 / 3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia - Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS)Treatment2Active Not RecruitingEUCTR2020-001750-22-GB
2020-07-09CysteineEffective of Elman tablet on illness severity and length of hospital stay in the patients with COVID-19 infectionTreatment3Active Not RecruitingIRCT20200609047707N1
2020-07-09Human immunoglobulin GEvaluating the efficacy and safety of intravenous immunoglobulin (IVIG) in COVID-19 patientsTreatment2, 3Active Not RecruitingIRCT20151227025726N20
2020-07-09IvermectinRANDOMIZED PHASE IIA CLINICAL TRIAL TO COMPARE THE EFFICACY OF IVERMECTIN VERSUS PLACEBO TO OBTAIN NEGATIVE PCR RESULTS IN PATIENTS WITH EARLY PHASE COVID-19Treatment2RecruitingPER-034-20
2020-07-09PTC299Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)Treatment2, 3Active Not RecruitingNCT04439071
2020-07-09IcatibantRandomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilation compared with standard care - HUB-MdI-ICAT-COVID-201Treatment2Unknown StatusEUCTR2020-002166-13-ES
2020-07-08Acetylsalicylic acidDynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical TrialTreatment3Active Not RecruitingNCT04466670
2020-07-08HeparinDynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical TrialTreatment3Active Not RecruitingNCT04466670
2020-07-08EnoxaparinDynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical TrialTreatment3Active Not RecruitingNCT04466670
2020-07-08BCG vaccineBCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial - BRACETreatment3Active Not RecruitingEUCTR2020-002503-19-NL
2020-07-07Povidone-iodineRole of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission : SHIELD StudyPrevention1Active Not RecruitingNCT04478019
2020-07-06MontelukastImpact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19) : an investigator-initiated open labelled randomized controlled pragmatic trialTreatment4Active Not RecruitingEUCTR2020-001747-21-PT
2020-07-06CannabidiolCannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019 : A Randomized, Double-blind, Placebo-controlled Clinical TrialTreatment2, 3Active Not RecruitingNCT04467918
2020-07-06COVID-19 convalescent plasmaCovid-19 Convalescent Plasma Used for Treatment of Patients in Norway - a Monitoring StudyBasic ScienceNot AvailableActive Not RecruitingNCT04463823
2020-07-06COVID-19 convalescent plasmaPilot Clinical, Statistical and Epidemiological Study on Efficacy and Safety of Convalescent Plasma for the Management of Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04452812
2020-07-06TofacitinibA MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE SAFETY AND EFFICACY OF TOFACITINIB IN HOSPITALIZED PARTICIPANTS WITH COVID-19 PNEUMONIA WHO ARE RECEIVING STANDARD OF CARE THERAPYTreatment2Active Not RecruitingNCT04412252
2020-07-06DegarelixHormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) : A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus DegarelixTreatment2Active Not RecruitingNCT04397718
2020-07-06ZanubrutinibA Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary DistressTreatment2Active Not RecruitingNCT04382586
2020-07-06COVID-19 convalescent plasmaPHASE 2 STUDY OF EFFICACY AND SAFETY OF PLASMA FROM CONVALESCENT PATIENTS WITH COVID-19 IN PATIENTS WITH MODERATE DISEASE (AUNA 20-01)Treatment2Active Not RecruitingPER-031-20
2020-07-06OxygenHyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe HypoxemiaTreatment2Active Not RecruitingNCT04477954
2020-07-05AcalabrutinibA PHASE 2, OPEN LABEL, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ACALABRUTINIB WITH BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE IN SUBJECTS HOSPITALIZED WITH COVID-19Treatment2Active Not RecruitingPER-018-20
2020-07-05CurcuminEvaluation of the effect of nano micelles containing curcumin (Sina Ccurcumin) as a therapeutic supplement in patients with COVID-19 and investigating of immune responses balance changes following treatment : A randomized double blind clinical trial.TreatmentNot AvailableActive Not RecruitingIRCT20200611047735N1
2020-07-05OzoneClinical, Open label, Phase III, Multicenter, Prospective, Comparative, Controlled, Randomized Study to Assess the Effectiveness of Systemic Oxygen Therapy with Medicinal Ozone in Early Control of Disease Progression in Patients with COVID-19 who have Acute Infectious Respiratory SymptomsTreatment3RecruitingRBR-5v3k5d
2020-07-04EnoxaparinUtilização da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com síndrome respiratória Aguda Grave Por COVID-19Treatment3Active Not RecruitingNCT04444700
2020-07-03TD-139Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19Treatment2, 3Active Not RecruitingNCT04473053
2020-07-03NafamostatRapid Experimental Medicine for COVID-19 - DEFINE COVID-19Treatment2, 3Active Not RecruitingNCT04473053
2020-07-03BeractantOpen-label Trial to Assess the Efficacy and Safety of Inhalation Use of the Approved Drug Surfactant-BL (Biosurf LLC, Russia) as a Part of Complex Therapy of Acute Respiratory Distress Syndrome (ARDS) in Patients With SARS-CoV-2 Coronavirus Infection (COVID-19)Basic ScienceNot AvailableActive Not RecruitingNCT04568018
2020-07-03DapagliflozinmulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)Treatment2, 3Active Not RecruitingNCT04393246
2020-07-03AmbrisentanmulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)Treatment2, 3Active Not RecruitingNCT04393246
2020-07-03Biomodulin TEvaluation of the effect and safety of BIOMODULIN T(R) for the stimulation of the immune response in patients with Stage 5 Chronic Kidney Disease under an iterated hemodialysis regimen. Exploratory study. (COVID-19)TreatmentNot AvailableCompletedRPCEC00000316
2020-07-02ABX-464A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).Treatment2Active Not RecruitingEUCTR2020-001673-75-GB
2020-07-02OpaganibOpaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive PneumoniaTreatment2Active Not RecruitingNCT04414618
2020-07-02KB109A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19TreatmentNot AvailableActive Not RecruitingNCT04414124
2020-07-02Zinc chlorideHigh-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients : A pilot randomized controlled trialTreatment1, 2Active Not RecruitingACTRN12620000454976
2020-07-02DutasterideAnti-Androgen Treatment for COVID-19TreatmentNot AvailableActive Not RecruitingNCT04446429
2020-07-01DiosminRandomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in EgyptTreatment1Active Not RecruitingNCT04452799
2020-07-01HesperidinRandomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in EgyptTreatment1Active Not RecruitingNCT04452799
2020-07-01BACTEK-RProspective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to SARS-CoV-2 Infection in Healthcare PersonnelPrevention3Active Not RecruitingNCT04452643
2020-07-01Povidone-iodineThe Efficacy of Topical Povidone-Iodine Rinses in the Management of the Coronavirus Disease 2019 (COVID-19)Treatment1Active Not RecruitingNCT04449965
2020-07-01Human interferon betaTreatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety StudyTreatment2Active Not RecruitingNCT04469491
2020-07-01PrasugrelPrasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised PatientsTreatment3Active Not RecruitingNCT04445623
2020-07-01Measles virus vaccine live attenuatedMeasles Vaccine : Is There a Protective Role in COVID 19 Pandemic?Basic ScienceNot AvailableActive Not RecruitingNCT04445610
2020-07-01SofosbuvirEfficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19Treatment2, 3Active Not RecruitingNCT04443725
2020-07-01HydroxychloroquineEfficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19Treatment2, 3Active Not RecruitingNCT04443725
2020-07-01DaclatasvirEfficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19Treatment2, 3Active Not RecruitingNCT04443725
2020-07-01NitazoxanideProspective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita -RJTreatment2, 3Active Not RecruitingNCT04441398
2020-07-01IvermectinComparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir / Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 InfectionTreatment4Active Not RecruitingNCT04435587
2020-07-01OzoneRandomized Clinical Trial to Evaluate Efficacy and Safety of Systemic Indirect Endovenous Ozone Therapy (SIEVOT) as Adjuvant Treatment in COVID19 Non-intubated PatientsTreatment3Active Not RecruitingNCT04359303
2020-07-01IvermectinPhase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)Treatment2Active Not RecruitingNCT04431466
2020-07-01Icosapent ethylPREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention TrialTreatment3Active Not RecruitingNCT04460651
2020-07-01Human Umbilical Cord Mesenchymal Stem CellsSafety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19Treatment2Active Not RecruitingNCT04429763
2020-07-01Covax-19™A Phase I Trial of a Therapeutic Vaccine (Covax-19™) in SARS-CoV-2 Infected PatientsTreatment1Active Not RecruitingNCT04428073
2020-07-01COVID-19 convalescent plasmaEffectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 : A Randomized, Controlled Study CRI-CP (Coronavirus Investigation - Convalescent Plasma)Treatment2, 3Active Not RecruitingNCT04425837
2020-07-01LopinavirA Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04459702
2020-07-01AzithromycinA Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04459702
2020-07-01HydroxychloroquineA Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04459702
2020-07-01RitonavirA Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04459702
2020-07-01COVID-19 convalescent plasmaConvalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients : A Feasibility StudyTreatment1Active Not RecruitingNCT04458363
2020-07-01Virus Specific T-CellPart Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19Treatment1, 2Active Not RecruitingNCT04457726
2020-07-01OseltamivirApplication of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 PatientsTreatment1Active Not RecruitingNCT04457609
2020-07-01Human Umbilical Cord Mesenchymal Stem CellsApplication of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 PatientsTreatment1Active Not RecruitingNCT04457609
2020-07-01AzithromycinApplication of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 PatientsTreatment1Active Not RecruitingNCT04457609
2020-07-01UlinastatinA Phase 3, Prospective, Randomized, Open Label, Comparative, Clinical Study To Evaluate Efficacy And Safety Of Ulinastatin Plus Standard-Of-Care Compared To Standard-Of-Care In Treatment Of Acute Respiratory Distress Syndrome (ARDS) In Hospitalized COVID-19 Infection PatientTreatment3Active Not RecruitingCTRI/2020/06/025704
2020-07-01Human Umbilical Cord Mesenchymal Stem CellsMesenchymal Stromal Cell-based Therapy for COVID-19-associated Acute Respiratory Distress Syndrome : a Pilot Clinical StudyTreatment1Active Not RecruitingNCT04525378
2020-07-01NitazoxanideProof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day, Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical ConditionTreatment2Active Not RecruitingNCT04423861
2020-07-01GaradacimabA Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)Treatment2Active Not RecruitingNCT04409509
2020-07-01AzithromycinHydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia : A Randomized,Open-label,Controlled Clinical TrialTreatment3Active Not RecruitingNCT04405921
2020-07-01HydroxychloroquineHydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia : A Randomized,Open-label,Controlled Clinical TrialTreatment3Active Not RecruitingNCT04405921
2020-07-01AtibuclimabPhase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)Treatment2Active Not RecruitingNCT04391309
2020-07-01Recombinant Bacterial ACE2 Receptors-like EnzymeCombination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2Treatment1Active Not RecruitingNCT04382950
2020-07-01IsotretinoinCombination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2Treatment1Active Not RecruitingNCT04382950
2020-07-01TocilizumabA Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-PneumoniaTreatment2Active Not RecruitingNCT04335305
2020-07-01PembrolizumabA Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-PneumoniaTreatment2Active Not RecruitingNCT04335305
2020-07-01Sodium bicarbonateSodium Bicarbonate for Treatment of COVID-19 Pneumonia : A Preliminary Prospective Controlled Crossover StudyTreatmentNot AvailableActive Not RecruitingNCT04374591
2020-07-01AMY-101A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)Treatment2Active Not RecruitingNCT04395456
2020-07-01AV-COVID-19Adaptive Phase IB-II Randomized Clinical Trial Of Preventive Vaccine Consisting Of Autologous Dendritic Cells Loaded With Antigens From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), With Or Without GM-CSF, In Subjects Negative For COVID-19 Infection And Anti-SARS-CoV-2 AntibodiesPrevention1, 2Active Not RecruitingNCT04386252
2020-07-01BeractantPhase I / II Trial : Exogenous Surfactant Administration for Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04375735
2020-07-01TelmisartanRandomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 PatientsTreatment2Active Not RecruitingNCT04360551
2020-07-01AviptadilInhaled Aviptadil for the Treatment of Moderate and Severe COVID-19Treatment2, 3Active Not RecruitingNCT04360096
2020-07-01RuxolitinibRuxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept StudyTreatment2Active Not RecruitingNCT04359290
2020-07-01DAS-181A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza InfectionTreatment2Active Not RecruitingNCT04298060
2020-07-01Alpha-1-proteinase inhibitorA Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (Prolastin®) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19Treatment2Active Not RecruitingNCT04495101
2020-07-01EnoxaparinEarly Thromboprophylaxis in COVID-19 (ETHIC Trial) : an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care in COVID-19 Positive PatientsTreatment3Active Not RecruitingNCT04492254
2020-07-01KB109An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient SettingTreatmentNot AvailableActive Not RecruitingNCT04486482
2020-07-01COVID-19 convalescent plasmaTherapeutic effectiveness of COVID-19 convalescent plasma produced by HEMOPE : a multicenter, randomized and controlled clinical trial - PLAVID-TRIAL : Covid convalescent plasma - Clinical TrialTreatment3Active Not RecruitingRBR-7jqpnw
2020-07-01Rubella virus vaccineEffectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19Treatment3Active Not RecruitingPACTR202006883882711
2020-07-01Mumps virus strain B level jeryl lynn live antigenEffectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19Treatment3Active Not RecruitingPACTR202006883882711
2020-07-01Measles virus vaccine live attenuatedEffectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19Treatment3Active Not RecruitingPACTR202006883882711
2020-07-01FavipiravirJapanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trialTreatment2Active Not RecruitingJPRN-jRCTs041200025
2020-07-01MethylprednisoloneJapanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trialTreatment2Active Not RecruitingJPRN-jRCTs041200025
2020-07-01CamostatMultiple-dose study of FOY-305 in Japanese healthy adult male subject(FOY-305-02)(COVID-19)Treatment1Active Not RecruitingJPRN-JapicCTI-205326
2020-07-01Bacillus calmette-guerin substrain connaught live antigenStudy to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in IndiaPrevention3Active Not RecruitingNCT04475302
2020-07-01PyronaridineA Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 PatientsTreatment2Active Not RecruitingNCT04475107
2020-07-01ArtesunateA Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 PatientsTreatment2Active Not RecruitingNCT04475107
2020-07-01Povidone-iodineVirucidal Effect of Povidone Iodine on COVID-19 In-Vivo : an Open Label Randomized Clinical TrialPrevention2Active Not RecruitingNCT04549376
2020-07-01DaclatasvirSofosbuvir Containing Regimens in Treatment of COVID 19 Patients : A Randomized Controlled Trial.Treatment2, 3Active Not RecruitingNCT04497649
2020-07-01SofosbuvirSofosbuvir Containing Regimens in Treatment of COVID 19 Patients : A Randomized Controlled Trial.Treatment2, 3Active Not RecruitingNCT04497649
2020-07-01HydroxychloroquineHydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers : A Randomized-Controlled TrialPreventionNot AvailableActive Not RecruitingNCT04438837
2020-07-01DiphenhydramineIntermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04456439
2020-07-01Remestemcel-LIntermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04456439
2020-07-01HydrocortisoneIntermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04456439
2020-07-01EnzalutamideCOVID_ENZA Trial : Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1Treatment2Active Not RecruitingNCT04456049
2020-07-01TramadolSafety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients : A Randomized Double Blind Controlled Clinical TrialTreatment1, 2Active Not RecruitingNCT04454307
2020-06-30OlokizumabA Multicenter, Randomized, Double-blind, Adaptive, Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe SARS-CoV-2 Infection (COVID-19)Treatment2, 3Active Not RecruitingNCT04452474
2020-06-30Prednisolone acetateCombined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis ; a Pilot StudyTreatmentNot AvailableActive Not RecruitingNCT04451239
2020-06-30CyclosporineCombined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis ; a Pilot StudyTreatmentNot AvailableActive Not RecruitingNCT04451239
2020-06-30VPM1002A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of the recombinant BCG VPM1002 on the Incidence or Disease Severity of SARS-COV-2 / COVID-19 Among High-Risk Participants in AustraliaTreatment3Active Not RecruitingACTRN12620000707965
2020-06-30Interleukin-7A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious CohortTreatment2Active Not RecruitingNCT04442178
2020-06-30AcetylcysteineA randomized, double blind, placebo controlled, comparative study to investigate the efficacy of N-acetylcysteine in COVID-19 patients with standard therapy.TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026194
2020-06-30GoldTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30Arsenic trioxideTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30SilverTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30CeleryTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30ZincTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30Povidone-iodinePovidone Iodine Gargle and Intranasal application : A Quasi-Experimental study to reduce the spread of coronavirus infection in community with Covid-19 positive clusters.TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/025928
2020-06-30COVID-19 convalescent plasmaInvestigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 PatientsTreatmentNot AvailableActive Not RecruitingNCT04420988
2020-06-30Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsA Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19Treatment2Active Not RecruitingNCT04362189
2020-06-30RuxolitinibA Pilot Study of Ruxolitinib to Combat COVID-19Treatment2Active Not RecruitingNCT04354714
2020-06-30Stem-cell derived exosome vesicle productsEffect of stromal vascular fraction (SVF), blood and condition medium derived exosomes on treatment of covid-19 patients with Acute Respiratory Distress Syndrome(ARDS) / clinical TrialTreatment2, 3RecruitingIRCT20200510047385N1
2020-06-30Interferon beta-1aEfficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in hospitalized Covid-19 patientsTreatment3Active Not RecruitingIRCT20200511047396N1
2020-06-30CetylpyridiniumEvaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settingsTreatmentNot AvailableRecruitingISRCTN95933274
2020-06-30Povidone-iodineEvaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settingsTreatmentNot AvailableRecruitingISRCTN95933274
2020-06-30ChlorhexidineEvaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settingsTreatmentNot AvailableRecruitingISRCTN95933274
2020-06-30PomegranateEvaluation of the effectiveness of dietary plan for pulmonary diseases based on Persian medicine in patients infected with COVID-19Treatment3RecruitingIRCT20200105046009N4
2020-06-30Covax-19™A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult SubjectsPrevention1Active Not RecruitingNCT04453852
2020-06-29Interferon beta-1aAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANYTreatment3Active Not RecruitingEUCTR2020-001549-38-DE
2020-06-29RemdesivirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANYTreatment3Active Not RecruitingEUCTR2020-001549-38-DE
2020-06-29LopinavirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANYTreatment3Active Not RecruitingEUCTR2020-001549-38-DE
2020-06-29RitonavirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANYTreatment3Active Not RecruitingEUCTR2020-001549-38-DE
2020-06-29AG0301-COVID19A Non-randomized, Open-label, Non-controlled Phase I / II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg / 2mg) in Healthy AdultsPrevention1, 2Active Not RecruitingNCT04463472
2020-06-29Amniotic Epithelial CellsAllogeneic Amniotic Epithelial Cells for the Treatment of COVID-19 related respiratory failure, a pilot feasibility randomised controlled trialTreatment1, 2Active Not RecruitingACTRN12620000676910
2020-06-29SeleniumThe effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19Treatment3RecruitingIRCT20190312043030N2
2020-06-29MethylprednisoloneThe effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19Treatment3RecruitingIRCT20190312043030N2
2020-06-29Ascorbic acidThe effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19Treatment3RecruitingIRCT20190312043030N2
2020-06-29PeppermintThe effect of nebulizing Peppermint extract and Rose extract on percentage of blood oxygen saturation in patients with COVID-19Treatment3RecruitingIRCT20190131042569N5
2020-06-29Human immunoglobulin GA Phase II Safety and Efficacy Study on prognosis of Moderate Pneumonia in COVID-19 patients with Regular Intravenous Immunoglobulin TherapyTreatment2Active Not RecruitingCTRI/2020/06/026222
2020-06-29AcalabrutinibA Phase II, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19Treatment2Active Not RecruitingCTRI/2020/06/026228
2020-06-29UmifenovirA Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients.Treatment3Active Not RecruitingCTRI/2020/06/025957
2020-06-29FavipiravirA Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients.Treatment3Active Not RecruitingCTRI/2020/06/025957
2020-06-29FenretinideRESOLUTION : A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 DiseaseTreatment2Active Not RecruitingNCT04417257
2020-06-29HeparinCoV-Hep Study : Randomized and Paired Clinical Trial Comparing Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04487990
2020-06-29Sodium citrateCoV-Hep study : Randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID-19TreatmentNot AvailableRecruitingRBR-45kf9p
2020-06-29HeparinCoV-Hep study : Randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID-19TreatmentNot AvailableRecruitingRBR-45kf9p
2020-06-28BivalirudinAnticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co TrialSupportive Care4Active Not RecruitingNCT04445935
2020-06-27Indian frankincensePhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27ClovePhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27Azadirachta indica leafPhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27SpearmintPhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27OrangePhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27CinnamonPhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27COVID-19 convalescent plasmaA Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19Treatment1Active Not RecruitingNCT04353206
2020-06-26MaravirocBicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).Treatment2Active Not RecruitingNCT04441385
2020-06-26BCG vaccineA multi-centre, randomised, double-blind, placebo-controlled phase III study assessing the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among healthcare workers in Poland during the COVID-19 pandemic.Treatment3Active Not RecruitingEUCTR2020-002111-22-PL
2020-06-26NitazoxanideEfficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group StudyTreatment2, 3Active Not RecruitingNCT04463264
2020-06-25TocilizumabAn open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive decline in respiratory function and evolving systemic inflammation on time to intubation, non-invasive ventilation and / or all-cause mortalityTreatment2Active Not RecruitingEUCTR2020-001767-86-IE
2020-06-25SARS-CoV-2 mRNA vaccineA Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and abovePrevention1Active Not RecruitingChiCTR2000034112
2020-06-25CiclesonideCiclesonide Clinical Trial for COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04435795
2020-06-25COVID-19 convalescent plasmaA phase II, Open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID-19. - PLATINA TRIAL.Treatment2Active Not RecruitingCTRI/2020/06/026123
2020-06-25IvermectinRandomised Controlled Trial of Ivermectin in hospitalised patients with COVID19 - RIVET-COVTreatment2, 3Active Not RecruitingCTRI/2020/06/026001
2020-06-25BCG vaccineStudy to Evaluate the Effectiveness of BCG vaccine in Reducing Morbidity and Mortality in Elderly individuals in COVID-19 Hotspots in India - BCG for COVID-19TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/025854
2020-06-25COVID-19 convalescent plasmaTreatment of Critically Ill Patients With Covid-19 With Convalescent PlasmaTreatment2Active Not RecruitingNCT04468009
2020-06-25IMM-101COV-IMMUNO : A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of ExposureTreatment3Active Not RecruitingNCT04442048
2020-06-25BrequinarThe CRISIS Study : A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)Treatment1, 2Active Not RecruitingNCT04425252
2020-06-25Plasma protein fraction (human)A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX) - PEX in severe COVID-19Treatment2Active Not RecruitingEUCTR2020-002668-29-GB
2020-06-25TocilizumabPHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVIDTreatment3Unknown StatusEUCTR2020-001707-16-ES
2020-06-25MethylprednisolonePHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVIDTreatment3Unknown StatusEUCTR2020-001707-16-ES
2020-06-24VPM1002A Randomized, Double-blind, Placebo-controlled Phase 3 Study : Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 SeverityPrevention3Active Not RecruitingNCT04439045
2020-06-24AstraZeneca COVID-19 VaccineAn Adaptive Phase I / II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIVPrevention1, 2Active Not RecruitingNCT04444674
2020-06-24COVID-19 convalescent plasmaCONCOR-1 : A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory IllnessTreatment3Active Not RecruitingNCT04418518
2020-06-24AstraZeneca COVID-19 VaccineCOVID-19 : An Adaptive Phase I / II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARSCoV-2 Vaccine in South African Adults Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV.Treatment1Active Not RecruitingPACTR202006922165132
2020-06-23NafamostatRapid Experimental Medicine for COVID-19 - DEFINETreatment2Active Not RecruitingEUCTR2020-002230-32-GB
2020-06-23TD-139Rapid Experimental Medicine for COVID-19 - DEFINETreatment2Active Not RecruitingEUCTR2020-002230-32-GB
2020-06-23ChloroquineDoes Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine / Hydroxychloroquine in Treatment of COVID-19?Treatment3Active Not RecruitingNCT04447534
2020-06-23ZincDoes Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine / Hydroxychloroquine in Treatment of COVID-19?Treatment3Active Not RecruitingNCT04447534
2020-06-23PrednisoneEarly Use of Corticosteroids in Hospitalized Patients With Moderate COVID19 Pneumonia (PREDCOVID)Treatment3Active Not RecruitingNCT04451174
2020-06-23Sodium chlorideHypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19 : Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04382131
2020-06-23Interferon beta-1aRandomized, controlled, open label, phase 2 clinical trial of Interferon-ß-1a (IFNß-1a) in COVID-19 patients. - Clinical study for the treatment with Interferon-ß-1a (IFNß-1a) of COVID-19 patientsTreatment2Unknown StatusEUCTR2020-002458-25-IT
2020-06-23COVID-19 convalescent plasmaConvalescent Plasma as a Treatment for Patients With Severe COVID-19 DiseaseTreatment2Active Not RecruitingNCT04542967
2020-06-22OseltamivirProspective, randomized, parallel-group, open-label study to evaluate the efficacy and safety of IMU-838, in combination with oseltamivir, in adults with coronavirus disease COVID-19Treatment2RecruitingISRCTN53038326
2020-06-22VidofludimusProspective, randomized, parallel-group, open-label study to evaluate the efficacy and safety of IMU-838, in combination with oseltamivir, in adults with coronavirus disease COVID-19Treatment2RecruitingISRCTN53038326
2020-06-22CHO Cells Recombinant VaccineA Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of AgePrevention1Active Not RecruitingNCT04445194
2020-06-22DoxycyclineRepurpoSing Old Drugs TO SuppRess a Modern Threat : The STORM TrialTreatment2Active Not RecruitingNCT04433078
2020-06-22COVID-19 convalescent plasmaExperimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04445207
2020-06-22RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22Interleukin-7A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology CohortTreatment2Active Not RecruitingNCT04426201
2020-06-22PentaglobinThe effect of pentaglobin in the treatment of critically ill patients with COVID-19Treatment2, 3Active Not RecruitingIRCT20151227025726N18
2020-06-22Nitric OxidePulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or moderate corona virus disease (COVID-19)Treatment2Active Not RecruitingEUCTR2020-002394-94-BE
2020-06-22CyclosporinePhase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19Treatment1Active Not RecruitingNCT04412785
2020-06-22Povidone-iodineA Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 PatientsTreatment2Active Not RecruitingNCT04410159
2020-06-22WaterA Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 PatientsTreatment2Active Not RecruitingNCT04410159
2020-06-22IvermectinA double-blind clinical trial to repurpose and assess the efficacy and safety of ivermectin in COVID-19Treatment3CompletedISRCTN40302986
2020-06-22ZincA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Active Not RecruitingNCT04335084
2020-06-22HydroxychloroquineA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Active Not RecruitingNCT04335084
2020-06-22Vitamin DA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Active Not RecruitingNCT04335084
2020-06-22Ascorbic acidA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Active Not RecruitingNCT04335084
2020-06-22AzithromycinA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22Ascorbic acidA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22ZincA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22Vitamin DA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22HydroxychloroquineA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22Peginterferon lambda-1aA Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19Treatment2Active Not RecruitingNCT04343976
2020-06-22BaricitinibA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2)Treatment3Active Not RecruitingJPRN-jRCT2031200035
2020-06-22RemdesivirA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2)Treatment3Active Not RecruitingJPRN-jRCT2031200035
2020-06-21Anakinra?Evaluation of Safety and efficacy of anakinra utilization in COVID-19, a randomized controlled clinical trialTreatment3Active Not RecruitingIRCT20120703010178N20
2020-06-21FamotidineThe effect of Famotidine on the improvement of patients with COVID-19Treatment3RecruitingIRCT20200509047364N2
2020-06-21ErythropoietinEvaluation of the effect of recombinant erythropoietin on the improvement of COVID-19 patientsTreatment2RecruitingIRCT20200509047364N1
2020-06-21TranscrocetinateEvaluation of the effect of trans sodium crocetinate in respiratory distress caused by COVID-19Treatment2Active Not RecruitingIRCT20081019001369N6
2020-06-21RivaroxabanRandomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION TrialTreatment4Active Not RecruitingNCT04394377
2020-06-21TocilizumabA RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIATreatment3RecruitingPER-027-20
2020-06-21EdaravoneEffect of edaravone on clinical improvement and outcome of patients with respiratory distress syndrome caused by COVID-19Treatment3Active Not RecruitingIRCT20200317046797N6
2020-06-21Vitamin DEffect of vitamin D supplementation in diagnosed cases of 2019 Novel Coronavirus ; a randomized clinical trialTreatment3RecruitingIRCT20110726007117N11
2020-06-21HydroxychloroquineThe prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patientsTreatment3RecruitingIRCT20200513047426N1
2020-06-21COVID-19 convalescent plasmaPlasma exchange in patients with COVID-19 to reduce viral load and inflammatory moleculesTreatment2RecruitingIRCT20200416047099N2
2020-06-21Albumin humanPlasma exchange in patients with COVID-19 to reduce viral load and inflammatory moleculesTreatment2RecruitingIRCT20200416047099N2
2020-06-20PamrevlumabRandomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 DiseaseTreatment2Active Not RecruitingNCT04432298
2020-06-20MelatoninA Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)Treatment2Active Not RecruitingNCT04568863
2020-06-20QuercetinThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19Treatment4Active Not RecruitingNCT04468139
2020-06-20ZincThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19Treatment4Active Not RecruitingNCT04468139
2020-06-20BromelainsThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19Treatment4Active Not RecruitingNCT04468139
2020-06-20Ascorbic acidThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19Treatment4Active Not RecruitingNCT04468139
2020-06-20RitonavirEvaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200517047485N1
2020-06-20LopinavirEvaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200517047485N1
2020-06-20HydroxychloroquineEvaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200517047485N1
2020-06-20AtazanavirEvaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200517047485N1
2020-06-20COVID-19 convalescent plasmaInactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19Treatment2Active Not RecruitingNCT04385186
2020-06-20EnoxaparinEffect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04508439
2020-06-20SofosbuvirEfficacy & Safety of Sofosbuvir / Daclatasvir treatment in COVID-19 : A randomized, controlled studyTreatment2, 3Active Not RecruitingDRKS00022203
2020-06-20DaclatasvirEfficacy & Safety of Sofosbuvir / Daclatasvir treatment in COVID-19 : A randomized, controlled studyTreatment2, 3Active Not RecruitingDRKS00022203
2020-06-19COVID-19 convalescent plasmaTreatment of Severe and Critical COVID-19 Pneumonia With Convalescent PlasmaTreatment3Active Not RecruitingNCT04432103
2020-06-19Interferon beta-1bEvaluation the effect of raltegravir, and raltegravir / interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020Treatment3Active Not RecruitingIRCT20200412047042N1
2020-06-19RaltegravirEvaluation the effect of raltegravir, and raltegravir / interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020Treatment3Active Not RecruitingIRCT20200412047042N1
2020-06-19SCB-2019A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.Prevention1Active Not RecruitingNCT04405908
2020-06-19ISS-1018A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.Prevention1Active Not RecruitingNCT04405908
2020-06-19LosartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19ValsartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19Angiotensin IIControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19CandesartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19EprosartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19TelmisartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19OlmesartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19IrbesartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19CamostatThe Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients : An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa TrialTreatment2Active Not RecruitingNCT04353284
2020-06-19Anti-SARS-CoV-2 immunoglobulinSevere Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04521309
2020-06-18CVnCoVA Phase 1, Partially Blind, Placebo-controlled, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy AdultsPrevention1Active Not RecruitingNCT04449276
2020-06-18CamostatSPIKE-1 TRIAL : A Randomised Phase II / III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. - SPIKE-1Treatment2Active Not RecruitingEUCTR2020-002110-41-GB
2020-06-18ChlorhexidineEfecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado médico en Casa en Cali - 2020.TreatmentNot AvailableActive Not RecruitingNCT04563689
2020-06-18CetylpyridiniumEfecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado médico en Casa en Cali - 2020.TreatmentNot AvailableActive Not RecruitingNCT04563689
2020-06-18COVID-19 convalescent plasmaEfficacy of Convalescent Plasma Therapy in Patients With COVID-19 : A Randomized Control TrialTreatment3Active Not RecruitingCTRI/2020/06/025803
2020-06-18Dornase alfaPulmozyme to Improve COVID-19 ARDS OutcomesTreatment2Active Not RecruitingNCT04402944
2020-06-18Human Umbilical Cord Mesenchymal Stem CellsPilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)Treatment1, 2Active Not RecruitingNCT04399889
2020-06-18VPM1002A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and / or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune SystemPrevention3Active Not RecruitingNCT04435379
2020-06-17MelatoninPHASE II CLINICAL TRIAL, SINGLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TO EXPLORE THE EFFECTIVENESS AND SAFETY OF MELATONIN I.V. IN PATIENTS WITH COVID-19 ENTERED INTO THE ICU (MELCOVID STUDY) - MELCOVIDTreatment2Unknown StatusEUCTR2020-001808-42-ES
2020-06-17CamostatA randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (“NICCAM”)Treatment2Active Not RecruitingEUCTR2020-002233-15-DE
2020-06-17NiclosamideA randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (“NICCAM”)Treatment2Active Not RecruitingEUCTR2020-002233-15-DE
2020-06-17Gam-COVID-VacAn Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac Lyo" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy VolunteersPrevention1, 2Active Not RecruitingNCT04437875
2020-06-17Gam-COVID-VacAn Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" a Solution for Intramuscular Injection With the Participation of Healthy VolunteersPrevention1, 2Active Not RecruitingNCT04436471
2020-06-17FavipiravirA Randomized, Open Label, Prospective, Comparative, Parallel Group, Multicentre Study To Evaluate Efficacy And Safety Of Favipiravir With Supportive Care Versus Supportive Care Alone In Subjects With Mild To Moderate Coronavirus Disease (COVID-19). - NATreatment3Active Not RecruitingCTRI/2020/06/025799
2020-06-17SofosbuvirEfficacy of Sofosbuvir in the management of hospitalized COVID 19 patients.Treatment3Active Not RecruitingCTRI/2020/06/025760
2020-06-17EculizumabSOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency TreatmentTreatmentNot AvailableActive Not RecruitingNCT04355494
2020-06-17HeparinEvaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patientTreatment3RecruitingIRCT20200515047456N1
2020-06-17AlteplaseEvaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patientTreatment3RecruitingIRCT20200515047456N1
2020-06-17TocilizumabCOVIDSTORM - study protocol COVID-19 : Slavage TOcilizumab as a Rescue Measure - COVIDSTORMTreatment3Active Not RecruitingEUCTR2020-002039-31-FI
2020-06-17GX-19 VaccineA Phase 1 / 2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy SubjectsPrevention1, 2Active Not RecruitingNCT04445389
2020-06-17EtesevimabA Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 IllnessTreatment2Active Not RecruitingNCT04427501
2020-06-17BamlanivimabA Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 IllnessTreatment2Active Not RecruitingNCT04427501
2020-06-16Nitrous acidAn open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with COVID-19 requiring supplemental oxygen (NOCoV2)Treatment2Active Not RecruitingEUCTR2020-002120-37-GB
2020-06-16MerimepodibA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04410354
2020-06-16RemdesivirA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04410354
2020-06-16TocilizumabA Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04409262
2020-06-16RemdesivirA Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04409262
2020-06-16IvermectinIvermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19 : a Randomised, Double-blind, Placebo-controlled Trial.Treatment2Active Not RecruitingNCT04407130
2020-06-16DoxycyclineIvermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19 : a Randomised, Double-blind, Placebo-controlled Trial.Treatment2Active Not RecruitingNCT04407130
2020-06-16MolnupiravirA Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19Treatment2Active Not RecruitingNCT04405570
2020-06-16Human interleukin-6Prognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19)Basic ScienceNot AvailableActive Not RecruitingNCT04359667
2020-06-16LNP-nCoVsaRNA VaccineA first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19Treatment1Active Not RecruitingISRCTN17072692
2020-06-16ChloroquineRemdesivir in COVID 19 Treatment : A Randomised TrialTreatment2, 3Active Not RecruitingNCT04345419
2020-06-16RemdesivirRemdesivir in COVID 19 Treatment : A Randomised TrialTreatment2, 3Active Not RecruitingNCT04345419
2020-06-16HydroxychloroquineRemdesivir in COVID 19 Treatment : A Randomised TrialTreatment2, 3Active Not RecruitingNCT04345419
2020-06-16NitazoxanideClinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04351347
2020-06-16IvermectinClinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04351347
2020-06-16COVID-19 convalescent plasmaAssessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda ; A Randomised Controlled TrialTreatmentNot AvailableActive Not RecruitingNCT04542941
2020-06-16CannabidiolBurnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19 : a Randomised Controlled TrialPrevention2, 3Active Not RecruitingNCT04504877
2020-06-16Anti-SARS-CoV-2 REGN-COV2A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04425629
2020-06-16PioglitazoneControlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19. - ESCORPIOTreatment4Unknown StatusEUCTR2020-001929-31-ES
2020-06-15HydroxychloroquineClinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine : a Case-control StudyBasic ScienceNot AvailableActive Not RecruitingNCT04471649
2020-06-15Remestemcel-LDouble-blind, randomized, controlled, clinical trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19Treatment2Unknown StatusEUCTR2020-002193-27-ES
2020-06-15FosaprepitantTo Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 PatientsTreatment3Active Not RecruitingNCT04468646
2020-06-15AprepitantTo Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 PatientsTreatment3Active Not RecruitingNCT04468646
2020-06-15COVID-19 convalescent plasmaEffectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 TrialTreatment2Active Not RecruitingNCT04428021
2020-06-15Vitamin DShort Term, High Dose Vitamin D Supplementation for COVID-19 Disease : Double Blind, Controlled, StudyTreatmentNot AvailableActive Not RecruitingNCT04459247
2020-06-15Sodium chlorideHomeopathy for Covid-19 in primary care : randomized, parallel-group, double-blind, placebo-controlled, clinical trial - Homeopathy for Covid-19 in primary care : randomized, parallel-group, double-blind, placebo-controlled, clinical trial (Covid-Simile study)Treatment2Active Not RecruitingJPRN-UMIN000040602
2020-06-15NitazoxanideA Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 PatientsTreatment2Active Not RecruitingCTRI/2020/06/025849
2020-06-15HydroxychloroquineA Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 PatientsTreatment2Active Not RecruitingCTRI/2020/06/025849
2020-06-15MelatoninMelatonin For COVID 19 pre exposure prophylaxis in High Risk population . (MELATONIN IMMUNE BOOST COVID 19 STUDY )Treatment4Active Not RecruitingCTRI/2020/06/025613
2020-06-15IloprostEfficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng) / Kilo(kg) / Minute(Min)) in Patients With COVID-19 Induced Pulmonary EndotheliopathyTreatment2Active Not RecruitingNCT04420741
2020-06-15SevofluraneSedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU : Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort StudyTreatment3Active Not RecruitingNCT04415060
2020-06-15IsofluraneSedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU : Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort StudyTreatment3Active Not RecruitingNCT04415060
2020-06-15NivolumabStudy of the Efficiency and Security of NIVOLUMAB Therapy, Used in Immuno-stimulation, in Hospitalized Obese Individuals at Risk to Evolve Towards Severe Forms of COVID-19 Infection. Multicentric, Paralleled, Randomized, Controlled TrialTreatment2Active Not RecruitingNCT04413838
2020-06-15SulodexideSulodexide in the treatment of early stages of COVID-19TreatmentNot AvailableActive Not RecruitingISRCTN59048638
2020-06-15Angiotensin IIAngiotensin II Infusion in COVID-19-Associated Vasodilatory Shock : A multinational, multicentre registryBasic ScienceNot AvailableActive Not RecruitingACTRN12620000620921
2020-06-15EnoxaparinEnoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus : The Multicenter Randomized Controlled Ovid TrialTreatment3Active Not RecruitingNCT04400799
2020-06-15HydroxychloroquineA randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19TreatmentNot AvailableActive Not RecruitingCTRI/2020/05/025067
2020-06-15AstraZeneca COVID-19 VaccineA phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating ChAdOx1 nCoV-19 vaccineTreatment3Active Not RecruitingISRCTN89951424
2020-06-15OseltamivirProspective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19Treatment2Active Not RecruitingNCT04516915
2020-06-15VidofludimusProspective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19Treatment2Active Not RecruitingNCT04516915
2020-06-15HeparinNebulized heparin in patients with mainly moderate coronavirus disease 2019 : Randomized controlled trial. COVID-19TreatmentNot AvailableRecruitingPACTR202007606032743
2020-06-15AnakinraAnti-interleukin IL-1 receptor antagonist (anakinra) for the treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome in patients admitted at Sultan Qaboos University HospitalTreatmentNot AvailableCompletedISRCTN74727214
2020-06-15HydroxychloroquinePilot trial on early treatment with hydroxychloroquine in patients with COVID-19 who do not have hospital admission at diagnosis. - PRE-COVIDTreatment3Unknown StatusEUCTR2020-002449-41-ES
2020-06-15MetoprololIntravenous Metoprolol in Respiratory Distress Due to COVID-19 : Pilot Study "MADRID-COVID" - “MADRID-COVID”Treatment2Unknown StatusEUCTR2020-002310-41-ES
2020-06-14COVID-19 convalescent plasmaEfficacy of Convalescent Plasma Therapy in Patients With COVID-19 : A Randomized Control TrialTreatment3Active Not RecruitingNCT04425915
2020-06-14Human Umbilical Cord Mesenchymal Stem CellsEvolution of Allogenic Mesenchymal stem cell- derived Umbilical cord transplantation for ARDS patients infected with COVID19.Treatment2, 3Active Not RecruitingIRCT20160809029275N1
2020-06-14AtazanavirEvaluation of Atazanavir / Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / RitonavirTreatment3Active Not RecruitingIRCT20200504047298N1
2020-06-14RitonavirEvaluation of Atazanavir / Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / RitonavirTreatment3Active Not RecruitingIRCT20200504047298N1
2020-06-14ResveratrolEvaluation of the effect of Resveratrol on the effectiveness of antiviral drug regimen in patients with COVID-19Treatment3RecruitingIRCT20200112046089N1
2020-06-14ValsartanTreatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trial - CovidVal01TreatmentNot AvailableActive Not RecruitingDRKS00021732
2020-06-13Oral Polio VaccineShort-term Protection for COVID-19 by Oral Polio VaccineTreatment3Active Not RecruitingIRCT20140428017469N1
2020-06-13Nitric OxideInhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)TreatmentNot AvailableActive Not RecruitingNCT04397692
2020-06-13AcalabrutinibA Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19Treatment2Active Not RecruitingNCT04380688
2020-06-12Remestemcel-LMesenchymal Stromal Cell Therapy for Severe Covid-19 InfectionTreatment1, 2Active Not RecruitingNCT04445454
2020-06-12COVID-19 convalescent plasmaThe efficacy and safety of convalescent plasma therapy in novel coronavirus pneumonia (COVID-19) : A medical records based retrospective cohort studyBasic ScienceNot AvailableActive Not RecruitingChiCTR2000033798
2020-06-12Hydroxychloroquineâ??Relative efficacy of hydroxy-chloroquine prophylaxis to healthcare-professionals for Covid-19 mitigation : a pragmatic prospective observational study (RE-HCP2 COVID study)â?? - RE-HCP2 COVID studyBasic ScienceNot AvailableActive Not RecruitingCTRI/2020/06/025593
2020-06-12BaricitinibA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 InfectionTreatment3Active Not RecruitingNCT04421027
2020-06-12AcalabrutinibA Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19Treatment2Active Not RecruitingNCT04346199
2020-06-12IvermectinRandomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the early Treatment of COVID-19 - COVERTreatment2Unknown StatusEUCTR2020-002283-32-IT
2020-06-12Human Umbilical Cord Mesenchymal Stem CellsMesenchymal stromal cell therapy for severe COVID-19 infection - MSC therapy for severe COVID-19 infectionTreatment2Active Not RecruitingEUCTR2020-002102-58-BE
2020-06-11AprotininAn Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04527133
2020-06-11AnakinraA Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) StudyTreatment2Active Not RecruitingNCT04412291
2020-06-11TocilizumabA Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) StudyTreatment2Active Not RecruitingNCT04412291
2020-06-11VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19Treatment2, 3Active Not RecruitingNCT04379271
2020-06-11FavipiravirMulticenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 PneumoniaTreatment3Active Not RecruitingJPRN-jRCTs031200026
2020-06-11NafamostatMulticenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 PneumoniaTreatment3Active Not RecruitingJPRN-jRCTs031200026
2020-06-11FavipiravirAn ObservationaI Study to Evaluate the Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age Who Are Receiving FavipiravirBasic ScienceNot AvailableActive Not RecruitingNCT04474457
2020-06-10TocilizumabA randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. - Tocilizumab vs. its combination with Vitamin D. Variation in IL-6Treatment3Active Not RecruitingEUCTR2020-001903-17-ES
2020-06-10CholecalciferolA randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. - Tocilizumab vs. its combination with Vitamin D. Variation in IL-6Treatment3Active Not RecruitingEUCTR2020-001903-17-ES
2020-06-10AcalabrutinibA Phase 2, Open-Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 - CALAVITreatment2Active Not RecruitingEUCTR2020-001644-25-DE
2020-06-10NafamostatTreatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia : Open Labelled Randomized Controlled Clinical TrialTreatment2, 3Active Not RecruitingNCT04418128
2020-06-10COVID-19 convalescent plasmaConvalescent Plasma to Stem Coronavirus : A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19Treatment2Active Not RecruitingNCT04323800
2020-06-10IvermectinIn vivo use of ivermectin (IVR) for treatment for corona virus infected patients : a randomized controlled trialTreatment0Active Not RecruitingChiCTR2000033627
2020-06-10BACTEK-RA Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19Treatment3Active Not RecruitingNCT04363814
2020-06-10Human Umbilical Cord Mesenchymal Stem CellsUse of mesenchymal cells for the treatment of patients with severe acute respiratory syndrome caused by SARS-CoV-2 - : Coronavirus infectionsTreatmentNot AvailableActive Not RecruitingRBR-3fz9yr
2020-06-10Anti-SARS-CoV-2 REGN-COV2A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04426695
2020-06-10SilibininPhase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infection by COVID-19 positive. - SilCOVID19Treatment2Unknown StatusEUCTR2020-001794-77-ES
2020-06-10Human immunoglobulin GDouble-blind randomized placebo-controlled clinical trial to evaluate the efficacy and safety of the use of intravenous gammaglobulins in the treatment of patients with COVID-19Treatment4Unknown StatusEUCTR2020-001890-56-ES
2020-06-09IvermectinThe Use of Ivermectin In the Treatment of COVID 19 PatientsTreatmentNot AvailableActive Not RecruitingNCT04425707
2020-06-09COVID-19 convalescent plasmaA Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized PatientsTreatment2Active Not RecruitingNCT04421404
2020-06-08Interleukin-7A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and BelgiumTreatment2Active Not RecruitingNCT04407689
2020-06-08CiclesonideA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 InfectionTreatment3Active Not RecruitingNCT04377711
2020-06-08OzoneEXPLORATORY STUDY OF THE THERAPEUTIC EFFECT AND SAFETY OF RECTAL OZONE THERAPY IN PATIENTS POSITIVE TO SARS-CoV 2 WITH MILD TO MODERATE SYMPTOMS (COVID-19) - ORCTreatmentNot AvailableCompletedRPCEC00000320
2020-06-08NitazoxanideEffects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19Treatment2Active Not RecruitingNCT04552483
2020-06-08NitazoxanideEffects of Early Use of Nitazoxanide in Patients with COVID-19Treatment2RecruitingRBR-4nr86m
2020-06-06PembrolizumabThe evaluation of safety and efficacy of Pembrolizumab (CinnaGen Co, Iran) in patients with COVID-19Treatment2Active Not RecruitingIRCT20150303021315N19
2020-06-06IbrutinibIbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)Treatment2Active Not RecruitingNCT04375397
2020-06-06AcetylcysteineComparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery processTreatment3Active Not RecruitingIRCT20200324046850N1
2020-06-06CholecalciferolComparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery processTreatment3Active Not RecruitingIRCT20200324046850N1
2020-06-06COVID-19 convalescent plasmaOpen-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)Treatment2, 3Active Not RecruitingNCT04502472
2020-06-05CurcuminEvaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200519047510N1
2020-06-05HydroxychloroquineLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05LopinavirLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05HeparinLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05AzithromycinLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05RitonavirLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05TocilizumabLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05SulodexideSulodexide in the Treatment of Early Stages of COVID-19Treatment2, 3Active Not RecruitingNCT04483830
2020-06-05ValsartanTreatment of Sars-CoV2 infections (Covid-19) in patients without or with chronic kidney disease (CKD) with valsartan vs placebo, a three-armed randomized, partly blinded trialTreatment2Active Not RecruitingEUCTR2020-001431-27-DE
2020-06-04Omega-3 fatty acidsThe effect of omega-3 supplementation on inflammatory and biochemical markers in critical ill patients with COVID-19 a randomized clinical trialTreatmentNot AvailableActive Not RecruitingIRCT20151226025699N3
2020-06-04AcetylcysteineEvaluating the effect of intravenous N-acetyl cysteine versus placebo in the treatment of patients with mild and moderate acute respiratory distress syndrome caused by COVID-19 : A double-blind randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N355
2020-06-04BCG vaccineInvestigating the Effect of BCG Vaccine on Preventing COVID-19 Infection in Healthcare Staff Exposed to SARS-CoV-2Treatment3Active Not RecruitingIRCT20200411047019N1
2020-06-04BemiparinA Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19Treatment2Active Not RecruitingNCT04420299
2020-06-04Icosapent ethylAn Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)Treatment2Active Not RecruitingNCT04412018
2020-06-04EthanolEvaluation of Shift, a smartphone application for New South Wales Junior Medical Officers, on depression and anxiety during the COVID-19 epidemic.Treatment1Active Not RecruitingACTRN12620000571976
2020-06-04DexamethasoneEvaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N354
2020-06-04MethylprednisoloneEvaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N354
2020-06-04HydrocortisoneEvaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N354
2020-06-04Deoxyribonuclease IAerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized StudyTreatment2Active Not RecruitingNCT04541979
2020-06-04COVID-19 convalescent plasmaPrevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.PreventionNot AvailableActive Not RecruitingNCT04479163
2020-06-03HydroxychloroquineThe NOR-SWE Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients. - S-ReCOVID 19Treatment3Active Not RecruitingEUCTR2020-000982-18-SE
2020-06-03RemdesivirThe NOR-SWE Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients. - S-ReCOVID 19Treatment3Active Not RecruitingEUCTR2020-000982-18-SE
2020-06-03RitonavirHydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition"Treatment3Active Not RecruitingNCT04403100
2020-06-03HydroxychloroquineHydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition"Treatment3Active Not RecruitingNCT04403100
2020-06-03LopinavirHydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition"Treatment3Active Not RecruitingNCT04403100
2020-06-03COVID-19 convalescent plasmaComparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19Treatment2Active Not RecruitingNCT04373460
2020-06-03MethylprednisoloneEfficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS) in COVID-19Treatment4Unknown StatusEUCTR2020-002186-34-ES
2020-06-02BudesonideUse of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation - The STOIC Study (STerOids in COVID)Treatment2Active Not RecruitingEUCTR2020-001889-10-GB
2020-06-02ImatinibRandomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19Treatment3Active Not RecruitingNCT04394416
2020-06-02AzithromycinEVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRATreatment3Active Not RecruitingNCT04347512
2020-06-02HydroxychloroquineEVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRATreatment3Active Not RecruitingNCT04347512
2020-06-02SargramostimUsing GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated TrialTreatment2Active Not RecruitingNCT04400929
2020-06-02EnoxaparinCOVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) TrialPrevention2Active Not RecruitingNCT04354155
2020-06-02Meningococcal polysaccharide vaccine group YA Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 VaccinePrevention3Active Not RecruitingNCT04536051
2020-06-02Meningococcal polysaccharide vaccine group W-135A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 VaccinePrevention3Active Not RecruitingNCT04536051
2020-06-02Meningococcal polysaccharide vaccine group CA Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 VaccinePrevention3Active Not RecruitingNCT04536051
2020-06-02AstraZeneca COVID-19 VaccineA Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 VaccinePrevention3Active Not RecruitingNCT04536051
2020-06-02Meningococcal polysaccharide vaccine group AA Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 VaccinePrevention3Active Not RecruitingNCT04536051
2020-06-02IvermectinPragmatic study "CORIVER" : Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19) - CORIVERTreatment3Unknown StatusEUCTR2020-001971-33-ES
2020-06-01Vitamin DVitamin D Supplementation in Patients With COVID-19 : A Randomized, Double-blind, Placebo-controlled TrialTreatmentNot AvailableActive Not RecruitingNCT04449718
2020-06-01COVID-19 convalescent plasmaA Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19Treatment2Active Not RecruitingNCT04433910
2020-06-01COVID-19 convalescent plasmaAssessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 InfectionTreatment1, 2Active Not RecruitingNCT04438694
2020-06-01Human Umbilical Cord Mesenchymal Stem CellsEfficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 PatientsTreatment2Active Not RecruitingNCT04437823
2020-06-01NitazoxanideProspective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable CommunitiesPrevention2Active Not RecruitingNCT04435314
2020-06-01IvermectinUSEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health PersonnelBasic ScienceNot AvailableActive Not RecruitingNCT04425850
2020-06-01iota-CarrageenanUSEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health PersonnelBasic ScienceNot AvailableActive Not RecruitingNCT04425850
2020-06-01Human immunoglobulin GA Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19Treatment2Active Not RecruitingNCT04432324
2020-06-01InfliximabA Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).Treatment2Active Not RecruitingNCT04425538
2020-06-01FavipiravirA Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients With COVID-19-Moderate TypeTreatment3Active Not RecruitingNCT04425460
2020-06-01CisatracuriumThe Use of Neuromuscular Blockade Monitor as a Strategy for Neuromuscular Blockade Agents Saving in ICU COVID-19 PatientsBasic ScienceNot AvailableActive Not RecruitingNCT04459533
2020-06-01AtracuriumThe Use of Neuromuscular Blockade Monitor as a Strategy for Neuromuscular Blockade Agents Saving in ICU COVID-19 PatientsBasic ScienceNot AvailableActive Not RecruitingNCT04459533
2020-06-01Dornase alfaA Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19Treatment3Active Not RecruitingNCT04459325
2020-06-01COVID-19 convalescent plasmaRandomized Prospective Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma in Prevention of Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 PatientsTreatmentNot AvailableActive Not RecruitingNCT04383548
2020-06-01HeparinEfficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2)Treatment4Active Not RecruitingNCT04530578
2020-06-01RemdesivirIs Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional StudyTreatment1Active Not RecruitingNCT04560231
2020-06-01HydroxychloroquineRandomized, placebo-controlled multiple dose study to evaluate the effect of hydroxychloroquine on the general immuno-competence in young and elderly healthy male volunteersTreatmentNot AvailableRecruitingNL8726
2020-06-01ImatinibImatinib for the Treatment of SARS-COV-2 Induced Pneumonia : A Pilot StudyTreatment3Active Not RecruitingNCT04422678
2020-06-01COVID-19 convalescent plasmaA Pilot Study to Explore the Efficacy and Safety of Rescue Therapy With Antibodies From Convalescent Patients Obtained With Double-filtration Plasmapheresis (DFPP) and Infused in Patients With Coronavirus Disease 2019 (COVID-19) and Need of Oxygen Support Without Mechanical VentilationTreatmentNot AvailableActive Not RecruitingNCT04418531
2020-06-01COVID-19 convalescent plasmaTreatment of Patients With COVID-19 With Convalescent Plasma Transfusion : a Multicenter, Open-labeled, Randomized and Controlled StudyTreatment2Active Not RecruitingNCT04415086
2020-06-01RuxolitinibSafety and Efficacy Study of Ruxolitinib in the Treatment of Severe Acute Respiratory Syndrome Due to SARS-COV-2Treatment2Active Not RecruitingNCT04414098
2020-06-01TocilizumabA Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19Treatment3Active Not RecruitingNCT04412772
2020-06-01COVID-19 convalescent plasmaAn Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19Treatment1Active Not RecruitingNCT04412486
2020-06-01Talactoferrin alfaClinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory Therapy in Patients Diagnosed With COVID-19 DiseaseTreatment2Active Not RecruitingNCT04412395
2020-06-01PrednisoneHome-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency : Incidence of Relapses in Overuse and Changes in Impact at One Year Follow upTreatmentNot AvailableActive Not RecruitingNCT04410536
2020-06-01IndomethacinHome-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency : Incidence of Relapses in Overuse and Changes in Impact at One Year Follow upTreatmentNot AvailableActive Not RecruitingNCT04410536
2020-06-01Dornase alfaPhase I Pilot Study Investigating the Safety and Tolerability of Inhaled rhDNase1 and Its Impact on Neutrophil Extracellular Traps (NETs) in Non-Ventilated COVID-19 Infected PatientsTreatment1Active Not RecruitingNCT04409925
2020-06-01LopinavirEvaluation of Additional Treatments for COVID-19 : a Randomized Trial in NigerTreatment3Active Not RecruitingNCT04409483
2020-06-01RitonavirEvaluation of Additional Treatments for COVID-19 : a Randomized Trial in NigerTreatment3Active Not RecruitingNCT04409483
2020-06-01Angiotensin IIEfficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress SyndromeBasic ScienceNot AvailableActive Not RecruitingNCT04408326
2020-06-01AnakinraEfficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress SyndromeBasic ScienceNot AvailableActive Not RecruitingNCT04408326
2020-06-01Nicotinamide ribosideEffects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19Treatment2Active Not RecruitingNCT04407390
2020-06-01MolnupiravirA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults With PCR-Confirmed COVID-19Treatment2Active Not RecruitingNCT04405739
2020-06-01HeparinNebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung InjuryTreatment4Active Not RecruitingNCT04397510
2020-06-01TamoxifenCombination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome CoronavirusTreatment2Active Not RecruitingNCT04389580
2020-06-01IsotretinoinCombination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome CoronavirusTreatment2Active Not RecruitingNCT04389580
2020-06-01Vitamin DImproving Vitamin D Status in the Management of COVID-19Treatment3Active Not RecruitingNCT04385940
2020-06-01HydroxychloroquineProphylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT)PreventionNot AvailableActive Not RecruitingNCT04371926
2020-06-01RuxolitinibInterleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation : Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and RuxolitinibTreatment2Active Not RecruitingNCT04366232
2020-06-01AnakinraInterleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation : Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and RuxolitinibTreatment2Active Not RecruitingNCT04366232
2020-06-01PrednisoneEfficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion FranceTreatment3Active Not RecruitingNCT04359511
2020-06-01HydrocortisoneEfficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion FranceTreatment3Active Not RecruitingNCT04359511
2020-06-01AldesleukinLow Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19Treatment2Active Not RecruitingNCT04357444
2020-06-01Remestemcel-LExploratory Clinical Study to Assess the Efficacy of NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04315987
2020-06-01ChloroquineAn international, multi-site, Bayesian platform adaptive, randomised, placebo-controlled trial assessing the effectiveness of varied doses of oral Chloroquine in preventing or reducing the severity of COVID-19 disease in healthcare workersTreatment3Active Not RecruitingISRCTN99916292
2020-06-01Stem-cell derived exosome vesicle productsRationale and investigational study for the treatment of COVID-19 with severe viral pneumonia with isolated, placental, mesenchymal stem cell exosomesTreatment2RecruitingISRCTN33578935
2020-06-01EnoxaparinRandomised Controlled Trial Comparing High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Not Requiring Invasive Mechanical VentilationTreatment3Active Not RecruitingNCT04408235
2020-06-01IvermectinMulticenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without SymptomsTreatment2Active Not RecruitingNCT04407507
2020-06-01Lithium carbonateSARS-CoV-2 Specific Memory B and T- CD4+ CellsBasic ScienceNot AvailableActive Not RecruitingNCT04402892
2020-06-01BudesonideARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)Treatment3Active Not RecruitingNCT04193878
2020-06-01FormoterolARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)Treatment3Active Not RecruitingNCT04193878
2020-06-01IvermectinThe Efficacy of Ivermectin and Doxycycline in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04403555
2020-06-01DoxycyclineThe Efficacy of Ivermectin and Doxycycline in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04403555
2020-06-01Human immunoglobulin GEfficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease ProgressionPrevention3Active Not RecruitingNCT04400058
2020-06-01Povidone-iodineA pilot study of virucidal activity of povidone-iodine (PVP-I) 0.5% aqueous solution oral / nasal spray and mouthwash in people with COVID-19 and confirmed oral / nasal shedding of SARS-CoV-2TreatmentNot AvailableActive Not RecruitingISRCTN13447477
2020-06-01Mesenchymoangioblast-derived mesenchymal stem cellsA pilot, open-label, randomised controlled clinical trial to investigate early efficacy of CYP-001 in adults admitted to intensive care with COVID-19Treatment1, 2Active Not RecruitingACTRN12620000612910
2020-06-01HeparinHeparins for Thromboprophylaxis in COVID-19 Patients : HETHICO Study in VenetoBasic ScienceNot AvailableActive Not RecruitingNCT04393805
2020-06-01COVID-19 convalescent plasmaEfficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection : A Randomized, Open Label Clinical TrialTreatment3Active Not RecruitingNCT04391101
2020-06-01RitonavirTrial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19Treatment2Active Not RecruitingNCT04372628
2020-06-01LopinavirTrial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19Treatment2Active Not RecruitingNCT04372628
2020-06-01Tranexamic acidExploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in OutpatientsTreatment2Active Not RecruitingNCT04338074
2020-06-01TofacitinibTOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia : a Multicenter Randomized Controlled Open Label TrialTreatment2Active Not RecruitingNCT04390061
2020-06-01HydroxychloroquineTOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia : a Multicenter Randomized Controlled Open Label TrialTreatment2Active Not RecruitingNCT04390061
2020-06-01DeferoxamineThe Use of Desferal and Adjuvants for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection : A Randomized Controlled TrialTreatment4Active Not RecruitingNCT04389801
2020-06-01DoxycyclineDoxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria : Prospective, Multicenter, Randomized, Double-blind StudyTreatment3Active Not RecruitingNCT04371952
2020-06-01LucinactantA Multicenter, Single-Treatment Study to Assess the Safety and Preliminary Efficacy of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung InjuryTreatment1, 2Active Not RecruitingNCT04389671
2020-06-01ResiniferatoxinA Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin (RTX) Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed Due to the COVID-19-related Moratoria on Elective ProceduresTreatment3Active Not RecruitingNCT04386980
2020-06-01FavipiravirAn Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia â?? An open-label randomized controlled study â??Treatment2, 3Active Not RecruitingTCTR20200514001
2020-06-01COVID19 s-vax loaded autologous dendritic cell vaccineA safety and immune response study of novel coronavirus pneumonia (COVID-19) s-vax loaded autologous dendritic cellsPrevention0Active Not RecruitingChiCTR2000033003
2020-06-01TocilizumabTreatment of Serious and Critical Patients With COVID-19 With TocilizumabTreatment2Active Not RecruitingNCT04363853
2020-06-01MRx-4DP0004A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection)Treatment2Active Not RecruitingNCT04363372
2020-06-01COVID-19 convalescent plasmaExpanded Access Protocol For The Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)TreatmentNot AvailableActive Not RecruitingNCT04360486
2020-06-01Umbilical Cord Blood Hematopoietic Stem CellsCord Blood Therapy to prevent progression of COVID-19 related pneumoniaTreatmentNot AvailableActive Not RecruitingACTRN12620000478910
2020-06-01HydroxychloroquineEvaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 InfectionTreatment4Active Not RecruitingNCT04338906
2020-06-01CamostatEvaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 InfectionTreatment4Active Not RecruitingNCT04338906
2020-06-01MorphineRetrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of LyonBasic ScienceNot AvailableActive Not RecruitingNCT04522037
2020-06-01COVID-19 convalescent plasmaA Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients.TreatmentNot AvailableActive Not RecruitingCTRI/2020/05/025346
2020-06-01ResveratrolA Phase-III, Open Label, Randomized Controlled Trial Of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment In Asymptomatic Or Mildly Symptomatic Patients With SARS-CoV-2 Infection (Covid-19)Treatment3Active Not RecruitingCTRI/2020/05/025336
2020-06-01COVID-19 convalescent plasmaTo Assess the Safety and Efficacy of Convalescent Plasma on outcome of COVID-19 Associated Complications - COVID PLASMA STUDYTreatment2Active Not RecruitingCTRI/2020/05/025328
2020-06-01LosartanAngiotensin Receptor Blocker Losartan for prevention of COVID 19 complications : a randomized placebo controlled trial - LICCITreatment3Active Not RecruitingCTRI/2020/05/025319
2020-06-01COVID-19 convalescent plasmaConvalescent Plasma to Limit Coronavirus Associated Complications : An Open label Clinical Study of Anti-SARS-CoV-2 Plasma in Hospitalized Patients with COVID-19Treatment2Active Not RecruitingCTRI/2020/05/025299
2020-06-01COVID-19 convalescent plasmaPERUCONPLASMA : RANDOMIZED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF THE USE OF CONVALESCENT PLASMA IN HOSPITALIZED PATIENTS WITH COVID-19Treatment2RecruitingPER-016-20
2020-06-01COVID-19 convalescent plasmaCONVALESCENT PLASMA USE AS TREATMENT FOR HOSPITALIZED PATIENTS WITH COVID-19 IN ESSALUDTreatment2RecruitingPER-013-20
2020-06-01AzithromycinA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01NaproxenA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01Clavulanic acidA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01AmoxicillinA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01LevofloxacinA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01OseltamivirA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01IvermectinA Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard CareTreatment3Active Not RecruitingNCT04523831
2020-06-01DoxycyclineA Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard CareTreatment3Active Not RecruitingNCT04523831
2020-06-01HydroxychloroquineEfficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19Treatment3Active Not RecruitingPACTR202005622389003
2020-06-01AzithromycinEfficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19Treatment3Active Not RecruitingPACTR202005622389003
2020-06-01ZincEfficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19Treatment3Active Not RecruitingPACTR202005622389003
2020-06-01InosineA low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM)TreatmentNot AvailableCompletedISRCTN34160010
2020-06-01GlutathioneA low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM)TreatmentNot AvailableCompletedISRCTN34160010
2020-06-01Potassium chlorideA low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM)TreatmentNot AvailableCompletedISRCTN34160010
2020-06-01AmodiaquineÉvaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans ComplicationsTreatment2Active Not RecruitingNCT04502342
2020-06-01ArtesunateÉvaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans ComplicationsTreatment2Active Not RecruitingNCT04502342
2020-06-01AzithromycinEvaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament " ACAR " en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômesTreatment2Active Not RecruitingNCT04501965
2020-06-01HydroxychloroquineEvaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament " ACAR " en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômesTreatment2Active Not RecruitingNCT04501965
2020-05-31IvermectinUse of Ivermectin as a Therapeutic Option for Patients With COVID-19Treatment2, 3Active Not RecruitingNCT04445311
2020-05-31IvermectinUse of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19Prevention2, 3Active Not RecruitingNCT04422561
2020-05-31DipyridamoleDipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19Treatment2Active Not RecruitingNCT04391179
2020-05-31COVID-19 convalescent plasmaClinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)TreatmentNot AvailableActive Not RecruitingChiCTR2000030039
2020-05-31Mycobacterium w. VaccineObservational study to assess safety and efficacy of Inj Sepsivac in patients of Covid-19 at R D Gardi Medical College, Ujjain, IndiaTreatment2Active Not RecruitingCTRI/2020/05/025350
2020-05-31Mycobacterium w. VaccineA Randomized, Double-blind, Two arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in preventing COVID-19 in subjects at risk of getting infected with COVID-19.Treatment3Active Not RecruitingCTRI/2020/05/025277
2020-05-31Mycobacterium w. VaccineA Randomized, Double-blind, Two arm, controlled clinical trial to compare the Efficacy and Safety of Mycobacterium w (Mw) administered along with Standard of care versus Placebo administered along with Standard of care, in adult, COVID 19 positive patients hospitalized but not critically ill.Treatment3Active Not RecruitingCTRI/2020/05/025271
2020-05-31MetronidazoleEvaluation of therapeutic effects of Metronidazole In Inpatients with Pneuomonia Due to COVID-19Treatment2Active Not RecruitingIRCT20200608047686N1
2020-05-30IvermectinA randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19)Treatment2, 3Active Not RecruitingIRCT20200422047168N2
2020-05-30HoneyComparison effect of N-Chromosome royal jelly, propolis, and mixed honey supplementation on clinical and laboratory findings of COVID-19 patients with standard treatment : a randomized clinical trialTreatmentNot AvailableRecruitingIRCT20200209046427N1
2020-05-30Propolis waxComparison effect of N-Chromosome royal jelly, propolis, and mixed honey supplementation on clinical and laboratory findings of COVID-19 patients with standard treatment : a randomized clinical trialTreatmentNot AvailableRecruitingIRCT20200209046427N1
2020-05-30EnoxaparinFull versus prophylactic heparinization for the treatment of severe forms of SARS-Covid-19 : clinical, randomized, open and controlled study - HeSAcovid trialTreatment2Active Not RecruitingRBR-949z6v
2020-05-29Omega-3 fatty acidsResolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids. - A single-blind, randomized, placebo-controlled feasibility studyTreatment2Active Not RecruitingEUCTR2020-002293-28-SE
2020-05-29COVID-19 convalescent plasmaEfficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill PatientsTreatment1Active Not RecruitingNCT04530370
2020-05-29AzithromycinA Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2)Treatment3Active Not RecruitingNCT04381962
2020-05-29LiothyronineTriiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)Treatment2Active Not RecruitingNCT04348513
2020-05-29Peginterferon lambda-1aPeginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 InfectionPrevention2Active Not RecruitingNCT04344600
2020-05-29VPM1002A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and / or severe respiratory infectious diseases in elderly in the SARS-CoV-2 pandemic by modulating the immune systemTreatment3Active Not RecruitingEUCTR2020-001675-33-DE
2020-05-29MRx-4DP0004A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)Treatment2Active Not RecruitingEUCTR2020-001597-30-GB
2020-05-29Moderna COVID-19 VaccineA Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and OlderPrevention2Active Not RecruitingNCT04405076
2020-05-29RitonavirEffectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectionTreatment4Unknown StatusEUCTR2020-001605-23-ES
2020-05-29HydroxychloroquineEffectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectionTreatment4Unknown StatusEUCTR2020-001605-23-ES
2020-05-29AzithromycinEffectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectionTreatment4Unknown StatusEUCTR2020-001605-23-ES
2020-05-29LopinavirEffectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectionTreatment4Unknown StatusEUCTR2020-001605-23-ES
2020-05-29Poractant alfaRandomized Controlled Phase II Trial of Poractant Alfa (Curosurf®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral PneumoniaTreatment2Active Not RecruitingNCT04384731
2020-05-29CiclesonideInhalation of Ciclesonide for Patients With COVID-19 : A Randomised Open Treatment Study (HALT COVID-19)Treatment2Active Not RecruitingNCT04381364
2020-05-28VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1Treatment2Active Not RecruitingEUCTR2020-001264-28-DE
2020-05-28CiclesonideInhalation of Ciclesonide for patients with Covid-19 : A randomised open treatment study (HALT Covid-19).Treatment2Active Not RecruitingEUCTR2020-001928-34-SE
2020-05-28AnakinraSubcutaneous and Intravenous IL-1Ra (Anakinra) in COVID-19 Infection - Feasibility & Pharmacokinetics / Pharmacodynamics StudyHealth Services Research2Active Not RecruitingNCT04462757
2020-05-28VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1Treatment2Active Not RecruitingEUCTR2020-001264-28-HU
2020-05-28BamlanivimabA Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19Basic Science1Active Not RecruitingNCT04411628
2020-05-28COVID-19 convalescent plasmaSafety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2Treatment1Active Not RecruitingNCT04377672
2020-05-28OtilimabA Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related DiseaseTreatment2Active Not RecruitingNCT04376684
2020-05-28TocilizumabTocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)Treatment2Active Not RecruitingNCT04370834
2020-05-28AstraZeneca COVID-19 VaccineA Phase 2 / 3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19Prevention2, 3Active Not RecruitingNCT04400838
2020-05-28CholecalciferolClinical trial, PHASE III, randomized, open-label, to evaluate the efficacy of administering high-dose cholecalciferol orally alongside standard therapy in patients with COVID-19 pneumonia (COVID-19 HUSO). - Efficacy of high dose vitamin D in COVID-19 pneumoniaTreatment3Unknown StatusEUCTR2020-002312-43-ES
2020-05-28RuxolitinibRuxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil) A single-arm, open-label, proof of concept studyTreatment2Active Not RecruitingEUCTR2020-001732-10-DE
2020-05-28Bacillus calmette-guerin substrain danish 1331 live antigenEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) - BCG-PLUSTreatment4Active Not RecruitingEUCTR2020-002456-21-NL
2020-05-28Alendronic acidEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) - BCG-PLUSTreatment4Active Not RecruitingEUCTR2020-002456-21-NL
2020-05-28MosedipimodPhase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to PneumoniaTreatment2Active Not RecruitingNCT04500132
2020-05-27VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1Treatment2Active Not RecruitingEUCTR2020-001264-28-BG
2020-05-27COVID-19 convalescent plasmaEarly transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.Prevention2, 3Active Not RecruitingNCT04374526
2020-05-27IvermectinA Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection - Not applicableTreatment3Active Not RecruitingCTRI/2020/05/025068
2020-05-27TocilizumabA Multi-center, Randomized Controlled, Phase III Study to evaluate the Clinical Outcomes and Safety of Tocilizumab along with Standard of Care in Patients with Cytokine Release Syndrome associated with COVID-19 infection - NoneTreatment3Active Not RecruitingCTRI/2020/05/025369
2020-05-27EculizumabEculizumab for the treatment of Covid-19 severe cases - : Eculizumabe for COVIDTreatment1, 2RecruitingRBR-876qb5
2020-05-26BCG vaccineA Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19 : The ACTIVATE II TrialPrevention4Active Not RecruitingNCT04414267
2020-05-26ZilucoplanA prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan® in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - ZILU-COVTreatment2Active Not RecruitingEUCTR2020-002130-33-BE
2020-05-26IbuprofenLipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19 : a Multicentre, Randomised, Controlled TrialTreatment4Active Not RecruitingNCT04334629
2020-05-26BCG vaccineA RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ?? COVID-19 : THE ACTIVATE II TRIALTreatment4Active Not RecruitingEUCTR2020-002448-21-GR
2020-05-26TurmericASSESSMENT OF CLINICAL ACCEPTABILITY OF MOUTH-DISSOLVING TURMERIC LOZENGES IN HEALTHCARE WORKERS INVOLVED IN COVID-19Other4CompletedCTRI/2020/05/025317
2020-05-25Dornase alfaDetermination of Dornase Alpha Effectiveness in COVID-19 TreatmentTreatment2Active Not RecruitingNCT04432987
2020-05-25VPM1002A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune SystemPrevention3Active Not RecruitingNCT04387409
2020-05-25ColchicinePREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19)Prevention3Active Not RecruitingNCT04416334
2020-05-25OzoneA Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 PneumoniaTreatment3Active Not RecruitingNCT04370223
2020-05-25NitazoxanideProof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.TreatmentNot AvailableActive Not RecruitingNCT04348409
2020-05-25NVX-CoV2373A 2-Part, Phase 1 / 2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy SubjectsPrevention1, 2Active Not RecruitingNCT04368988
2020-05-25Matrix-MA 2-Part, Phase 1 / 2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy SubjectsPrevention1, 2Active Not RecruitingNCT04368988
2020-05-25ColchicineColchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19Treatment3Unknown StatusEUCTR2020-001841-38-ES
2020-05-25Vitamin DEfficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19)Treatment4Unknown StatusEUCTR2020-001960-28-ES
2020-05-25SarilumabMulticenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized PatientsTreatment2Unknown StatusEUCTR2020-002037-15-ES
2020-05-25Rubella virus vaccineEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25BCG vaccineEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25Alendronic acidEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25Measles virus vaccine live attenuatedEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25Mumps virus strain B level jeryl lynn live antigenEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25TocilizumabA Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in JapanTreatment3Active Not RecruitingJPRN-JapicCTI-205270
2020-05-25NafamostatTreatment effect of Nafamostat mesilate in patients with COVID-19 pneumonia : open labelled randomized controlled clinical trialTreatment2Active Not RecruitingKCT0005003
2020-05-25HydroxychloroquinePopulation pharmacokinetics of hydroxychloroquine sulphate in healthcare workers given for prophylaxis against Corona Virus Disease 2019 (COVID 19) pandemic in IndiaTreatmentNot AvailableActive Not RecruitingCTRI/2020/05/025242
2020-05-25Ascorbic acidA prospective, single centre, randomized open labelled comparative clinical study to evaluate the effectiveness of Siddha medicine, Kabasura kudineer and vitamin c-zinc supplementation in the management of asymptomatic COVID 19 patients.Treatment1, 2Active Not RecruitingCTRI/2020/05/025215
2020-05-25COVID-19 convalescent plasmaImmediate uses of convalescent covid-19 plasma in the treatment of new infected patients at the first day of hospitalization in a clinical trailTreatment3RecruitingIRCT20200525047562N1
2020-05-25OxygenA Randomized, Controlled, Open Label, Multicentre Clinical Trial to explore Safety and Efficacy of Hyperbaric Oxygen for preventing ICU admission, Morbidity and Mortality in Adult Patients With COVID-19 - COVID-19-HBOTreatment2Active Not RecruitingDRKS00021626
2020-05-24RuxolitinibA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)Treatment3Active Not RecruitingNCT04377620
2020-05-24IvermectinInterventional study to assess the efficacy of Ivermectin with standard of care treatment versus standard of care in patients of COVID-19 at R D Gardi Medical College, Ujjain, IndiaTreatment2Active Not RecruitingCTRI/2020/05/025224
2020-05-23IloprostInhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory FailureTreatment2Active Not RecruitingNCT04445246
2020-05-23COVID19 s-vax loaded autologous dendritic cell vaccineA safety and immune response trial of novel coronavirus pneumonia (COVID-19) S-Vax loaded autologous dendritic cellsTreatment0RecruitingChiCTR2000034076
2020-05-23Interferon alfaEvaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19Treatment2, 3RecruitingIRCT20161206031256N3
2020-05-23Human interferon betaEvaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19Treatment2, 3RecruitingIRCT20161206031256N3
2020-05-22TocilizumabA Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia : the BREATH-19 StudyTreatment2Active Not RecruitingNCT04445272
2020-05-22EnoxaparinIntermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19 : A Pilot Phase II Single-arm Study, INHIXACOVID19Treatment2Active Not RecruitingNCT04427098
2020-05-22PacritinibA Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without CancerTreatment3Active Not RecruitingNCT04404361
2020-05-22MavrilimumabA Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)Treatment2Active Not RecruitingNCT04397497
2020-05-22AzithromycinAzithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19Treatment3Active Not RecruitingNCT04332107
2020-05-22HydroxychloroquinePrevention of COVID19 infection with hydroxychloroquine in institutionalized older people and nursing home staff. An open, randomized controlled stepped-wedge clinical trial by clusters. PREVICHARM Study - PREVICHARMTreatment3Unknown StatusEUCTR2020-002287-31-ES
2020-05-22CoronaVacA Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged =60 YearsPrevention1, 2Active Not RecruitingNCT04383574
2020-05-22ZilucoplanA Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory FailureTreatment2Active Not RecruitingNCT04382755
2020-05-21GingerThe effects of Ginger on clinical manifestations and paraclinical features of patients with COVID-19 : A randomized double-blind placebo-control clinical trialTreatment3RecruitingIRCT20200506047323N1
2020-05-21SeleniumEffect of the combination of BCc1 & Hep-S on the improvement of clinical & laboratory symptoms of hospitalized COVID-19 patients in a randomized, double-blind, clinical trialTreatment3RecruitingIRCT20170731035423N2
2020-05-21LicoriceEvaluation of the effects of Licorice on clinical symptoms and laboratory signs in patients with COVID-19 : An open-label randomized clinical trialTreatment3RecruitingIRCT20200506047323N2
2020-05-21AcetylcysteineEvaluation of the efficacy and safety of oral N-acetylcysteine in treatment and recovery of patients with COVID-19 who are under treatment with routine protocolsTreatment3Active Not RecruitingIRCT20200623047897N1
2020-05-21CinnamonComparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19Treatment2, 3Active Not RecruitingIRCT20081011001323N25
2020-05-21Ginger oilComparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19Treatment2, 3Active Not RecruitingIRCT20081011001323N25
2020-05-21Vitamin AThe effect of supplementation with vitamin A on improvement of symptoms of acute respiratory syndrome in patients with COVID-19 : A randomized clinical trialTreatment3RecruitingIRCT20200405046951N1
2020-05-21FilgrastimEvaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia (less than 1000)Treatment1, 2Active Not RecruitingIRCT20200502047268N1
2020-05-21NitazoxanidePrevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With NitazoxanideTreatment4Active Not RecruitingNCT04406246
2020-05-21DexamethasoneHigh Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS : a Multicenter and Randomized Open-label Clinical TrialTreatment3Active Not RecruitingNCT04395105
2020-05-21HydroxychloroquineA Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19TreatmentNot AvailableActive Not RecruitingNCT04392973
2020-05-21FavipiravirA Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19TreatmentNot AvailableActive Not RecruitingNCT04392973
2020-05-21TocilizumabEvaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapyTreatment3Active Not RecruitingIRCT20200510047383N1
2020-05-21CoviGlobulinEvaluation of the efficacy and safety of Rabbit polyclonal antibody (CoviGlobulin) in patients with coronavirus COVID-19 virus moderate to severeTreatment3Active Not RecruitingIRCT20200508047346N1
2020-05-21Propolis waxThe effect of propolis supplementation on clinical manifestations and inflammatory biomarkers in patients with COVID-19Treatment3Active Not RecruitingIRCT20200326046868N1
2020-05-21IvermectinEffectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020Treatment3RecruitingIRCT20111224008507N3
2020-05-21FavipiravirOpen-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19Treatment3Active Not RecruitingNCT04542694
2020-05-21CurcuminEffect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19TreatmentNot AvailableRecruitingIRCT20131125015536N13
2020-05-21COVID-19 convalescent plasmaCOVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients : Multicenter Interventional StudyTreatment1Active Not RecruitingNCT04474340
2020-05-20AnakinraSubcutaneous and Intravenous anakinra in COVID-19 Infection - Feasibility & Pharmacokinetics / Pharmacodynamics study - SCIL-COV19 PK / PD trialTreatment2Active Not RecruitingEUCTR2020-001636-95-GB
2020-05-20HeparinAntithrombotic Therapy to Ameliorate Complications of COVID-19Treatment2, 3Active Not RecruitingNCT04372589
2020-05-20COVID-19 convalescent plasmaDETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19Treatment1, 2Active Not RecruitingNCT04356482
2020-05-20FavipiravirGlasgow Early Treatment Arm FavIpiravir? : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients - GETAFIXTreatment2Active Not RecruitingEUCTR2020-001904-41-GB
2020-05-20COVID-19 convalescent plasmaPlasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind TrialTreatment2Active Not RecruitingNCT04405310
2020-05-20COVID-19 convalescent plasmaConvalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCTTreatment2Active Not RecruitingNCT04403477
2020-05-20MavrilimumabMavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Active Not RecruitingNCT04399980
2020-05-20OtilimabA randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease. - OSCARTreatment2Active Not RecruitingEUCTR2020-001759-42-GB
2020-05-20VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1Treatment2Active Not RecruitingEUCTR2020-001264-28-GR
2020-05-20LiothyronineTriiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study) - Thy-Support STUDYTreatment2Active Not RecruitingEUCTR2020-001623-13-GR
2020-05-20AprotininA randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCoTreatment2Active Not RecruitingEUCTR2020-001739-28-BE
2020-05-20NadroparinA randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCoTreatment2Active Not RecruitingEUCTR2020-001739-28-BE
2020-05-20EnoxaparinA randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCoTreatment2Active Not RecruitingEUCTR2020-001739-28-BE
2020-05-20AnakinraA randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCoTreatment2Active Not RecruitingEUCTR2020-001739-28-BE
2020-05-20AcetaminophenEvaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19Treatment1, 2Active Not RecruitingRPCEC00000309
2020-05-20Sodium chlorideEvaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19Treatment1, 2Active Not RecruitingRPCEC00000309
2020-05-20BrensocatibA randomised double-blind placebo-controlled trial of brensocatib (INS1007) in patients with severe COVID-19Treatment3Active Not RecruitingISRCTN30564012
2020-05-20BaricitinibBARICIVID-19 STUDY : MultiCentre, Randomised, Phase IIa Clinical Trial Evaluating Efficacy and Tolerability of Baricitinib as add-on Treatment of In-patients With COVID-19 Compared to Standard TherapyTreatment2Active Not RecruitingNCT04393051
2020-05-20AtorvastatinProspective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19Treatment2Active Not RecruitingNCT04380402
2020-05-20BCG vaccineRandomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care WorkersPrevention3Active Not RecruitingNCT04384549
2020-05-20FavipiravirA Randomized, Open-label, multicenter study to evaluate the efficacy and safety of Favipiravir combined with STANDARD supportive care in adult Indian patients with mild to moderate COVID-19Treatment3CompletedCTRI/2020/05/025114
2020-05-20SeleniumThe effect of addition of selenium to treatment regimen of hospitalized patients with COVID-19 on the outcome of disease compared with control groupTreatment2Active Not RecruitingIRCT20160706028815N5
2020-05-20COVID-19 convalescent plasmaExchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19Treatment2Active Not RecruitingNCT04376788
2020-05-20Methylene blueExchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19Treatment2Active Not RecruitingNCT04376788
2020-05-20LevamisoleImpact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19Prevention3Active Not RecruitingNCT04360122
2020-05-20Inosine pranobexImpact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19Prevention3Active Not RecruitingNCT04360122
2020-05-20HydroxychloroquineEffectiveness of Prophylactic Hydroxychloroquine on incidence of COVID-19 infection in Front-line Health and Allied Health Care Workers : The COVID-SHIELD TrialTreatment2, 3Active Not RecruitingACTRN12620000501943
2020-05-20MavrilimumabMavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Active Not RecruitingNCT04492514
2020-05-20COVID-19 convalescent plasmaAN OPEN LABEL RANDOMISED CONTROL TRIAL ON PASSIVE IMMUNIZATION WITH CONVALESCENT PLASMA IN SEVERE COVID-19 DISEASE - PICP19Treatment2Active Not RecruitingCTRI/2020/05/025209
2020-05-20Dotatate gallium Ga-68[68Ga]Ga-DOTA-(RGD)2 PET / CT imaging of activated endothelium in lung parenchyma of COVID-19 patients. - RDG-PET / CT imaging in COVID-19 patients.Treatment2Active Not RecruitingEUCTR2020-001325-31-NL
2020-05-20FavipiravirRandomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2 / COVID-19)Treatment3Active Not RecruitingNCT04501783
2020-05-19AzithromycinEvaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unitTreatment3RecruitingIRCT20200428047228N2
2020-05-19HydroxychloroquineEvaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unitTreatment3RecruitingIRCT20200428047228N2
2020-05-19TelmisartanTelmisartan for Treatment of COVID-19 Patients : an Open Label Randomized TrialTreatment4Active Not RecruitingNCT04355936
2020-05-19CholecalciferolVitamin D Testing and Treatment for Adults With COVID 19Treatment1Active Not RecruitingNCT04407286
2020-05-19AnakinraAn open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOVTreatment3Active Not RecruitingEUCTR2020-001754-21-FR
2020-05-19RuxolitinibAn open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOVTreatment3Active Not RecruitingEUCTR2020-001754-21-FR
2020-05-19TocilizumabAn open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOVTreatment3Active Not RecruitingEUCTR2020-001754-21-FR
2020-05-19HydroxychloroquineSafety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care : A Double-blind Randomized Control TrialPrevention3Active Not RecruitingNCT04397328
2020-05-19CholecalciferolUsefulness of vitamin D on morbidity and mortality of SARS-COV-2 virus infection (Covid-19) at the Central University Hospital of Asturias - Vitamin D and COVID-19Treatment4Unknown StatusEUCTR2020-002274-28-ES
2020-05-19PiperaquineA clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patientsTreatment4Active Not RecruitingChiCTR2000033049
2020-05-19ArtemisininA clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patientsTreatment4Active Not RecruitingChiCTR2000033049
2020-05-19HydroxychloroquineEvaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19Treatment3Active Not RecruitingIRCT20200428047228N1
2020-05-19FavipiravirEvaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19Treatment3Active Not RecruitingIRCT20200428047228N1
2020-05-19CurcuminEvaluation of SinaCurcumin as a complementary therapy in mild to moderate COVID-19 : An open label non-randomized clinical trialTreatment3Active Not RecruitingIRCT20200408046990N1
2020-05-18BudesonideA Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of SeverityTreatment3Active Not RecruitingNCT04361474
2020-05-18Dornase alfaAerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trialTreatment2Active Not RecruitingEUCTR2020-001849-39-SE
2020-05-18IvermectinA Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19Treatment2Active Not RecruitingNCT04381884
2020-05-18COVID-19 convalescent plasmaEffectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in IndonesiaTreatment2, 3Active Not RecruitingNCT04380935
2020-05-18Glycyrrhiza glabraObservational Study of YASHTIMADHU TABLET intake as a preventive measure in pandemic of COVID-19 â?? An open label, Randomized, Controlled, Prospective, interventional, Community-based Cclinical study on healthy subjectsTreatment2, 3Active Not RecruitingCTRI/2020/05/025093
2020-05-18HydroxychloroquineEffect of Hydroxychloroquine Prophylaxis on QTc Interval of Health Care Workers during COVID-19 Pandemic : An Observational StudyBasic ScienceNot AvailableActive Not RecruitingCTRI/2020/05/025089
2020-05-18SelinexorA Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 InfectionTreatment2Active Not RecruitingEUCTR2020-001411-25-DE
2020-05-16CurcuminEvaluation efficacy of "Curcumin and Resveratrol" capsule in controlling symptoms in patients with COVID-19Treatment3RecruitingIRCT20080901001165N56
2020-05-16ResveratrolEvaluation efficacy of "Curcumin and Resveratrol" capsule in controlling symptoms in patients with COVID-19Treatment3RecruitingIRCT20080901001165N56
2020-05-16BromhexineOpen Label Randomized Clinical Trial BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalizationTreatment3Active Not RecruitingNCT04424134
2020-05-16SpironolactoneOpen Label Randomized Clinical Trial BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalizationTreatment3Active Not RecruitingNCT04424134
2020-05-16Gemtuzumab ozogamicinA randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.Treatment2Active Not RecruitingISRCTN40580903
2020-05-16TurmericEvaluation of the Immuno-stimulatory(Shareera Bala) potential of Ayurveda management protocol in Cohort of Delhi Police - An Exploratory clinical Study - EBAMDTreatment2Active Not RecruitingCTRI/2020/05/025171
2020-05-16BaricitinibBaricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19 : an Open-label, Pilot StudyTreatment2, 3Active Not RecruitingNCT04320277
2020-05-16Lavender oilInvestigating the effect of Lavender (Lavandula angustifolia L.) syrup on improving the severity of cough in patients with definite or highly suspicious COVID-19Treatment3RecruitingIRCT20110907007511N4
2020-05-15COVID-19 convalescent plasmaEffectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress SyndromeTreatmentNot AvailableActive Not RecruitingNCT04442958
2020-05-15COVID-19 convalescent plasmaReal-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19Treatment2Active Not RecruitingNCT04569188
2020-05-15MethylprednisoloneTreatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled TrialTreatment3Active Not RecruitingNCT04438980
2020-05-15AnakinraA multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment. The Immunomodulation-CoV Assessment (ImmCoVA) study. - The Immunomodulation-CoV Assessment (ImmCoVA) study.Treatment2Active Not RecruitingEUCTR2020-001748-24-SE
2020-05-15TocilizumabA multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment. The Immunomodulation-CoV Assessment (ImmCoVA) study. - The Immunomodulation-CoV Assessment (ImmCoVA) study.Treatment2Active Not RecruitingEUCTR2020-001748-24-SE
2020-05-15HydroxychloroquineEvaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative StudyTreatment3Active Not RecruitingNCT04528927
2020-05-15DoxycyclineEvaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative StudyTreatment3Active Not RecruitingNCT04528927
2020-05-15ZincEvaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative StudyTreatment3Active Not RecruitingNCT04528927
2020-05-15AzithromycinEvaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative StudyTreatment3Active Not RecruitingNCT04528927
2020-05-15Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)A Randomized, Double-blind, Placebo-controlled, Phase Ia / IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 YearsPrevention1, 2Active Not RecruitingNCT04412538
2020-05-15AviptadilIntravenous Aviptadil for Critical COVID-19 With Respiratory FailureTreatment2Active Not RecruitingNCT04311697
2020-05-15IvermectinMulticenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and manifested clinical symptoms.Treatment2Active Not RecruitingEUCTR2020-002091-12-BG
2020-05-15BaricitinibA proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related PneumoniaTreatment2Active Not RecruitingNCT04399798
2020-05-15V-SARSClinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral PillTreatment1, 2Active Not RecruitingNCT04380532
2020-05-15Chloride ionHypernatremia in critically ill patients with Covid-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021611
2020-05-15UreaHypernatremia in critically ill patients with Covid-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021611
2020-05-15PotassiumHypernatremia in critically ill patients with Covid-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021611
2020-05-15Remestemcel-LCellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) the Vanguard StudyTreatment1Active Not RecruitingNCT04400032
2020-05-15LopinavirRetrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)Basic ScienceNot AvailableActive Not RecruitingNCT04275388
2020-05-15RitonavirRetrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)Basic ScienceNot AvailableActive Not RecruitingNCT04275388
2020-05-15HydroxychloroquineControlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19 -SANsinCOVID-19). - Sanitarios sin COVID -SANsinCOVID-Treatment4Unknown StatusEUCTR2020-001704-42-ES
2020-05-15TocilizumabA multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia : the BREATH-19 StudyTreatment2Unknown StatusEUCTR2020-001995-13-ES
2020-05-15RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-IE
2020-05-15RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-IE
2020-05-15Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-IE
2020-05-15LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-IE
2020-05-15CalfactantA clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults - COVID-19 Surfactant Clinical TrialTreatment2Active Not RecruitingEUCTR2020-001886-35-GB
2020-05-15VidofludimusProspective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel CoronavirusTreatment2Active Not RecruitingEUCTR2020-001805-21-GB
2020-05-15OseltamivirProspective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel CoronavirusTreatment2Active Not RecruitingEUCTR2020-001805-21-GB
2020-05-15BrensocatibA randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 - STOP-COVID19 : Superiority Trial Of Protease inhibition in COVID-19Treatment3Active Not RecruitingEUCTR2020-001643-13-GB
2020-05-15HydroxychloroquinePreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Active Not RecruitingNCT04386070
2020-05-15LopinavirPreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Active Not RecruitingNCT04386070
2020-05-15RitonavirPreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Active Not RecruitingNCT04386070
2020-05-15COVID-19 convalescent plasmaRandomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity CriteriaTreatmentNot AvailableActive Not RecruitingNCT04383535
2020-05-15NiclosamideEFFICACY OF ORAL NICLOSAMIDE IN TREATMENT OF MILD AND VERY MILD COVID-19 CASES : AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL - EONIC-COVIDTreatment2Active Not RecruitingCTRI/2020/04/024949
2020-05-15CiclesonideEFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVIDTreatment2Active Not RecruitingCTRI/2020/04/024948
2020-05-15HydroxychloroquineEFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVIDTreatment2Active Not RecruitingCTRI/2020/04/024948
2020-05-15IvermectinEFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVIDTreatment2Active Not RecruitingCTRI/2020/04/024948
2020-05-15HeparinA Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-DimerTreatment2Active Not RecruitingNCT04377997
2020-05-15EnoxaparinA Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-DimerTreatment2Active Not RecruitingNCT04377997
2020-05-15HydroxychloroquineEfficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure : Randomised Control TrialPreventionNot AvailableActive Not RecruitingNCT04370015
2020-05-14MethylprednisoloneSteroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. - Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infectioTreatment3Unknown StatusEUCTR2020-001921-30-IT
2020-05-14HeparinSteroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. - Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infectioTreatment3Unknown StatusEUCTR2020-001921-30-IT
2020-05-14HydroxychloroquineAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14FavipiravirAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14DarunavirAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14RitonavirAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14LopinavirAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14HydroxychloroquineRandomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 InfectionPrevention3Active Not RecruitingNCT04372017
2020-05-14HydroxychloroquinePROTECT : A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)Treatment2Active Not RecruitingNCT04363827
2020-05-14AlteplaseFibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection : A Phase 2a Clinical TrialTreatment2Active Not RecruitingNCT04357730
2020-05-14COVID-19 convalescent plasmaA Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)Treatment3Active Not RecruitingNCT04348656
2020-05-14BromhexinePrevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease : a Randomised Controlled TrialPrevention4Active Not RecruitingNCT04405999
2020-05-14TocilizumabA Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04372186
2020-05-14EnoxaparinEnoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients : Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical TrialTreatment3Active Not RecruitingNCT04366960
2020-05-14FT516Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With HypoxiaTreatment1Active Not RecruitingNCT04363346
2020-05-14Interleukin-7A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UKTreatment2Active Not RecruitingNCT04379076
2020-05-14Interferon beta-1aInvestigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19Treatment3Active Not RecruitingIRCT20080901001165N53
2020-05-14COVID-19 convalescent plasmaEffect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19 : a randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N353
2020-05-14Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsA Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19Prevention2Active Not RecruitingNCT04348435
2020-05-14MRx-4DP0004Investigation of the effect of Lactocare® synbiotic on the prevention of COVID-19 infection in the staff of emergency departmentTreatment3RecruitingIRCT20101020004976N6
2020-05-14Interleukin-7InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK)Treatment2RecruitingISRCTN15913068
2020-05-13HydroxychloroquineA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13ZincA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13IvermectinA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13Povidone-iodineA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13AcetylcysteineInvestigating the efficacy and safety of N-Acetyl Cysteine (NAC) inhalation spray in controlling the symptoms of patients with COVID-19Treatment3RecruitingIRCT20080901001165N55
2020-05-13BarleyInvestigating the effect of barely-based traditional remedy on controlling of clinical symptoms and paraclinical results in hospitalized patients with COVID-19Treatment3RecruitingIRCT20180923041093N6
2020-05-13HydroxychloroquineHydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During PregnancyTreatment3Active Not RecruitingNCT04410562
2020-05-13COVID-19 convalescent plasmaAn Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.Treatment1Active Not RecruitingNCT04397757
2020-05-13NitazoxanideA Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 InfectionPrevention3Active Not RecruitingNCT04359680
2020-05-13HydroxychloroquineAzithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled TrialTreatment3Active Not RecruitingNCT04339816
2020-05-13AzithromycinAzithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled TrialTreatment3Active Not RecruitingNCT04339816
2020-05-13CYNK-001A Phase I / II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19Treatment1, 2Active Not RecruitingNCT04365101
2020-05-13VPM1002A phase III, double-blind, randomized, placebo-controlled multicentre clinical trial to assess the efficacy and safety of VPM1002 in reducing healthcare professionals’ absenteeism in the SARS-CoV-2 pandemic by modulating the immune systemTreatment3Active Not RecruitingEUCTR2020-001376-15-DE
2020-05-13Human Umbilical Cord Mesenchymal Stem CellsA Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19Treatment1, 2Active Not RecruitingNCT04390139
2020-05-13EnoxaparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13NadroparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13DalteparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13HeparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13TinzaparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13PrazosinAlpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome : A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 InfectionTreatment2Active Not RecruitingNCT04365257
2020-05-13Peginterferon lambda-1aInterferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD) : A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19Treatment2Active Not RecruitingNCT04354259
2020-05-13Arsenic trioxideEFFECTIVENESS OF ARSENICUM ALBUM 30C IN PREVENTION OF COVID-19 IN INDIVIDUALS RESIDING IN HOSPOTS OF RED ZONES IN DELHIâ?? A PROSPECTIVE COHORT STUDYTreatmentNot AvailableActive Not RecruitingCTRI/2020/05/024986
2020-05-13COVID-19 convalescent plasmaConvalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infectionsTreatmentNot AvailableActive Not RecruitingNL8633
2020-05-12HydroxychloroquinePragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19Treatment4Active Not RecruitingNCT04466540
2020-05-12IvermectinIvermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled TrialTreatmentNot AvailableActive Not RecruitingNCT04429711
2020-05-12MelatoninEvaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 PatientsTreatmentNot AvailableActive Not RecruitingNCT04409522
2020-05-12FamotidineFamotidine Use in Non-hospitalized Patients With COVID-19 : A Case SeriesBasic ScienceNot AvailableActive Not RecruitingNCT04389567
2020-05-12PlitidepsinMulticenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring HospitalizationTreatment1Active Not RecruitingNCT04382066
2020-05-12NitazoxanideA Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)Prevention3Active Not RecruitingNCT04343248
2020-05-12RavulizumabA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress SyndromeTreatment3Active Not RecruitingEUCTR2020-001497-30-FR
2020-05-12AnakinraInterleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation : Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib - JAKINCOVTreatment3Active Not RecruitingEUCTR2020-001963-10-FR
2020-05-12RuxolitinibInterleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation : Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib - JAKINCOVTreatment3Active Not RecruitingEUCTR2020-001963-10-FR
2020-05-12Nitric OxidePrevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.Treatment2Active Not RecruitingNCT04388683
2020-05-12Hydroxychloroquine#StayHome : Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland : A Double-blind, Randomised, Placebo-controlled TrialTreatment2, 3Active Not RecruitingNCT04385264
2020-05-12Human Umbilical Cord Mesenchymal Stem CellsAssessment of safety, efficacy and effective dose determination of human umbilical cord Wharton’s jelly mesenchymal stem cell transplantation on treatment of COVID-19 (coronavirus) pneumonia and complications in humansTreatment2, 3RecruitingIRCT20200421047150N1
2020-05-12COVID-19 convalescent plasmaThe Effect of Convalescent Plasma Therapy on the Outcomes of Patients with 19-COVIDTreatment1, 2Active Not RecruitingIRCT20150808023559N21
2020-05-12MolnupiravirAGILE : Seamless Phase I / IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment - AGILETreatment1Active Not RecruitingEUCTR2020-001860-27-GB
2020-05-12NomacopanAGILE : Seamless Phase I / IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment - AGILETreatment1Active Not RecruitingEUCTR2020-001860-27-GB
2020-05-11AstraZeneca COVID-19 VaccineA phase II / III study to determine the efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19Treatment2, 3Active Not RecruitingISRCTN90906759
2020-05-11Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem CellsTreatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem CellsTreatment1, 2Active Not RecruitingNCT04382547
2020-05-11COVID-19 convalescent plasmaSevere Reluctant COVID-19 Patients Responding to Convalescent Plasma ; A case seriesTreatmentNot AvailableActive Not RecruitingChiCTR2000033323
2020-05-11EnoxaparinCoagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)Treatment3Active Not RecruitingNCT04362085
2020-05-11DalteparinCoagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)Treatment3Active Not RecruitingNCT04362085
2020-05-11HeparinCoagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)Treatment3Active Not RecruitingNCT04362085
2020-05-11TinzaparinCoagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)Treatment3Active Not RecruitingNCT04362085
2020-05-11COVID-19 convalescent plasmaAn Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 InfectionTreatment2Active Not RecruitingNCT04354831
2020-05-11HydroxychloroquineChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)Prevention3Active Not RecruitingNCT04352933
2020-05-11BromhexineLow-dose Hydroxychloroquine and Bromhexine : a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)Prevention1Active Not RecruitingNCT04340349
2020-05-11HydroxychloroquineLow-dose Hydroxychloroquine and Bromhexine : a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)Prevention1Active Not RecruitingNCT04340349
2020-05-11HydroxychloroquineRandomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZESTreatment3Active Not RecruitingCTRI/2020/04/024904
2020-05-11AzithromycinRandomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZESTreatment3Active Not RecruitingCTRI/2020/04/024904
2020-05-11COVID-19 convalescent plasmaOpen Label, parallel arm, phase I / II clinical trial to evaluate Safety and efficacy of Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 DiseaseTreatment1, 2Active Not RecruitingCTRI/2020/04/024804
2020-05-11RavulizumabA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress SyndromeTreatment3Active Not RecruitingNCT04369469
2020-05-11RamiprilA Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19Treatment2Active Not RecruitingNCT04366050
2020-05-10COVID-19 convalescent plasmaInvestigating the use of convalescent plasma from patients who have recovered from COVID-19 in the management of Ecuadorian patients infected with SARS-CoV-2 with clinical deterioration : IMPACTTreatment2, 3RecruitingISRCTN85216856
2020-05-09Human immunoglobulin GIntravenous immunoglubolin (IVIG) effect on improvement of severe pulmonary damage in COVID 19 diseaseTreatment3Active Not RecruitingIRCT20200501047259N1
2020-05-09COVID-19 convalescent plasmaA Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated ComplicationsTreatment2Active Not RecruitingCTRI/2020/04/024915
2020-05-09DoxycyclineStudy of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19Treatment3Active Not RecruitingIRCT20200418047121N1
2020-05-09Ascorbic acidStudy of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19Treatment3Active Not RecruitingIRCT20200418047121N1
2020-05-09AzithromycinStudy of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19Treatment3Active Not RecruitingIRCT20200418047121N1
2020-05-09MetforminStudy of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19Treatment3Active Not RecruitingIRCT20200418047121N1
2020-05-09Remestemcel-LInvestigation the adipose and placenta-derived mesenchymal stem cells effect on the respiratory distress syndrome in patients with COVID-19 : a pilot studyTreatment1, 2Active Not RecruitingIRCT20200418047121N2
2020-05-09COVID-19 convalescent plasmaA Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated ComplicationsTreatment2Active Not RecruitingNCT04374487
2020-05-09ThalidomideEffectiveness and safety of thalidomide in moderate COVID-19 pneumonia : A randomized clinical trialTreatment3Active Not RecruitingIRCT20200428047232N1
2020-05-08AnakinraClinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2 / 3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 InfectionTreatment2, 3Active Not RecruitingNCT04443881
2020-05-08ChloroquineChloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine / hydroxychloroquine in healthcare settingTreatment3Unknown StatusEUCTR2020-001441-39-IT
2020-05-08HydroxychloroquineChloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine / hydroxychloroquine in healthcare settingTreatment3Unknown StatusEUCTR2020-001441-39-IT
2020-05-08HydroxychloroquineAn Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19Treatment3Active Not RecruitingNCT04411433
2020-05-08AzithromycinAn Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19Treatment3Active Not RecruitingNCT04411433
2020-05-08FavipiravirAn Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19Treatment3Active Not RecruitingNCT04411433
2020-05-08BaricitinibA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II)Treatment3Active Not RecruitingNCT04401579
2020-05-08RemdesivirA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II)Treatment3Active Not RecruitingNCT04401579
2020-05-08ArtemisininA Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19Treatment2Active Not RecruitingNCT04382040
2020-05-08CurcuminA Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19Treatment2Active Not RecruitingNCT04382040
2020-05-08Ascorbic acidA Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19Treatment2Active Not RecruitingNCT04382040
2020-05-08Indian frankincenseA Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19Treatment2Active Not RecruitingNCT04382040
2020-05-08VerapamilAmiodarone or Verapamil in COVID-19 hospitalized patients with symptoms : Randomized clinical trial - ReCOVery-SIRIOTreatment3Active Not RecruitingEUCTR2020-001951-42-PL
2020-05-08AmiodaroneAmiodarone or Verapamil in COVID-19 hospitalized patients with symptoms : Randomized clinical trial - ReCOVery-SIRIOTreatment3Active Not RecruitingEUCTR2020-001951-42-PL
2020-05-08TocilizumabSafety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers : a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS)Treatment3Active Not RecruitingNCT04403685
2020-05-08ColchicineCOLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized TrialTreatment2Active Not RecruitingNCT04403243
2020-05-08SecukinumabCOLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized TrialTreatment2Active Not RecruitingNCT04403243
2020-05-08RuxolitinibCOLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized TrialTreatment2Active Not RecruitingNCT04403243
2020-05-08BaricitinibmulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Treatment4Active Not RecruitingNCT04390464
2020-05-08RavulizumabmulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Treatment4Active Not RecruitingNCT04390464
2020-05-08IvermectinNovel Treatment Regimens in Treatment of COVID-19Treatment3Active Not RecruitingNCT04382846
2020-05-08NitazoxanideNovel Treatment Regimens in Treatment of COVID-19Treatment3Active Not RecruitingNCT04382846
2020-05-08ChloroquineNovel Treatment Regimens in Treatment of COVID-19Treatment3Active Not RecruitingNCT04382846
2020-05-08AzithromycinNovel Treatment Regimens in Treatment of COVID-19Treatment3Active Not RecruitingNCT04382846
2020-05-08EtoposideA Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 InfectionSupportive Care2Active Not RecruitingNCT04356690
2020-05-08Nitric OxideMulti-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of InfectionPrevention2Active Not RecruitingNCT04337918
2020-05-08IndomethacinEfficacy and safety of oral indomethacin for treatment of covid 19 induced pneumoniaTreatment2, 3Active Not RecruitingIRCT20200427047215N1
2020-05-08COVID-19 convalescent plasmaPhase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 InfectionTreatment1Active Not RecruitingNCT04333355
2020-05-08Alpha-1-proteinase inhibitorA Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19.Treatment2Active Not RecruitingEUCTR2020-001953-36-ES
2020-05-08Human immunoglobulin GA Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19 - Study to Evaluate the Safety and Efficacy of High Dose IVIG in Patients with Mild / Moderate COVID19Treatment2Active Not RecruitingEUCTR2020-001696-32-ES
2020-05-08Washed Microbiota TransplantationClinical trial for the washed microbiota transplantation in the treatment of novel coronavirus pneumonia (COVID-19) patients suspected with gut microbiota dysbiosisTreatment0Active Not RecruitingChiCTR2000032737
2020-05-07MavrilimumabA randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation : the COMBAT-19 trial - Mavrilimumab in COVID-19 pneumonia with hyperinflammationTreatment2Unknown StatusEUCTR2020-001795-15-IT
2020-05-07HydroxychloroquineHydroxychloroquine Use in Hospitalized Patients With COVID-19 : Impact on Progression to Severe or Critical DiseaseTreatment4Active Not RecruitingNCT04429867
2020-05-07RavulizumabCOVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress SyndromeTreatment3Active Not RecruitingEUCTR2020-001497-30-GB
2020-05-07COVID-19 convalescent plasmaConvalescent Plasma for Treatment of COVID-19 : An Exploratory Dose Identifying StudyTreatment1, 2Active Not RecruitingNCT04384497
2020-05-07BaricitinibmulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R)Treatment4RecruitingISRCTN11188345
2020-05-07RavulizumabmulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R)Treatment4RecruitingISRCTN11188345
2020-05-07ClazakizumabA Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTreatment2Active Not RecruitingNCT04363502
2020-05-07HydroxychloroquineA Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)Prevention2Active Not RecruitingNCT04381988
2020-05-07Remestemcel-LPhase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19Treatment2Active Not RecruitingNCT04366271
2020-05-07PiperaquineA randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and AbidorTreatment4RecruitingChiCTR2000032915
2020-05-07ArtemisininA randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and AbidorTreatment4RecruitingChiCTR2000032915
2020-05-07IvermectinPilot study to evaluate the potential of ivermectin to reduce COVID-19 transmissionTreatment2Unknown StatusEUCTR2020-001474-29-ES
2020-05-07HydroxychloroquineRANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDYTreatment4Unknown StatusEUCTR2020-002123-11-ES
2020-05-07CyclosporineRANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDYTreatment4Unknown StatusEUCTR2020-002123-11-ES
2020-05-07MethylprednisoloneUSE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 - USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTIONTreatment4Unknown StatusEUCTR2020-001934-37-ES
2020-05-07ClarithromycinANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY : THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIALTreatment2Active Not RecruitingEUCTR2020-001882-36-GR
2020-05-07AzithromycinA Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent HospitalizationTreatment3Active Not RecruitingNCT04365582
2020-05-07LopinavirA Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent HospitalizationTreatment3Active Not RecruitingNCT04365582
2020-05-07RitonavirA Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent HospitalizationTreatment3Active Not RecruitingNCT04365582
2020-05-07HydroxychloroquineA Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent HospitalizationTreatment3Active Not RecruitingNCT04365582
2020-05-07Human immunoglobulin GAn Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2Treatment3Active Not RecruitingNCT04500067
2020-05-06HydroxychloroquinePRECOV : a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk - PRECOVTreatment3Unknown StatusEUCTR2020-001987-28-IT
2020-05-06DefibrotideUse of Defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia - Defibrotide in COVID19Treatment2Unknown StatusEUCTR2020-001513-20-IT
2020-05-06ClarithromycinAnti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early : The ACHIEVE Open-label Non-randomized Clinical TrialPrevention2Active Not RecruitingNCT04398004
2020-05-06IloprostEfficacy and safety of 72-hour infusion of Prostacyclin (1 ng / kg / min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trialTreatment2Active Not RecruitingEUCTR2020-001296-33-DK
2020-05-06ABX-464A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).Treatment2Active Not RecruitingEUCTR2020-001673-75-FR
2020-05-06AcalabrutinibA Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 - CALAVITreatment2Active Not RecruitingEUCTR2020-001644-25-FR
2020-05-06COVID-19 convalescent plasmaEfficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia : A Randomized Controlled TrialTreatment3Active Not RecruitingNCT04381858
2020-05-06Human immunoglobulin GEfficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia : A Randomized Controlled TrialTreatment3Active Not RecruitingNCT04381858
2020-05-06ClevudineA Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19Treatment2Active Not RecruitingNCT04347915
2020-05-06HydroxychloroquineAn open label randomised controlled trial to assess the efficacy of Hydroxychloroquine in patients with mild COVID -19 illness with risk factors for severe disease.Treatment2Active Not RecruitingCTRI/2020/05/025022
2020-05-06BCG vaccinePhase 2 Clinical Trial for the Evaluation of BCG as potential therapy for CoVID-I9 - COVID-19 BCGTreatment2Active Not RecruitingCTRI/2020/05/025013
2020-05-06EnoxaparinCOVID-19-associated Coagulopathy : Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19Treatment4Active Not RecruitingNCT04360824
2020-05-06IvermectinRamdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19Treatment3Unknown StatusEUCTR2020-001994-66-ES
2020-05-06ColchicineA RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOPING SEVERE PULMONARY COMPLICATIONS ASSOCIATED WITH CORONAVIRUS SARS-CoV2 PNEUMONIA (COVID-19) - COLCHI-COVIDTreatment3Unknown StatusEUCTR2020-001603-16-ES
2020-05-06RuxolitinibRuxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN - RAVENTreatment4Active Not RecruitingEUCTR2020-001777-71-GB
2020-05-06BCG vaccineREDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION - BACH (BCG Against COVID-19 in HungaTreatment3Active Not RecruitingEUCTR2020-001783-28-HU
2020-05-06Interleukin-7Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial” - ILIADTreatment2Active Not RecruitingEUCTR2020-001786-36-GB
2020-05-06CaptoprilEfficacy of captopril nebulization in Covid-19 patients suffering of SARS-CoV-2 pneumonia. A randomized phase II study - CAPTOCOVIDTreatment2Active Not RecruitingEUCTR2020-001700-42-FR
2020-05-06COVID-19 convalescent plasmaConvalescent Plasma for the Treatment of Patients With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04372368
2020-05-06ReparixinAdaptive phase 2 / 3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia - REPAVID-19Treatment2Unknown StatusEUCTR2020-001645-40-IT
2020-05-05COVID-19 convalescent plasmaInfusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19) : A Double-blinded, Placebo-controlled, Proof-of-concept StudyTreatment2Active Not RecruitingNCT04442191
2020-05-05Inosine pranobexThe Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19 : A Proposed Therapeutic TrialTreatment3Active Not RecruitingNCT04383717
2020-05-05LevamisoleThe Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19 : A Proposed Therapeutic TrialTreatment3Active Not RecruitingNCT04383717
2020-05-05AzithromycinAssessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisiaTreatment4Active Not RecruitingNCT04351919
2020-05-05HydroxychloroquineAssessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisiaTreatment4Active Not RecruitingNCT04351919
2020-05-05COVID-19 convalescent plasmaEfficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications : A Phase II TrialTreatment2Active Not RecruitingNCT04374565
2020-05-05TocilizumabA Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg / kg or 4mg / kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04363736
2020-05-05RuxolitinibPhase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID) - RUXCOVIDTreatment3Active Not RecruitingEUCTR2020-001662-11-DE
2020-05-05Human immunoglobulin G"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19Treatment2Active Not RecruitingNCT04403269
2020-05-05NamilumabCATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19Treatment2Active Not RecruitingEUCTR2020-001684-89-GB
2020-05-05InfliximabCATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19Treatment2Active Not RecruitingEUCTR2020-001684-89-GB
2020-05-05Gemtuzumab ozogamicinCATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19Treatment2Active Not RecruitingEUCTR2020-001684-89-GB
2020-05-05COVID-19 convalescent plasmaA Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 InfectionTreatment2Active Not RecruitingNCT04392232
2020-05-05LeflunomideLeflunomide for the Treatment of Ambulatory Patients With Mild COVID-19Treatment1Active Not RecruitingNCT04361214
2020-05-05RemdesivirMulticenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.Basic ScienceNot AvailableActive Not RecruitingNCT04365725
2020-05-05HydroxychloroquineSingle-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) InfectionTreatment2Active Not RecruitingNCT04379492
2020-05-05LidocaineUsage of topical lignocaine to decrease the gag reflex while sampling for Covid-19 : Does it affect the yield of specimen?TreatmentNot AvailableActive Not RecruitingCTRI/2020/05/024983
2020-05-05Povidone-iodineEffectiveness of topical povidone iodine (PVP-I) oropharyngeal and intranasal application during the current coronavirus pandemic amongst COVID-19 positive patients in Andhra Pradesh, IndiaTreatmentNot AvailableActive Not RecruitingCTRI/2020/05/024962
2020-05-05HydroxychloroquineRCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without AntibioticsTreatment2Active Not RecruitingNCT04374552
2020-05-05AzithromycinRCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without AntibioticsTreatment2Active Not RecruitingNCT04374552
2020-05-05AzithromycinA multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2) - ATOMIC2, Version 1.0Treatment2Active Not RecruitingEUCTR2020-001740-26-GB
2020-05-05CaptoprilEfficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II StudyTreatment2Active Not RecruitingNCT04355429
2020-05-05Remestemcel-LPhase I trial on safety and tolerability of bone-marrow derived mesenchymal stromal cells (MSC) for deteriorating COVID-19 pneumoniaTreatment1RecruitingACTRN12620000840987
2020-05-05COVID-19 convalescent plasmaTRANSFUSION WITH CONVALING PLASMA IMMUNIZES THE ASYMPTOMATIC PATIENT WITH COVID INFECTION 19 THAT FOR MORE THAN 30 DAYS IS POSITIVE SARS CoV-2 PCR (COVID-19)Basic ScienceNot AvailableCompletedRPCEC00000323
2020-05-05FilgrastimTreatment of lung lesions with autologous stem cells in patients recovered from COVID-19 (COVID-19)TreatmentNot AvailableRecruitingRPCEC00000322
2020-05-04TocilizumabUnicenter, Randomized, Open-label Clinical Trial on the Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19Treatment2Active Not RecruitingNCT04435717
2020-05-04Vitamin AAssessment of vitamin A effectiveness on COVID-19 patients and treatment outcomes referred to health centers of Qom provinceTreatment3Active Not RecruitingIRCT20200314046774N1
2020-05-04TranilastAssessment of the effect of Tranilast on the efficacy of antiviral drug regimens in the treatment of patients with severe COVID19Treatment3Active Not RecruitingIRCT20200419047128N1
2020-05-04HydroxychloroquineEfficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection : Randomized Controlled TrialTreatment3Active Not RecruitingNCT04391127
2020-05-04IvermectinEfficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection : Randomized Controlled TrialTreatment3Active Not RecruitingNCT04391127
2020-05-04Interferon alfa-2bPharmacodynamics and safety of recombinant interferon alfa 2b, by different routes of administration, in healthy volunteers (COVID-19).Treatment1CompletedRPCEC00000308
2020-05-04Ascorbic acidEffect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients : a medical records based retrospective studyBasic ScienceNot AvailableRecruitingChiCTR2000033050
2020-05-04COVID-19 convalescent plasmaThe Use of Convalescent Plasma for Patients Hospitalized With COVID-19 DiseaseTreatment2Active Not RecruitingNCT04385199
2020-05-04HydroxychloroquineGeneric Protocol on Hydroxychloroquine Prophylaxis for COVID-19 Infection Among Healthcare Workers : A Proof-of-Concept, Observational Study - HCQPRoBasic ScienceNot AvailableActive Not RecruitingCTRI/2020/05/025010
2020-05-04CamphorProving the efficacy of Homeopathic treatment in prevention and cure of COVID-19.Treatment1, 2Active Not RecruitingCTRI/2020/04/024857
2020-05-04HydroxychloroquineHydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel : a placebo-controlled, randomized, clinical trialTreatment4Active Not RecruitingSLCTR/2020/011
2020-05-04ColchicineEvaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19Treatment3RecruitingIRCT20200418047126N1
2020-05-04COVID-19 convalescent plasmaInvestigation of the effects of COVID-19 convalescent plasma in acute respiratory distress syndrome due to COVID-19Treatment2, 3Active Not RecruitingIRCT20200501047258N1
2020-05-04CurcuminEffect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19) : A randomized, double-blind, placebo-controlled clinical trial studyTreatmentNot AvailableActive Not RecruitingIRCT20121216011763N46
2020-05-04PiperineEffect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19) : A randomized, double-blind, placebo-controlled clinical trial studyTreatmentNot AvailableActive Not RecruitingIRCT20121216011763N46
2020-05-04DeferiproneInvestigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)Treatment3Active Not RecruitingIRCT20180114038350N3
2020-05-04SitagliptinEvaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19Treatment2, 3Active Not RecruitingIRCT20200420047147N1
2020-05-04TrifluoperazineEvaluation of Trifluoperazine Effectiveness in Treatment Process, Survival rate and Cure rate of COVID-19 PatientsTreatment2, 3Active Not RecruitingIRCT20200329046892N1
2020-05-04SugarcaneEffect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of COVID-19 diseaseTreatment2, 3Active Not RecruitingIRCT20200415047082N1
2020-05-04COVID-19 convalescent plasmaEfficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patientsTreatment2, 3Active Not RecruitingIRCT20200406046968N2
2020-05-04IvermectinDose-Finding study of Ivermectin treatment on patients infected with Covid-19 : A clinical trialTreatment3Active Not RecruitingIRCT20200408046987N1
2020-05-04LevamisoleAssessment of effect of levamisole on pneumonia caused by COVID-19Treatment4Active Not RecruitingIRCT20131215015805N2
2020-05-04BCG vaccineReducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled TrialPrevention3Active Not RecruitingNCT04379336
2020-05-04HydroxychloroquineA Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)Prevention3Active Not RecruitingNCT04377646
2020-05-04ZincA Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)Prevention3Active Not RecruitingNCT04377646
2020-05-04COVID-19 convalescent plasmaEfficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection : a Randomized Phase II TrialTreatment2Active Not RecruitingNCT04375098
2020-05-04TocilizumabSingle-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19Treatment2Unknown StatusEUCTR2020-002032-69-ES
2020-05-04EnoxaparinImpact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) - Heparin-SARS-CoV2Treatment2Unknown StatusEUCTR2020-001891-14-ES
2020-05-04AstraZeneca COVID-19 VaccineA phase 2 / 3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 - Investigating a Vaccine Against COVID-19 (COV002)Treatment2Active Not RecruitingEUCTR2020-001228-32-GB
2020-05-04COVID-19 convalescent plasmaA Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease - RECOVERTreatment2Active Not RecruitingEUCTR2020-001632-10-DE
2020-05-04Poractant alfaPreliminary randomized controlled trial of poractant alfa (Curosurf®) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. - CAARDS-1Treatment2Active Not RecruitingEUCTR2020-001598-66-FR
2020-05-04IsoquercetinA Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.Treatment2Active Not RecruitingEUCTR2020-001635-27-FR
2020-05-04HydroxychloroquineA Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.Treatment2Active Not RecruitingEUCTR2020-001635-27-FR
2020-05-04MasitinibA Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.Treatment2Active Not RecruitingEUCTR2020-001635-27-FR
2020-05-03DipyridamoleA Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 PatientsTreatment2Active Not RecruitingNCT04424901
2020-05-03Basic Fibroblast Growth FactorIdentification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-03Interleukin-10Identification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-03Interleukin-1 alpha, human recombinantIdentification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-03Human interferon betaIdentification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-03Interferon GammaIdentification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-02HydroxychloroquineA Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in BangladeshBasic ScienceNot AvailableActive Not RecruitingNCT04434144
2020-05-02DoxycyclineA Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in BangladeshBasic ScienceNot AvailableActive Not RecruitingNCT04434144
2020-05-02AzithromycinA Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in BangladeshBasic ScienceNot AvailableActive Not RecruitingNCT04434144
2020-05-02IvermectinA Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in BangladeshBasic ScienceNot AvailableActive Not RecruitingNCT04434144
2020-05-02Placental Mesenchymal Stem CellsTreatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical CordTreatment1, 2Active Not RecruitingNCT04461925
2020-05-02Human Umbilical Cord Mesenchymal Stem CellsTreatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical CordTreatment1, 2Active Not RecruitingNCT04461925
2020-05-02COVID-19 convalescent plasmaA Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19 : DAWN-PLASMATreatment2Active Not RecruitingNCT04429854
2020-05-02RuxolitinibPhase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)Treatment3Active Not RecruitingNCT04362137
2020-05-02HeparinIntermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 : A Cluster Based Randomized Selection Trial (IMPROVE-COVID)Treatment4Active Not RecruitingNCT04367831
2020-05-02EnoxaparinIntermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 : A Cluster Based Randomized Selection Trial (IMPROVE-COVID)Treatment4Active Not RecruitingNCT04367831
2020-05-02Lithium carbonateClinical trial of lithium in improving the clinical and laboratory symptoms of patients with COVID-19Treatment2Active Not RecruitingIRCT20081019001369N5
2020-05-02AzithromycinEfficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients : Randomized Controlled Trial : MG-COVIDTreatment3Active Not RecruitingNCT04371406
2020-05-02HydroxychloroquineEfficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients : Randomized Controlled Trial : MG-COVIDTreatment3Active Not RecruitingNCT04371406
2020-05-02EnoxaparinEvaluation of the Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention in COVID-19 Intensive Unit Care Patients.Treatment4Active Not RecruitingNCT04520620
2020-05-01Remestemcel-LProspective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19)Treatment2Active Not RecruitingNCT04444271
2020-05-01EnoxaparinEVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19Basic ScienceNot AvailableActive Not RecruitingNCT04425863
2020-05-01DexamethasoneEVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19Basic ScienceNot AvailableActive Not RecruitingNCT04425863
2020-05-01Acetylsalicylic acidEVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19Basic ScienceNot AvailableActive Not RecruitingNCT04425863
2020-05-01IvermectinEVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19Basic ScienceNot AvailableActive Not RecruitingNCT04425863
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma for Passive Immunization in COVID-19 ICU Patients : An Interventional StudyTreatment1Active Not RecruitingNCT04565197
2020-05-01TocilizumabTocilizumab : A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19Treatment1Active Not RecruitingNCT04560205
2020-05-01MethylprednisolonePerks of Methylprednisolone for Hospitalized COVID-19 Patients : A Clinical TrialTreatmentNot AvailableActive Not RecruitingNCT04559113
2020-05-01Remestemcel-LMesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot StudyTreatment2Active Not RecruitingNCT04416139
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma Therapy in Patients With COVID-19Health Services Research1Active Not RecruitingNCT04407208
2020-05-01COVID-19 convalescent plasmaRandomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 DiseaseTreatment2Active Not RecruitingNCT04392414
2020-05-01IbuprofenExtended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.TreatmentNot AvailableActive Not RecruitingNCT04382768
2020-05-01CalciumEvaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients With Covid-19 Pneumonia : A Single Center Experience in TurkeyBasic ScienceNot AvailableActive Not RecruitingNCT04379310
2020-05-01AcetylcysteinePhase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 InfectionTreatment2Active Not RecruitingNCT04374461
2020-05-01HydroxychloroquineA Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19Treatment2Active Not RecruitingNCT04373044
2020-05-01BaricitinibA Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19Treatment2Active Not RecruitingNCT04373044
2020-05-01AzithromycinA Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19Treatment2Active Not RecruitingNCT04358068
2020-05-01HydroxychloroquineA Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19Treatment2Active Not RecruitingNCT04358068
2020-05-01TocilizumabA Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 InfectionTreatment2Active Not RecruitingNCT04377659
2020-05-01COVID-19 convalescent plasmaEfficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled TrialTreatment3Active Not RecruitingNCT04345289
2020-05-01FavipiravirStudy on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of BangladeshTreatment2, 3Active Not RecruitingNCT04402203
2020-05-01COVID-19 convalescent plasmaA pilot randomized clinical trial of therapeutic plasma exchange (TPE) in serious SARS CoV-2 disease (COVID-19)TreatmentNot AvailableRecruitingISRCTN21363594
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma To Limit COVID-19 Associated Complications : A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma To Placebo in COVID-19 Hospitalized PatientsTreatment2Active Not RecruitingNCT04404634
2020-05-01Human Umbilical Cord Mesenchymal Stem CellsA Phase 1 / 2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 PneumoniaTreatment1, 2Active Not RecruitingNCT04398303
2020-05-01Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned MediaA Phase 1 / 2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 PneumoniaTreatment1, 2Active Not RecruitingNCT04398303
2020-05-01Povidone-iodineCan a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?Treatment1Active Not RecruitingNCT04393792
2020-05-01COVID-19 convalescent plasmaTransfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2 : a Multicenter Open Label Randomized Control TrialTreatment2Active Not RecruitingNCT04393727
2020-05-01ABX-464A Phase 2 / 3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged = 65 and Patients Aged =18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.Treatment2, 3Active Not RecruitingNCT04393038
2020-05-01HydroxychloroquineA Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 DiseaseTreatment3Active Not RecruitingNCT04358081
2020-05-01AzithromycinA Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 DiseaseTreatment3Active Not RecruitingNCT04358081
2020-05-01ColchicineRandomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)Treatment2Active Not RecruitingNCT04355143
2020-05-01COVID-19 convalescent plasmaA Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 CasesTreatment2Active Not RecruitingNCT04390503
2020-05-01COVID-19 convalescent plasmaEvaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.Treatment3Active Not RecruitingNCT04372979
2020-05-01HydroxychloroquineComparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare PersonnelPrevention2Active Not RecruitingNCT04359537
2020-05-01SarilumabPilot Study on the Use of Sarilumab in Patients With COVID-19 InfectionTreatment1Active Not RecruitingNCT04386239
2020-05-01COVID-19 convalescent plasmaEfficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe InfectionTreatment2, 3Active Not RecruitingNCT04385043
2020-05-01COVID-19 convalescent plasmaExperimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020TreatmentNot AvailableActive Not RecruitingNCT04352751
2020-05-01ClazakizumabA Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTreatment2Active Not RecruitingNCT04381052
2020-05-01ItolizumabA Multi-Centre, Open label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 ComplicationsTreatment2CompletedCTRI/2020/05/024959
2020-05-01BCG vaccineEffect of BCG-Denmark (Green Signal) on prevention of COVID 19 infection in health care workers â?? a double blind randomized controlled trialTreatmentNot AvailableActive Not RecruitingCTRI/2020/04/024833
2020-05-01LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01ChloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01AzithromycinEvaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19 : randomized clinical trialTreatment2Active Not RecruitingRBR-3k4wxb
2020-05-01HydroxychloroquineEvaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19 : randomized clinical trialTreatment2Active Not RecruitingRBR-3k4wxb
2020-05-01HydroxychloroquineInvestigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19Treatment3Active Not RecruitingIRCT20080901001165N51
2020-05-01AzithromycinInvestigating the efficacy and safety of Azithromycin inhaled spray in controlling the symptoms of patients with COVID-19Treatment3Active Not RecruitingIRCT20080901001165N50
2020-05-01Dialyzable leukocyte extractAssessment of the Clinical Effect of Dialyzable Leukocyte Extracts in Individuals With Acute Respiratory Infection (Suspected or Confirmed Cases of COVID-19) (FUTURE-T)Treatment2Active Not RecruitingNCT04379479
2020-05-01Methylprednisolone hemisuccinateComparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II TrialTreatment2Active Not RecruitingNCT04377503
2020-05-01TocilizumabComparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II TrialTreatment2Active Not RecruitingNCT04377503
2020-05-01FluoxetineFluoxetine to Reduce Intubation and Death After COVID19 InfectionTreatment4Active Not RecruitingNCT04377308
2020-05-01TridecactideAn Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 InfectionTreatment2, 3Active Not RecruitingNCT04374032
2020-05-01MetenkefalinAn Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 InfectionTreatment2, 3Active Not RecruitingNCT04374032
2020-05-01IvermectinRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01AzithromycinRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01WormwoodRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01CamostatRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01HydroxychloroquineRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01SirolimusA Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)Treatment1Active Not RecruitingNCT04371640
2020-05-01Ascorbic acidPharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 TreatmentTreatment2Active Not RecruitingNCT04363216
2020-05-01HydroxychloroquineHydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label TrialTreatmentNot AvailableActive Not RecruitingNCT04374903
2020-05-01AzithromycinHydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label TrialTreatmentNot AvailableActive Not RecruitingNCT04374903
2020-05-01SirolimusHydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label TrialTreatmentNot AvailableActive Not RecruitingNCT04374903
2020-05-01FavipiravirA Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19 : Favipiravir and StaNdard Care vErsEs Standard CaReTreatment3Active Not RecruitingNCT04373733
2020-05-01BCG vaccineUsing BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center TrialPrevention3Active Not RecruitingNCT04373291
2020-05-01NiclosamideEfficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled TrialTreatment3Active Not RecruitingNCT04372082
2020-05-01HydroxychloroquineEfficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled TrialTreatment3Active Not RecruitingNCT04372082
2020-05-01DiltiazemEfficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled TrialTreatment3Active Not RecruitingNCT04372082
2020-05-01HydroxychloroquineEfficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health : A Randomized, Double-blind, Placebo-controlled TrialPrevention3Active Not RecruitingNCT04364815
2020-05-01FondaparinuxIncreased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19)Basic ScienceNot AvailableActive Not RecruitingNCT04359212
2020-05-01HeparinIncreased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19)Basic ScienceNot AvailableActive Not RecruitingNCT04359212
2020-05-01HydroxychloroquineA Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 PatientsPreventionNot AvailableActive Not RecruitingNCT04354597
2020-05-01AzithromycinA Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 PatientsPreventionNot AvailableActive Not RecruitingNCT04354597
2020-05-01Povidone-iodineCan a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals? - SINUS WASH pilot studyTreatment2Active Not RecruitingEUCTR2020-001721-31-GB
2020-05-01HydroxychloroquineHydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE) : A Parallel Randomized Controlled TrialPrevention3Active Not RecruitingNCT04371523
2020-05-01Dornase alfaA Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19Treatment2Active Not RecruitingNCT04359654
2020-05-01MethotrexateTreatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles : A Phase I / II StudyTreatment1, 2Active Not RecruitingNCT04352465
2020-05-01HydroxychloroquineA Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19)Treatment4Active Not RecruitingNCT04363866
2020-05-01Acetylsalicylic acidThe LEAD COVID-19 Trial : Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 HospitalizationsTreatment2Active Not RecruitingNCT04363840
2020-05-01Vitamin DThe LEAD COVID-19 Trial : Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 HospitalizationsTreatment2Active Not RecruitingNCT04363840
2020-05-01NitazoxanideClinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients : A Tanta University HopeTreatment2, 3Active Not RecruitingNCT04361318
2020-05-01HydroxychloroquineClinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients : A Tanta University HopeTreatment2, 3Active Not RecruitingNCT04361318
2020-05-01ChloroquineMulti-centre Randomised Controlled Trial of Chloroquine / Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South AfricaTreatment3Active Not RecruitingNCT04360759
2020-05-01HydroxychloroquineMulti-centre Randomised Controlled Trial of Chloroquine / Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South AfricaTreatment3Active Not RecruitingNCT04360759
2020-05-01IvermectinClinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients : A Tanta University HopeTreatment2, 3Active Not RecruitingNCT04360356
2020-05-01NitazoxanideClinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients : A Tanta University HopeTreatment2, 3Active Not RecruitingNCT04360356
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04358211
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma for Patients With COVID-19 : A Pilot StudyTreatment2Active Not RecruitingNCT04332380
2020-05-01HydroxychloroquineRandomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection : HyPreC TrialTreatment2Active Not RecruitingNCT04354441
2020-05-01MavrilimumabMavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Active Not RecruitingNCT04337216
2020-05-01HydroxychloroquinePhase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infectionTreatment2Active Not RecruitingRBR-8h7q82
2020-05-01ChloroquinePhase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infectionTreatment2Active Not RecruitingRBR-8h7q82
2020-05-01IvermectinPhase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infectionTreatment2Active Not RecruitingRBR-8h7q82
2020-05-01ItolizumabA Multi-Centre, Open Label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 ComplicationsTreatment2Active Not RecruitingNCT04475588
2020-04-30COVID-19 convalescent plasmaAn Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 PatientsBasic ScienceNot AvailableActive Not RecruitingNCT04471051
2020-04-30Dornase alfaA single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised participants with COVID-19 (The COVASE trial) - Dornase alfa to reduce hyperinflammation in COVID19 - The COVASE trialTreatment2Unknown StatusEUCTR2020-001937-11-GB
2020-04-30Remestemcel-LMesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress SyndromeTreatment3Active Not RecruitingNCT04371393
2020-04-30CanakinumabPhase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)Treatment3Active Not RecruitingNCT04362813
2020-04-30HoneyThe Role of Honey and Nigella Sativa in the Management of COVID-19 ; A Randomized Controlled, Open-label, Add-on Trial in Lahore, PakistanTreatment3Active Not RecruitingNCT04347382
2020-04-30COVID-19 convalescent plasmaAn Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2Treatment1Active Not RecruitingNCT04388527
2020-04-30LenzilumabA Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04351152
2020-04-30YohimbineImpact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPITreatment1CompletedDRKS00021573
2020-04-30MidazolamImpact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPITreatment1CompletedDRKS00021573
2020-04-30PantoprazoleImpact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPITreatment1CompletedDRKS00021573
2020-04-30HydroxychloroquineImpact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPITreatment1CompletedDRKS00021573
2020-04-30COVID-19 convalescent plasmaUse of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and SafetyTreatmentNot AvailableActive Not RecruitingNCT04397523
2020-04-30COVID-19 convalescent plasmaA Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate SeverityTreatment3Active Not RecruitingNCT04361253
2020-04-30BCG vaccineUsing BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. - BCG-DENMARK-COVIDTreatment3Active Not RecruitingEUCTR2020-001888-90-DK
2020-04-30MelphalanSingle-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19Treatment2Active Not RecruitingNCT04380376
2020-04-30HydroxychloroquineVA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)Treatment3Active Not RecruitingNCT04363203
2020-04-30AzithromycinVA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)Treatment3Active Not RecruitingNCT04363203
2020-04-30Mycobacterium w. VaccineA Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04347174
2020-04-30Mycobacterium w. VaccineA clinical trial to evaluate the safety and efficacy of Mycobacterium W in critically ill patients suffering from COVID 19 infectionTreatmentNot AvailableActive Not RecruitingCTRI/2020/04/024846
2020-04-30HydroxychloroquineProtecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis : A Randomized, Placebo-controlled Multi-Site Trial in Toronto, CanadaPrevention3Active Not RecruitingNCT04374942
2020-04-30Alunacedase alfaRecombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19Treatment2Active Not RecruitingNCT04335136
2020-04-30RuxolitinibInterventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)Treatment2Active Not RecruitingNCT04374149
2020-04-30ColchicineAdministration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.Treatment3Active Not RecruitingNCT04350320
2020-04-30MethylprednisoloneEARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL - CORTIVIDTreatment3Unknown StatusEUCTR2020-001827-15-ES
2020-04-30AzithromycinAzithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled TrialTreatment3Active Not RecruitingNCT04363060
2020-04-30AmoxicillinAzithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled TrialTreatment3Active Not RecruitingNCT04363060
2020-04-30Clavulanic acidAzithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled TrialTreatment3Active Not RecruitingNCT04363060
2020-04-30HydroxychloroquineHydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19)Treatment3Active Not RecruitingNCT04361461
2020-04-30Mycobacterium w. VaccineA Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19.Prevention3Active Not RecruitingNCT04353518
2020-04-30SelinexorA Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19Treatment2Active Not RecruitingNCT04355676
2020-04-30HydroxychloroquineHydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or DeathTreatment1Active Not RecruitingNCT04323631
2020-04-30LosartanAspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trialTreatment3Active Not RecruitingPACTR202006473370201
2020-04-30Acetylsalicylic acidAspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trialTreatment3Active Not RecruitingPACTR202006473370201
2020-04-30SimvastatinAspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trialTreatment3Active Not RecruitingPACTR202006473370201
2020-04-29QuercetinEvaluation of the effect of quercetin on the effectiveness of antiviral drug regimen in patients with COVID19Treatment3Active Not RecruitingIRCT20200419047128N2
2020-04-29AzithromycinProactive Care of Ambulatory COVID19 Patients : Open-labeled Randomized TrialTreatment3Active Not RecruitingNCT04371107
2020-04-29BNT162b1 SARS-CoV-2 VaccineA PHASE 1 / 2 / 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALSPrevention2, 3Active Not RecruitingNCT04368728
2020-04-29Pfizer-BioNTech COVID-19 VaccineA PHASE 1 / 2 / 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALSPrevention2, 3Active Not RecruitingNCT04368728
2020-04-29RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29ChloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29HydroxychloroquineChloroquine / Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting ; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)PreventionNot AvailableActive Not RecruitingNCT04303507
2020-04-29ChloroquineChloroquine / Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting ; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)PreventionNot AvailableActive Not RecruitingNCT04303507
2020-04-29Povidone-iodinePovidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 PandemicPrevention2Active Not RecruitingNCT04364802
2020-04-29Azoximer bromideA Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).Treatment2, 3Active Not RecruitingNCT04381377
2020-04-29KetamineStudy of Immunomodulation Using Naltrexone and Ketamine for COVID-19Treatment2Active Not RecruitingNCT04365985
2020-04-29NaltrexoneStudy of Immunomodulation Using Naltrexone and Ketamine for COVID-19Treatment2Active Not RecruitingNCT04365985
2020-04-29ColchicineEvaluation of colchicine tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad : A triple-blind randomized placebo controlled clinical trialTreatment3Active Not RecruitingIRCT20200408046990N2
2020-04-29HydroxychloroquineTherapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19Treatment3Active Not RecruitingIRCT20200421047155N1
2020-04-29TenofovirTherapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19Treatment3Active Not RecruitingIRCT20200421047155N1
2020-04-29Interferon beta-1beffect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospitalTreatment2RecruitingIRCT20200406046968N3
2020-04-29HydroxychloroquineEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19Treatment1, 2Active Not RecruitingIRCT20150808023559N20
2020-04-29LopinavirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19Treatment1, 2Active Not RecruitingIRCT20150808023559N20
2020-04-29RitonavirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19Treatment1, 2Active Not RecruitingIRCT20150808023559N20
2020-04-29FavipiravirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19Treatment1, 2Active Not RecruitingIRCT20150808023559N20
2020-04-29UmifenovirEvaluation of the effect of Arbidol drug in the treatment of hospitalized patients with COVID-19Treatment3Active Not RecruitingIRCT20180725040596N2
2020-04-29Albumin humanPlasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation : a Randomized Controlled TrialTreatment2Active Not RecruitingNCT04374539
2020-04-29Human immunoglobulin GPlasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation : a Randomized Controlled TrialTreatment2Active Not RecruitingNCT04374539
2020-04-29FavipiravirA Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEERTreatment3Active Not RecruitingEUCTR2020-001449-38-GB
2020-04-29HydroxychloroquineA Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEERTreatment3Active Not RecruitingEUCTR2020-001449-38-GB
2020-04-29ZincA Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEERTreatment3Active Not RecruitingEUCTR2020-001449-38-GB
2020-04-29AzithromycinA Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEERTreatment3Active Not RecruitingEUCTR2020-001449-38-GB
2020-04-29DalteparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29NadroparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29HeparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29EnoxaparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29TinzaparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29CanakinumabPhase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).Treatment3Active Not RecruitingEUCTR2020-001370-30-DE
2020-04-29LosartanLosartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCETreatment2Active Not RecruitingEUCTR2020-001766-11-FR
2020-04-29SpironolactoneLosartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCETreatment2Active Not RecruitingEUCTR2020-001766-11-FR
2020-04-29RemdesivirWHO SOLIDARITY Finland : The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - SOLIDARITY FinlandTreatment3Active Not RecruitingEUCTR2020-001784-88-FI
2020-04-29ChlorpromazineRepurposing of Chlorpromazine in Covid-19 TreatmentTreatment3Active Not RecruitingNCT04366739
2020-04-29BBIBP-CorVEvaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above : a randomized, double-blind, placebo parallel-controlled phase I / II clinical trialTreatment1, 2Active Not RecruitingChiCTR2000032459
2020-04-29ChloroquineChloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis studyTreatment3RecruitingISRCTN10207947
2020-04-29HydroxychloroquineChloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis studyTreatment3RecruitingISRCTN10207947
2020-04-29ArtesunateRandomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19Treatment2Active Not RecruitingPACTR202006899597082
2020-04-29Ascorbic acidRandomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19Treatment2Active Not RecruitingPACTR202006899597082
2020-04-29TocilizumabStudy of Tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients : a ?crinical trial studyTreatment2RecruitingIRCT20081027001411N4
2020-04-29AdalimumabEvaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19Treatment3RecruitingIRCT20171105037262N4
2020-04-29COVID-19 convalescent plasmaA Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)Treatment2Active Not RecruitingNCT04547127
2020-04-29Methylene blueA Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)Treatment2Active Not RecruitingNCT04547127
2020-04-28Dornase alfaDouble Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory FailureTreatment2Active Not RecruitingNCT04445285
2020-04-28HydroxychloroquinePROTECT : A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). - PROTECTTreatment2Unknown StatusEUCTR2020-001501-24-IT
2020-04-28COVID-19 convalescent plasmaOpen, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19Prevention2Active Not RecruitingNCT04434131
2020-04-28HydroxychloroquineAssessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative StudyPrevention3Active Not RecruitingNCT04349228
2020-04-28Human immunoglobulin GRandomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 InfectionTreatment4Active Not RecruitingNCT04411667
2020-04-28ZilucoplanACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28HeparinACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28BemcentinibACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28AcalabrutinibACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28TD-139ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28COVID-19 convalescent plasmaConvalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 DiseaseTreatment1Active Not RecruitingNCT04355897
2020-04-28HydroxychloroquineA Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient SettingTreatment4Active Not RecruitingNCT04370782
2020-04-28Zinc sulfateA Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient SettingTreatment4Active Not RecruitingNCT04370782
2020-04-28DoxycyclineA Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient SettingTreatment4Active Not RecruitingNCT04370782
2020-04-28AzithromycinA Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient SettingTreatment4Active Not RecruitingNCT04370782
2020-04-28MultiStemA Phase 2 / 3 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)Treatment2, 3Active Not RecruitingNCT04367077
2020-04-28AnakinraCLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 - ANA-COVID-GEASTreatment2Unknown StatusEUCTR2020-001825-29-ES
2020-04-28CanakinumabPhase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).Treatment3Active Not RecruitingEUCTR2020-001370-30-GB
2020-04-28CalcifediolPrevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)Treatment2Active Not RecruitingNCT04366908
2020-04-28EnoxaparinPreventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation : a Multicentric Randomized, Open-label Clinical TrialTreatment3Active Not RecruitingNCT04345848
2020-04-28BCG vaccineRandomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.” COVID-BCG - COVID BCGTreatment3Active Not RecruitingEUCTR2020-001678-31-FR
2020-04-28EnoxaparinEvaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study - COV-ENOXTreatment4Active Not RecruitingEUCTR2020-001823-15-FR
2020-04-28AtibuclimabCompassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04346277
2020-04-27SiltuximabCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27HydroxychloroquineCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27TocilizumabCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27CanakinumabCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27SarilumabCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27BaricitinibCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27SarilumabA phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia - ESCAPETreatment3Unknown StatusEUCTR2020-001390-76-IT
2020-04-27Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsPhase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19Treatment1, 2Active Not RecruitingNCT04366323
2020-04-27COVID-19 convalescent plasmaPhase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 PneumoniaTreatment2Active Not RecruitingNCT04358783
2020-04-27AnakinraEfficacy and Safety of ANAkinra During Adult " COVID-19 " With Aggravating Respiratory Symptoms : a Multicenter Open-label Controlled Randomized TrialTreatment3Active Not RecruitingNCT04364009
2020-04-27ChloroquineComparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patientsTreatment4CompletedTCTR20200404004
2020-04-27Ascorbic acidComparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patientsTreatment4CompletedTCTR20200404004
2020-04-27Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27ChloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27Natural Killer CellEvaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trialTreatment1, 2Active Not RecruitingIRCT20200417047113N1
2020-04-27Human immunoglobulin G"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19 - GERONIMO19Treatment2Active Not RecruitingEUCTR2020-001768-27-FR
2020-04-27AzithromycinA Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) PandemicPrevention2Active Not RecruitingNCT04369365
2020-04-27HydroxychloroquineHydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)Prevention3Active Not RecruitingNCT04363450
2020-04-27COVID-19 convalescent plasmaConvalescent Plasma for the Treatment of Moderate-severe COVID-19 : A Proof-of-principle StudyTreatmentNot AvailableActive Not RecruitingNCT04365439
2020-04-27ProgesteroneA Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized MenTreatment1Active Not RecruitingNCT04365127
2020-04-27SarilumabClinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release SyndromeTreatment2Active Not RecruitingNCT04357860
2020-04-27AmiodaroneAmiodarone or Verapamil in COVID-19 Hospitalized Patients With SymptomsTreatment2, 3Active Not RecruitingNCT04351763
2020-04-27VerapamilAmiodarone or Verapamil in COVID-19 Hospitalized Patients With SymptomsTreatment2, 3Active Not RecruitingNCT04351763
2020-04-27CIGB-258 peptideExpanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19)TreatmentNot AvailableCompletedRPCEC00000321
2020-04-26SeleniumInvestigating the effectiveness of selenium on recovery of hospitalized patients with COVID-19Treatment3RecruitingIRCT20190418043307N1
2020-04-26EnoxaparinSystemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)Treatment3Active Not RecruitingNCT04401293
2020-04-26IsofluraneVolatile agents for sedation in patients with COVID-19-associated acute respiratory distress syndrome – a pilot studyTreatmentNot AvailableActive Not RecruitingNL8523
2020-04-26ImatinibEfficacy of Imatinib in mild SARS CoV2 infection : A randomized studyTreatment2Active Not RecruitingCTRI/2020/04/024806
2020-04-26PirfenidoneThe evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19Treatment3Active Not RecruitingIRCT20200314046764N1
2020-04-26ColchicineCOlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)Treatment2Active Not RecruitingNCT04363437
2020-04-26D-glucoseControl of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19Treatment4Unknown StatusEUCTR2020-000705-86-ES
2020-04-26Omega-3 fatty acidsControl of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19Treatment4Unknown StatusEUCTR2020-000705-86-ES
2020-04-26Amino acidsControl of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19Treatment4Unknown StatusEUCTR2020-000705-86-ES
2020-04-26TocilizumabCORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)Treatment2Active Not RecruitingNCT04335071
2020-04-26COVID-19 convalescent plasmaConvalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in PakistanTreatmentNot AvailableActive Not RecruitingNCT04476888
2020-04-25OzoneInvestigation the effects medical Ozone Autohemotherapy on clinical and para clinical features of patients with Covid19Treatment2, 3RecruitingIRCT20190618043923N4
2020-04-25VazegepantBHV3500-203 : Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant* (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental OxygenTreatment2, 3Active Not RecruitingNCT04346615
2020-04-25Angiotensin 1-7Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19TreatmentNot AvailableActive Not RecruitingNCT04375124
2020-04-25Ivermectinâ??To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID 19 cases. A Pilot StudyTreatmentNot AvailableActive Not RecruitingCTRI/2020/04/024858
2020-04-25HydroxychloroquinePROTECT-SurgTreatment3Active Not RecruitingPACTR202004893013257
2020-04-25RitonavirPROTECT-SurgTreatment3Active Not RecruitingPACTR202004893013257
2020-04-25LopinavirPROTECT-SurgTreatment3Active Not RecruitingPACTR202004893013257
2020-04-25NiacinEvaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection : A Clinical TrialTreatment2, 3RecruitingIRCT20200418047122N1
2020-04-25ApocyninEvaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection : A Clinical TrialTreatment2, 3RecruitingIRCT20200418047122N1
2020-04-25IvermectinTo Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot StudyTreatmentNot AvailableActive Not RecruitingNCT04373824
2020-04-25Human Umbilical Cord Mesenchymal Stem CellsUmbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)Treatment1, 2Active Not RecruitingNCT04355728
2020-04-25HeparinUmbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)Treatment1, 2Active Not RecruitingNCT04355728
2020-04-25RuxolitinibCOVID-19 : Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE StudyBasic ScienceNot AvailableActive Not RecruitingNCT04361903
2020-04-25HydroxychloroquineEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative StudyTreatment3Active Not RecruitingNCT04359953
2020-04-25AzithromycinEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative StudyTreatment3Active Not RecruitingNCT04359953
2020-04-25TelmisartanEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative StudyTreatment3Active Not RecruitingNCT04359953
2020-04-24Human Umbilical Cord Mesenchymal Stem CellsA Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus PatientsTreatment1Active Not RecruitingNCT04573270
2020-04-24DexamethasoneEvolution of the efficacy and safety of Dexamethasone administration in patients with mild to moderate COVID-19 acute respiratory disease syndromeTreatment2, 3Active Not RecruitingIRCT20151227025726N17
2020-04-24DexmedetomidineImmunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19TreatmentNot AvailableActive Not RecruitingNCT04413864
2020-04-24ClazakizumabA Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 InfectionTreatment2Active Not RecruitingNCT04348500
2020-04-24VA-MENGOC-BC®Population impact of intervention based on the administration of a single dose of the Outer Membrane Vesicle (OMV) complex contained in VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2 (COVID-19) - VME-CORONATreatmentNot AvailableCompletedRPCEC00000314
2020-04-24CanakinumabCanakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened InflammationTreatment2Active Not RecruitingNCT04365153
2020-04-24SirolimusSirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)Treatment2Active Not RecruitingNCT04341675
2020-04-24SelinexorA Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection - Low Dose Oral Selinexor in Patients with Severe COVID-19 InfectionTreatment2Active Not RecruitingEUCTR2020-001411-25-GB
2020-04-24SirukumabPhase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 DiseaseTreatment2Active Not RecruitingNCT04380961
2020-04-24AzithromycinSafety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial studyTreatment3Active Not RecruitingIRCT20200415047092N1
2020-04-24Lactobacillus coryniformis K8Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19PreventionNot AvailableActive Not RecruitingNCT04366180
2020-04-24COVID-19 convalescent plasmaA Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized AdultsTreatment3Active Not RecruitingNCT04362176
2020-04-24BevacizumabPilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19Treatment2Unknown StatusEUCTR2020-001541-39-ES
2020-04-24HydroxychloroquineProtecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis : A Randomized, Placebo-controlled TrialPrevention3Active Not RecruitingNCT04352946
2020-04-24Peginterferon lambda-1aA Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19Treatment2Active Not RecruitingNCT04331899
2020-04-24Alpha-1-proteinase inhibitorA randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.Treatment2Active Not RecruitingEUCTR2020-001391-15-IE
2020-04-24ColistinA multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19)Treatment0Active Not RecruitingChiCTR2000032242
2020-04-23SarilumabPILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION - COVID-SARI-001Treatment2Unknown StatusEUCTR2020-001745-40-IT
2020-04-23FavipiravirAn Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19Treatment2, 3Active Not RecruitingNCT04434248
2020-04-23AstraZeneca COVID-19 VaccineA Phase I / II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult VolunteersTreatment1, 2Active Not RecruitingNCT04324606
2020-04-23COVID-19 convalescent plasmaConvalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II TrialTreatmentNot AvailableActive Not RecruitingNCT04408209
2020-04-23COVID-19 convalescent plasmaPhase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 InfectionTreatment1, 2Active Not RecruitingNCT04366245
2020-04-23TocilizumabOutcomes of patients with COVID-19 related cytokine release syndrome under immunosuppressive treatmentBasic ScienceNot AvailableActive Not RecruitingNL8551
2020-04-23MethylprednisoloneOutcomes of patients with COVID-19 related cytokine release syndrome under immunosuppressive treatmentBasic ScienceNot AvailableActive Not RecruitingNL8551
2020-04-23OzoneComparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patientsTreatment2, 3Active Not RecruitingIRCT20191125045492N2
2020-04-23OxygenComparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patientsTreatment2, 3Active Not RecruitingIRCT20191125045492N2
2020-04-23OlokizumabAn International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)Treatment2, 3Active Not RecruitingNCT04380519
2020-04-23HydroxychloroquinePRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) - COVIDNATreatment3Unknown StatusEUCTR2020-001697-30-ES
2020-04-23Human Umbilical Cord Mesenchymal Stem CellsDouble-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in patients with acute respiratory distress syndrome secondary to infection by COVID-19 - COVIDMESTreatment1Unknown StatusEUCTR2020-001505-22-ES
2020-04-23Albumin humanPlasma turnover in patients with COVID-19 disease and invasive mechanical ventilation : a randomized study - REP-COVIDTreatment2Unknown StatusEUCTR2020-001722-66-ES
2020-04-23Human immunoglobulin GPlasma turnover in patients with COVID-19 disease and invasive mechanical ventilation : a randomized study - REP-COVIDTreatment2Unknown StatusEUCTR2020-001722-66-ES
2020-04-23RitonavirEfficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized TrialPrevention3Active Not RecruitingNCT04364022
2020-04-23LopinavirEfficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized TrialPrevention3Active Not RecruitingNCT04364022
2020-04-23SevofluraneSevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury : a Randomized Controlled TrialTreatment3Active Not RecruitingNCT04355962
2020-04-23AzithromycinOpen, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 VirusTreatment1Active Not RecruitingNCT04329572
2020-04-23HydroxychloroquineOpen, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 VirusTreatment1Active Not RecruitingNCT04329572
2020-04-23HydroxychloroquineCOVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents – a randomized controlled trial - COVID-19 PREVENTIONTreatment3Active Not RecruitingEUCTR2020-001363-85-DK
2020-04-22RuxolitinibFront line treatment with Ruxolitinib in stage II / III Covid-19 patients with defined Hyperinflammation - RuxCoFlamTreatment2Active Not RecruitingEUCTR2020-001481-11-DE
2020-04-22HydroxychloroquineHydroxychloroquine for the treatment of mild COVID-19 diseaseTreatment2Active Not RecruitingEUCTR2020-001512-26-DE
2020-04-22AzithromycinCovid-19 : A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19 DAWN AZITHROTreatment2Active Not RecruitingEUCTR2020-001614-38-BE
2020-04-22HydroxychloroquineHealthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)Prevention3Active Not RecruitingNCT04334148
2020-04-22HydroxychloroquineHydroxychloroquine for the Treatment of Mild COVID-19 DiseaseTreatment3Active Not RecruitingNCT04340544
2020-04-22COVID-19 convalescent plasmaA Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. - PLACIDTreatment2Active Not RecruitingCTRI/2020/04/024775
2020-04-22Hydroxychloroquineevaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections : A randomized interventional study in Imam Reza Hospital, Mashhad.Treatment2, 3RecruitingIRCT20200325046859N2
2020-04-22Umifenovirevaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections : A randomized interventional study in Imam Reza Hospital, Mashhad.Treatment2, 3RecruitingIRCT20200325046859N2
2020-04-22AlteplaseA Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)Treatment2Active Not RecruitingNCT04356833
2020-04-22Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsA Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus DiseasePrevention2Active Not RecruitingNCT04349631
2020-04-22RuxolitinibA Phase-II Clinical Trial for First Line Treatment of Stage II / III Covid-19 Patients to Treat HyperinflammationTreatment2Active Not RecruitingNCT04338958
2020-04-22UlinastatinEfficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)Treatment4Active Not RecruitingChiCTR2000032135
2020-04-22RuxolitinibRuxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study. - Ruxolitinib Treatment in Patients with Severe COVID-19 Infection.A Danish Safety and Efficacy StudyTreatment2Active Not RecruitingEUCTR2020-001459-42-DK
2020-04-22DapagliflozinAn International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19Treatment3Active Not RecruitingNCT04350593
2020-04-22OseltamivirPakistan Randomized and Observational Trial to Evaluate Coronavirus TreatmentTreatment3Active Not RecruitingNCT04338698
2020-04-22HydroxychloroquinePakistan Randomized and Observational Trial to Evaluate Coronavirus TreatmentTreatment3Active Not RecruitingNCT04338698
2020-04-22AzithromycinPakistan Randomized and Observational Trial to Evaluate Coronavirus TreatmentTreatment3Active Not RecruitingNCT04338698
2020-04-21Dornase alfaEfficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced Acute Respiratory Distress Syndrome (ARDS)Treatment3Active Not RecruitingNCT04355364
2020-04-21HydroxychloroquineRandomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 PatientsTreatment2, 3Active Not RecruitingNCT04351516
2020-04-21TazobactamLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21PiperacillinLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21HydroxychloroquineLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21LopinavirLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21HeparinLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21MethylprednisoloneLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21TocilizumabLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21AzithromycinLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21RitonavirLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21TocilizumabCOVID 19 : Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia.Treatment2Active Not RecruitingEUCTR2020-001770-30-BE
2020-04-21VPM1002A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2 / COVID-19 Among High-Risk SubjectsTreatment3Active Not RecruitingCTRI/2020/04/024749
2020-04-21ChloroquineTopical Chloroquine Nasal Drops in Early Stage Covid 19- Impact on Viral load and cure ratesTreatment2Active Not RecruitingCTRI/2020/04/024729
2020-04-21TocilizumabThe effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failureTreatment2, 3Active Not RecruitingIRCT20200406046968N1
2020-04-21BudesonideTreatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 PneumoniaTreatment4Active Not RecruitingNCT04355637
2020-04-21COVID-19 convalescent plasmaA Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19Treatment2Active Not RecruitingNCT04359810
2020-04-21EnoxaparinA Randomized Trial of Anticoagulation Strategies in COVID-19Treatment3Active Not RecruitingNCT04359277
2020-04-21TocilizumabA prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia - TOC-COVIDTreatment2Active Not RecruitingEUCTR2020-001408-41-DE
2020-04-21Human interferon betaAnti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized TrialTreatment3Active Not RecruitingNCT04324463
2020-04-21Acetylsalicylic acidAnti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized TrialTreatment3Active Not RecruitingNCT04324463
2020-04-21ColchicineAnti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized TrialTreatment3Active Not RecruitingNCT04324463
2020-04-21RivaroxabanAnti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized TrialTreatment3Active Not RecruitingNCT04324463
2020-04-21AzithromycinA SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMICTreatment2Active Not RecruitingEUCTR2020-001327-13-AT
2020-04-21ChloroquineCOVID-19 : addition of azithromycin to chloroquine treatment - CO VOR ITTreatment4Active Not RecruitingEUCTR2020-001527-14-NL
2020-04-21AzithromycinCOVID-19 : addition of azithromycin to chloroquine treatment - CO VOR ITTreatment4Active Not RecruitingEUCTR2020-001527-14-NL
2020-04-21SpironolactoneThe Effect of Spironolactone on Oxygenation in Covid-19 ARDS PatientsTreatment4Active Not RecruitingNCT04345887
2020-04-21PrednisoneCorticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 InfectionTreatment2Active Not RecruitingNCT04344288
2020-04-21COVID-19 convalescent plasmaEfficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients : A Pilot Randomized Controlled Trial.Treatment2CompletedCTRI/2020/04/024706
2020-04-20ColchicineCOLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA - ColCOVID19Treatment2Active Not RecruitingEUCTR2020-001258-23-IT
2020-04-20UmifenovirEvaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital ComplexTreatment3Active Not RecruitingIRCT20200523047550N1
2020-04-20BeractantThe effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilationTreatment3RecruitingIRCT20091201002804N12
2020-04-20Remestemcel-LCell therapy in patients with COVID-19 using mesenchymal stem cellsTreatment1RecruitingIRCT20190717044241N2
2020-04-20COVID-19 convalescent plasmaEfficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients : A Pilot Randomized Controlled TrialTreatment2Active Not RecruitingNCT04346446
2020-04-20AtovaquoneOpen-Label, Non-Randomized Study to Evaluate Anti-Malarial / Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 InfectionTreatment2Active Not RecruitingNCT04339426
2020-04-20AzithromycinOpen-Label, Non-Randomized Study to Evaluate Anti-Malarial / Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 InfectionTreatment2Active Not RecruitingNCT04339426
2020-04-20BNT162c2 SARS-CoV-2 VaccineA Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19Treatment1Active Not RecruitingEUCTR2020-001038-36-DE
2020-04-20BNT162a1 SARS-CoV-2 VaccineA Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19Treatment1Active Not RecruitingEUCTR2020-001038-36-DE
2020-04-20Pfizer-BioNTech COVID-19 VaccineA Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19Treatment1Active Not RecruitingEUCTR2020-001038-36-DE
2020-04-20BNT162b1 SARS-CoV-2 VaccineA Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19Treatment1Active Not RecruitingEUCTR2020-001038-36-DE
2020-04-20CyanocobalaminZinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant WomenBasic ScienceNot AvailableActive Not RecruitingNCT04407572
2020-04-20Vitamin DZinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant WomenBasic ScienceNot AvailableActive Not RecruitingNCT04407572
2020-04-20ZincZinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant WomenBasic ScienceNot AvailableActive Not RecruitingNCT04407572
2020-04-20Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsAllogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled StudyTreatment1, 2Active Not RecruitingNCT04341610
2020-04-20BCG vaccineBacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2 : A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune ResponsesPrevention4Active Not RecruitingNCT04348370
2020-04-20AnakinraEfficacy and safety of ANAkinra during Adult « COVID-19 » with Aggravating respiratory symptoms : a multicenter open-label controlled randomized trial - ANACONDA-COVID-19Treatment3Active Not RecruitingEUCTR2020-001734-36-FR
2020-04-20ColchicineColchicine to Counteract Inflammatory Response in COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04322565
2020-04-20Folic acidThe host Epigenetic methylation repair in COVID-19 using Folic acid : A new suggested prevention and treatment.Treatment2Active Not RecruitingPACTR202005599385499
2020-04-20HydroxychloroquineA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.Treatment3Active Not RecruitingPACTR202004801273802
2020-04-20LopinavirA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.Treatment3Active Not RecruitingPACTR202004801273802
2020-04-20ChloroquineA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.Treatment3Active Not RecruitingPACTR202004801273802
2020-04-20RitonavirA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.Treatment3Active Not RecruitingPACTR202004801273802
2020-04-20PrednisoloneInvestigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19Treatment3RecruitingIRCT20080901001165N52
2020-04-20MethylprednisoloneInvestigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19Treatment3RecruitingIRCT20080901001165N52
2020-04-20ZincThe effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)Treatment2, 3RecruitingIRCT20180425039414N2
2020-04-20Ascorbic acidComparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19)Treatment2, 3RecruitingIRCT20140305016852N4
2020-04-20Vitamin DComparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19)Treatment2, 3RecruitingIRCT20140305016852N4
2020-04-20PomegranateThe effect of pomegranate tea on symptom relief of COVID-19 patients : a double-blind randomized clinical trial studyTreatmentNot AvailableRecruitingIRCT20200416047104N1
2020-04-20HydroxychloroquinePrevention of COVID-19 disease after contact with an infected patient with coronavirus after taking hydroxychloroquine in the communityTreatment3Active Not RecruitingIRCT20190122042450N4
2020-04-20Human immunoglobulin GTo evaluate the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of COVID-19-induced cytokine stormTreatment3Active Not RecruitingIRCT20200317046797N3
2020-04-20TranscrocetinateClinical trial of the effect of crocetin in improving the clinical and laboratory symptoms of patients with COVID-19Treatment2Active Not RecruitingIRCT20081019001369N3
2020-04-20MinocyclineClinical trial of minocycline against COVID-19Treatment2Active Not RecruitingIRCT20081019001369N4
2020-04-20HydroxychloroquineProspective post-exposure hydroxycloroquine prophylaxis for Covid 19 (PROSCLOROCOV 19)Treatment3Active Not RecruitingIRCT20130306012728N8
2020-04-20COVID-19 convalescent plasmaEvaluation of the therapeutic effects of Convalescent Plasma (CP) of recovered people from Covid-19 in improving clinical and laboratory symptoms of hospitalized patientsTreatment3Active Not RecruitingIRCT20151228025732N53
2020-04-20LicoriceEvaluation the effect of aqueous extract of licorice on coronavirus outpatients : A randomized, double-blind, placebo-controlled clinical trialTreatment2Active Not RecruitingIRCT20200404046933N1
2020-04-20BerberineClinical trial of berberine against COVID-19Treatment2Active Not RecruitingIRCT20081019001369N2
2020-04-20NaproxenThe effect of naproxen on the healing process of patients with COVID-19Treatment3Active Not RecruitingIRCT20200324046850N3
2020-04-20CalcifediolPrevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS)Treatment2Unknown StatusEUCTR2020-001717-20-ES
2020-04-20Remestemcel-LPhase I / II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumoniaTreatment1Unknown StatusEUCTR2020-001364-29-ES
2020-04-20Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsPhase I / II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumoniaTreatment1Unknown StatusEUCTR2020-001364-29-ES
2020-04-20BaricitinibClinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older AdultsBasic ScienceNot AvailableActive Not RecruitingNCT04362943
2020-04-20AnakinraClinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older AdultsBasic ScienceNot AvailableActive Not RecruitingNCT04362943
2020-04-20FavipiravirEfficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized, Controlled, Double-Blind, Clinical TrialTreatment4Active Not RecruitingNCT04359615
2020-04-20EstradiolPhase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ PatientsTreatment2Active Not RecruitingNCT04359329
2020-04-20AzithromycinEfficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19 : A Randomized, Controlled, Double-Blind, Clinical TrialTreatment4Active Not RecruitingNCT04359316
2020-04-20MelatoninMulticenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.Prevention2, 3Active Not RecruitingNCT04353128
2020-04-20AzithromycinOpen Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 VirusTreatment1Active Not RecruitingNCT04348474
2020-04-20HydroxychloroquineOpen Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 VirusTreatment1Active Not RecruitingNCT04348474
2020-04-20TocilizumabTocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19Treatment3Active Not RecruitingNCT04356937
2020-04-20FavipiravirClinical Study Evaluating the Efficacy of Faviprevir in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04351295
2020-04-20BCG vaccineApplication of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19Prevention3Active Not RecruitingNCT04350931
2020-04-20DexmedetomidineProspective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 InfectionTreatment4Active Not RecruitingNCT04350086
2020-04-20COVID-19 convalescent plasmaPlasma Rich Antibodies From Recovered Patients From COVID19TreatmentNot AvailableActive Not RecruitingNCT04348877
2020-04-20Ascorbic acidProphylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19 : A RCTPrevention2Active Not RecruitingNCT04347889
2020-04-20HydroxychloroquineProphylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19 : A RCTPrevention2Active Not RecruitingNCT04347889
2020-04-20HydroxychloroquineImmune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2Prevention3Active Not RecruitingNCT04346329
2020-04-20HeparinCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG TrialTreatment2Active Not RecruitingNCT04344756
2020-04-20TinzaparinCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG TrialTreatment2Active Not RecruitingNCT04344756
2020-04-20Human Umbilical Cord Mesenchymal Stem CellsClinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19TreatmentNot AvailableActive Not RecruitingNCT04273646
2020-04-20Povidone-iodineVirucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.Treatment0Active Not RecruitingACTRN12620000470998
2020-04-20RuxolitinibA Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 PneumoniaTreatmentNot AvailableActive Not RecruitingNCT04331665
2020-04-20IsofluraneTo Observe Whether Isoflurane Can Treat COVID-19 PatientsBasic ScienceNot AvailableActive Not RecruitingNCT04492943
2020-04-20BromelainsThe effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patientsTreatment3RecruitingIRCT20150725023332N3
2020-04-20MontelukastThe effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patientsTreatment3RecruitingIRCT20150725023332N3
2020-04-20Ascorbic acidThe effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19)Treatment2, 3Active Not RecruitingIRCT20180425039414N3
2020-04-20Vitamin EThe effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19)Treatment2, 3Active Not RecruitingIRCT20180425039414N3
2020-04-20BromhexineVerification of the efficacy of bromhexine hydrochloride in the prevention of COVID-19 diseaseTreatment2Active Not RecruitingIRCT20200317046797N7
2020-04-19IvermectinEvaluation of the effect of oral Ivermectin on the outcome of patients with COVID-19 and compare it with the effect of conucntional therapics in patients admitted to Ziaeian, Baharloo, Imam Khomeini in the spring and summer 2020Treatment3Active Not RecruitingIRCT20180922041089N4
2020-04-19COVID-19 convalescent plasmaUse of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia : a Prospective Randomized TrialTreatmentNot AvailableActive Not RecruitingNCT04356534
2020-04-19COVID-19 convalescent plasmaUse of convalescent plasma submitted to pathogen inactivation for the treatment of patients with severe COVID-19TreatmentNot AvailableRecruitingRBR-4vm3yy
2020-04-19Ascorbic acidThe Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 PatientsTreatment1Active Not RecruitingNCT04370288
2020-04-19CysteineThe Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 PatientsTreatment1Active Not RecruitingNCT04370288
2020-04-19Methylene blueThe Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 PatientsTreatment1Active Not RecruitingNCT04370288
2020-04-19HydroxychloroquinePilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare personnel. - PrevenCOVID-19Treatment3Unknown StatusEUCTR2020-001440-26-ES
2020-04-19PrednisoneOUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASETreatment4Unknown StatusEUCTR2020-001622-64-ES
2020-04-19Ascorbic acidStudy of the effect of Vitamin C on duration of hospital stay in patients with Covid-19Treatment2Active Not RecruitingIRCT20200324046850N5
2020-04-19Methylene blueEvaluation of the efficacy and safety of methylene blue administration for treatment of COVID-19 patientsTreatment3Active Not RecruitingIRCT20191228045924N1
2020-04-18IvermectinEfficacy of Ivermectin as Add on Therapy in COVID19 Patients : A Pilot Randomized StudyTreatment1Active Not RecruitingNCT04343092
2020-04-18HydroxychloroquineProphylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection.Treatment3Active Not RecruitingEUCTR2020-001536-98-ES
2020-04-18COVID-19 convalescent plasmaA National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19Treatment2Active Not RecruitingNCT04347681
2020-04-18Nitric OxideNitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency DepartmentTreatment2Active Not RecruitingNCT04338828
2020-04-18ChloroquineComparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patientsTreatment2, 3RecruitingIRCT20200422047168N1
2020-04-18RitonavirComparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patientsTreatment2, 3RecruitingIRCT20200422047168N1
2020-04-18LopinavirComparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patientsTreatment2, 3RecruitingIRCT20200422047168N1
2020-04-18TenofovirComparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patientsTreatment2, 3RecruitingIRCT20200422047168N1
2020-04-18EchinaceaThe effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient casesTreatment3Active Not RecruitingIRCT20200415047089N1
2020-04-18GingerThe effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient casesTreatment3Active Not RecruitingIRCT20200415047089N1
2020-04-18Human immunoglobulin GComparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 : A randomized clinical trialTreatment3Active Not RecruitingIRCT20200413047056N1
2020-04-18COVID-19 convalescent plasmaComparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 : A randomized clinical trialTreatment3Active Not RecruitingIRCT20200413047056N1
2020-04-18FormoterolThe efficacy of inhaled formoterol on symptom improvement in covid 19 patientsTreatment3RecruitingIRCT20170210032478N3
2020-04-18Ascorbic acidEvaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?Treatment2, 3Active Not RecruitingIRCT20200411047025N1
2020-04-18HydroxychloroquineEvaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?Treatment2, 3Active Not RecruitingIRCT20200411047025N1
2020-04-18AtazanavirEvaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?Treatment2, 3Active Not RecruitingIRCT20200411047025N1
2020-04-18RitonavirEvaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?Treatment2, 3Active Not RecruitingIRCT20200411047025N1
2020-04-18BromhexineEffect of Bromhexine Hydrochloride on clinical improvement and outcome of COVID-19-induced pneumoniaTreatment3Active Not RecruitingIRCT20200317046797N4
2020-04-18FennelEvaluation of the effect of herbal medicine containing Saatar, Hofarigon and Fennel on reduction of pulmonary complications of COVID-19 in patients : a clinical trialTreatment3RecruitingIRCT20200404046935N1
2020-04-18ColchicineTreatment With COLchicine of Patients Affected by COVID-19 : a Pilot StudyTreatment2Active Not RecruitingNCT04375202
2020-04-18MethylprednisoloneEfficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2) : a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.Treatment2Active Not RecruitingNCT04343729
2020-04-18SarilumabClinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndromeTreatment2Unknown StatusEUCTR2020-001531-27-ES
2020-04-18Antithrombin III humanPilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19Treatment2Unknown StatusEUCTR2020-001659-42-ES
2020-04-18FavipiravirEfficacy and Safety of Favipiravir in Management of COVID-19Treatment3Active Not RecruitingNCT04349241
2020-04-18Human interferon betaEfficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trialTreatment2, 3Active Not RecruitingIRCT20120225009124N4
2020-04-18Human immunoglobulin GEfficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trialTreatment2, 3Active Not RecruitingIRCT20120225009124N4
2020-04-18DexamethasoneEfficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trialTreatment2, 3Active Not RecruitingIRCT20120225009124N4
2020-04-18HydroxychloroquineEvaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workersTreatmentNot AvailableRecruiting